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Abstract 
 
INTRACEREBRAL IMPLANTATION OF ECM HYDROGEL FOR THE TREATMENT 
 
OF STROKE 
Harmanvir Ghuman, Ph.D. 
University of Pittsburgh, 2018 
 
Stroke is the leading cause of serious, long-term disability affecting nearly 15 million 
people worldwide each year. One of the key challenges in treating chronic stroke is the 
dramatic loss of brain tissue, and the formation of a cavity filled with extracellular fluid 
(ECF). Physical therapy and intracerebral implantation of cells has shown limited success 
in improving motor dysfunction, however there is no replacement of the lost tissue and 
hence a large tissue cavity remains in the brains of stroke survivors. Extracellular matrix 
(ECM), which fills the space between the cells, makes up 20% of the whole brain tissue 
volume and contains proteins such as laminin, fibronectin, myelin and growth factors. The 
objectives of this work were to determine if hydrogels composed of decellularized 
mammalian ECM implanted in a stroke cavity promotes cellular infiltration and 
constructive tissue remodeling, as well as optimization of 19F MR imaging to visualize 
the peripheral macrophages invading the lesion cavity.  
At ECM concentrations that have similar rheological properties as brain tissue, the 
ECM exists in fluid phase at room temperature, while forming hydrogels at body 
temperature. However, large volumes of hydrogel injection into the lesion cavity will 
increase the intracerebral pressure and further damage brain tissue. Using non-invasive 
magnetic resonance imaging (MRI)-guidance, the hydrogel can be reliably delivered to 
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the lesion cavity, while draining the ECF through another cannula. We evaluated 
histologically 0, 3, 4 and 8 mg/mL of porcine-derived urinary bladder matrix (UBM)-ECM 
hydrogel concentrations implanted in a 14-day old stroke cavity. Less concentrated 
hydrogels (3 and 4 mg/mL) were efficiently degraded with a 95% decrease in volume by 
90 days, whereas only 32% of the more concentrated and stiffer hydrogel (8 mg/mL) was 
resorbed. The less concentrated hydrogels showed a robust invasion of endothelial cells 
that supported neovascularization. No neovascularization occurred with the stiffer 
hydrogel. Invasion of neural cells increased with time in all hydrogel concentrations. 
Differentiation of neural progenitors into mature neurons with axonal projections was 
evident, as well as a robust invasion of oligodendrocytes. Macrophage infiltration and 
density within the bioscaffold affected the hydrogel biodegradation and progressively 
increased in the less concentrated hydrogels and decreased in the 8 mg/mL hydrogels.  
Optimization of 19F imaging parameters revealed fast imaging with steady state 
precession (FISP) sequence being the most efficient for the detection of perfluorocarbons 
(PFCs). In vivo 19F MRI shows robust visualization of peripheral macrophages invading 
the lesion cavity implanted with 4 mg/mL ECM hydrogel. Intravenous administration of 
PFCs results in accumulation of 19F labeled cells within the ECM hydrogel and in the 
peri-infarct tissue. Histological analysis at 1 day post-injection revealed all infiltrating 
Iba1+ cells to also be 19F labeled, indicating that these are peripheral macrophages 
rather than brain derived microglia. This body of work demonstrates that implantation of 
an ECM hydrogel induced neural tissue regeneration, but a more complete understanding 
is required to evaluate its potential therapeutic application.  
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1.0 INTRODUCTION 
Work in this chapter has been adapted from the following manuscript: 
Ghuman H, Modo M. Biomaterial applications in neural therapy and repair. Chinese 
Neurosurgical Journal. 2016; 2:34. 
 
 
1.1  CLINICAL MANIFESTATION OF STROKE 
 
Stroke or a cerebrovascular accident (CVA) is the leading cause of adult disability 
affecting nearly 800,000 Americans (15 million worldwide) each year, with ischemic stroke 
accounting for 80% of all cases [1]. This injury is characterized by occlusion of blood flow 
to brain tissue, cell death, and blood-brain barrier disruption, resulting in transmigration 
of leukocytes into the surrounding brain tissues [2]. Disruption of the blood-brain barrier 
and release of various proteases and reactive oxygen species (ROS) by leukocytes into 
the brain tissue results in cerebral edema and irreversible damage to the viable cells in 
the ischemic core. These mechanisms may clinically manifest as significantly worsened 
sensory, motor, or cognitive functions, or even death. The only approved treatment for 
acute ischemic stroke is the intravenous administration of recombinant tissue 
plasminogen activator (rtPA) to dissolve the clot [3], with the therapeutic windown open 
for up to 4.5 hours after stroke, and thus applicable to a very small proportion of all stroke 
patients (up to 5%) [4].  
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With the increasing incidences of stroke, and declining mortality, the number of 
disabled stroke survivors is expected to increase [5]. While patients currently rely on 
physical therapy to restore motor function after stroke, these improvements are 
modulated through existing brain circuitry [6], and not through replacing lost cells and 
tissue, with one-third of all stroke patients remaining permanently disabled even with 
intensive task specific training [7, 8]. In other words, there is a loss of functional tissue 
after stroke, and thus the physical therapy and rehabilitation is limited in restoring the lost 
cognitive and physiological functions. The lack of effective treatments for stroke and other 
neurological diseases can also be explained by the limited regenerative potential of the 
central nervous system [9].  
 
1.2   ANIMAL MODELS OF STROKE 
 
Over the past four decades, a variety of animal models of stroke have been developed to 
identify mechanisms that underlie ischemia and develop strategies for therapy. The 
majority of the stroke experiments are carried out in small animals (ex. mice, rats etc) 
since these present lower costs and greater acceptability from an ethical perspective.  
Photothrombosis model: The photothrombotic stroke model is based on intravascular 
photo-oxidation, which leads to well defined and reproducible lesions in the cortex [10]. 
To achieve this, a photoactive dye (eg. Rose Bengal, erythrosine B) is injected i.p. or i.v. 
and the intact cortex is irradiated by a light beam [10, 11], which generates oxygen 
radicals leading to endothelial damage, platelet activation, and aggregation in all vessels 
within the irradiated light beam. This techniques enables cerebral ischemia to be induced 
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in a desired region (eg. motor, sensory cortex), as well as high reproducibility of the lesion, 
and low mortality. However, the endothelial damage and ischemic injury using this model 
leads to vasogenic (extracellular) edema formation [12], with no ischemic penumbra and 
reperfusion possible in this model.  
Endothelin-1 model: ET-1 is a potent vasoconstrictive peptide, produced by vascular 
endothelium [13]. It can be applied directly onto the exposed middle cerebral artery  
(MCA) [14], or injected intracerebrally [15], to produce dose-dependent ischemic lesions 
with some edema [16]. After ET1 administration, a rapid and severe CBF reduction (up 
to 90%) is seen, followed by reperfusion over several hours [17]. This technique offers 
low mortality and the choice of inducing ischemia in deep brain regions. However, ET1 
has been shown to induce astrocytosis and axonal sprouting [18], making it difficult to 
interpret neural tissue repair experiments.  
Embolic stroke model: The embolic stroke model involves injection the of 
microspheres/macrospheres (20-400 μm in diameter) [19], or homologous clots into the 
internal carotid artery (ICA) or MCA to mimic human infarcts [20, 21]. Microphere-induced 
stroke results in multifocal and heterogenous infarcts [22], with the extent and severity of 
lesions dependent on the size and dose of microspheres [23]. For the thromboembolic 
clot model, the mechanism of vascular occlusion mimics very closely to human stroke 
with volume of the infarts dependant on the size and elasticity of the clot [24]. However, 
lesion volume in this model is much more variable compared to the suture MCA occlusion 
model [25].  
Intraluminal suture MCAo model: The middle cerebral artery (MCA) is one of the cerebral 
vessels most often affected in human ischemic stroke, accounting for nearly 70% of all 
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infarcts [26]. The transient MCA occlusion (MCAo) is one of the models that most closely 
resembles human ischemic stroke and is characterized by reliable and reproducible 
infarcts. This model involves blocking the common carotid artery (CCA), introducing a 
suture into the internal carotid artery (ICA), and advancing the suture until it interrupts 
blood flow to the MCA. This technique offers transient ischemia with reperfusion, but also 
the choice of permanent MCAo. Depending on the duration of occlusion, this model leads 
to territorial infarction involving striatum, somatosensory cortex, as well as some portion 
of the occipital cortex and thalamus [27]. Thus, the MCAo model is considered the most 
suitable for mimicking human ischemic stroke and subsequent cell death, inflammation, 
blood brain barrier disruption, as well as producing reliable behavioral results [28].   
 
1.3 DISTINGUISHING PATHOLOGY MICROENVIRONMENTS 
 
In the very early stages of ischemic stroke, adenosine triphosphate (ATP) consumption 
continues despite insufficient synthesis due to reduced glucose and oxygen flow in the 
tissue. This leads to a drop in total ATP available to the cells and ionic homeostasis. 
Severe ischemia results in an excess release of the main excitotoxic neurotransmitter 
called glutamate, which promotes a major influx of calcium into the cells and activates the 
phospholipases and proteases to degrade proteins and membranes in neuronal cells [29]. 
The core of the infarct results in an area of complete cell death leading to irreversibly 
damaged tissue [30] (Figure 1.1). Cerebral blood flow (CBF) is highly compromised in 
this region with < 20% of baseline blood flow levels [31]. With fast degradation (7-10 days) 
of the damaged host tissue extracellular matrix (ECM), the cavity is filled with extracellular 
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fluid after liquefactive necrosis [32], and transplantation of cells in this region would result 
in severe loss of the injected graft [33, 34]. 
The brain tissue surrounding the core, or the ischemic penumbra (IP), contains partially 
dying cells as well as activated microglia, peripheral macrophages and astrocytes. 
 
 
 
 
 
Figure 1.1. Right human MCA infarct shows a collapsed cavity void of all cells and tissue. 
 
 
 
Microglia, the resident immune cells of the brain constantly monitor the microenvironment 
and respond to the insult with typical macrophagic roles, such as secretion of cytokines, 
phagocytosis and antigen presentation. Microglia are activated within minutes of the 
stroke onset and accumulate surrounding the lesion cavity in the peri-infarct tissue. The 
proliferation of these immune cells peaks at 48-72 hours after ischemia and may last for 
several weeks depending on the extent of damage [35, 36]. While traditionally these cells 
were considered to be deleterious and neurotoxic by releasing pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF)-alpha and Interleukin (IL)-1 [37-39], it has 
been shown that activated microglia can maintain and support neuronal survival [40, 41] 
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by releasing anti-inflammatory and neurotrophic factors. Microglia have also been shown 
to promote neurogenesis by guiding stem cells to the site of injury [42-44].  
The astrocytic response after the injury, or reactive gliosis, is characterized by 
excessive expression of glial fibrillary acidic protein (GFAP), cellular hypertrophy and 
process extension, creating a glial scar tissue surrounding the lesion [45-47] (Figure 1.2). 
It is well known that astrocytes are more resistant to oxygen and glucose deprivation [45], 
which enables them to survive for a prolonged period in the IP, where the vasculature is 
partially maintained [48].  
 
 
 
 
 
 
Figure 1.2. Peri-infarct cavity in a rat brain shows active tissue remodeling with 
upregulation of ECM proteins (eg. collagen), endothelial marker protein RECA1, and 
expression of GFAP reslting in a reactive glial scar around the cavity.  
 
 
 
Astrocytes are involved in a number of activities during ischemia, including regulating the 
blood brain barrier (BBB), CBF regulation, glutamate and ion homeostasis [48-52]. 
Although astrocytes limit axon outgrowth by expressing inhibitory molecules (e.g. 
proteoglycans) and forming a glial scar [53], they are also known to release extracellular 
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matrix proteins, such as thrombospondins 1 and 2, which have been shown to increase 
the number of synapes and axonal sprouting in stroke-damaged brains [54]. In the days 
to weeks following brain tissue damage, microglia and astrocyte activation shifts its 
cytokine release profile through the secretion of anti-inflammatory and neurotrophic 
factors, such as TGF-β, BDNF and NGF [55].  
 
1.4  CELL THERAPY TO SUPPLEMENT ENDOGENOUS REPAIR RESPONSES 
 
Cellular and molecular approaches to achieve tissue repair includes cell therapy [56-58], 
using molecular mechanisms to induce axonal growth [59, 60], modulating the neural 
responses using light (optogenetics) [61], and immunotherapy [62, 63]. With a limited 
endogenous neurogenesis and capacity to regenerate following injury, delivery of 
exogenous cells to the site of injury has been shown to modulate the inflammatory 
response, stimulate endogenous stem cells and promote neuroprotection and plasticity 
[64]. These transplanted cells can help in the tissue repair process by directly integrating 
into the host tissue or by secreting factors that promote neurogenesis [65]. Indeed, human 
NSCs transplanted in the ischemic parenchyma in rats have been shown to release 
factors, such as VEGF and FGF-2, which are effective in stimulating endogenous 
neurogenesis [66, 67]. In addition, transplanted NSCs have been shown to induce a 
downregulation of pro-inflammatory cytokines, such as interleukin-1B and tumor necrosis 
factor alpha, in ischemic mice’s brains [68], drastically decreasing the microglia driven 
inflammatory response. Studies have also shown that injecting cells directly into the lesion 
cavity results in their migration into the existing parenchyma with poor survival [69]. One 
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key parameter that has been shown to affect cell survival is the regulation of inflammatory 
cytokines. The stroke cavity is surrounded by resident immune cells, i.e. microglia, as well 
as perivascular macrophages who respond to the injury by releasing inflammatory 
cytokines [70], that have a detrimental effect on the cells transplanted in a close proximity 
to the cavity [33]. These exogenously delivered cells by themselves do not replace lost 
tissue. To achieve a retention of injected cells within the lesion cavity, it is essential to 
provide a permissive structural and functional microenvironmental niche [69, 71-73]. Such 
niche support may be achieved by biomaterials specifically engineered to be compatible 
with neural tissue and amenable to delivery through a small gauge needle for 
intracerebral injections, with minimal damage to healthy tissue [74, 75]. Matrigel, a 
commonly used biomaterial derived from a mouse sarcoma with ECM components 
collagen, entactin and laminin has been shown to reduce the infarct size after injury, only 
when used in combination with transplanting cells [72]. Also, transplantation of NPCs 
mixed with HA/collagen hydrogel into the stroke cavity 7 days post-stroke improved the 
survival of NPCs and reduced the infiltration of inflammatory cells to the graft [76]. These 
attributes allow biomaterials to not only benefit the transplanted cells, but also supports 
the invasion and migration of endogenous host cells surrounding the implant. With the 
ability to protect the cells to improve survival and promote neural cell integration, more 
studies on cell therapy in combination with protective hydrogels would greatly advance 
the neural tissue engineering. 
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1.5  BARRIERS TO TISSUE REPAIR AND REGENERATION 
 
Regenerative strategies, such as stem cell therapy have shown limited success in 
improving behavioral outcomes, but there is no replacement of the lost tissue [57, 77], 
and hence a large tissue cavity remains in the brains of stroke survivors [78]. There are 
2 major limitations with stem cell therapy. Firstly, there is a large scale loss of the 
transplanted cells in the days following intracerebral implantation, with survival ranging 
from 1% to 32% [79]. Similarly, systemic administration of cells in ischemic rats 
accumulates cells primarily in internal organs instead of brain [80]. Secondly, intracerebral 
cell injection requires transplantation into the peri-infarct region, which is considered to 
be an active site for cerebral reorganization after stroke [81], and multiple injections into 
this site can potentially damage the tissue even further. Pro-aniogeneic growth factors 
like VEGF have also been been administered to stroke rats using systemic and 
intracerebral routes. Results suggest that early delivery of VEGF after stroke increases 
the formation of disorganized and immature blood vessels, worsens edema and disrupts 
the blood brain barrier while its antagonist reduces the tissue damage [82].  
 In addition, the ECMs (specifically chondroitin sulfate proteoglycans) produced by 
reactive astrocytes are known to impede axonal regeneration by forming a physical 
barrier along the lesion cavity [83]. The glial scar provides a biochemical and mechanical 
barrier to neuronal regeneration [84, 85], consitituing a stiff barrier that neurons cannot 
penetrate [85]. In order to modulate the immune and glial cell responses, an ideal 
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treatment strategy will be to protect the implanted or infiltrating host cells from the 
inflammatory response and allow the host cells to cross the glail scar into the lesion cavity.   
 
1.6  PROVIDING SCAFFOLDING SUPPORT FOR TISSUE REPAIR 
 
Biomaterial scaffolds are natural or synthetic 3D polymer networks that provide an 
appropriate environment for cells to attach, proliferate, and differentiate to facilitate the 
formation of extracellular matrix (ECM) [86]. Although biomaterials based tissue repair 
strategies have been studies for at least two decades, they have not been extensively 
applied to repair the post-stroke brain. It is important to note that the chemical and 
mechanical properties of a biomaterial determine the fate of transplanted cells, as well as 
the drug release profile. The extent of cross-linking and rate of degradation are directly 
affected by the chemical characteristics of the preparation and determine the overall 
functionality of the biomaterial.   
 
1.6.1  Natural versus synthetic scaffolds 
 
Extracellular matrix makes up 20% of the whole brain tissue volume and plays a role in 
maintaining key cellular functions [87]. Hydrogels derived from ECM may provide the 
mechanical properties and signaling molecules to attract host cells into the lesion cavity 
and obviating the need for exogenous cells [71, 77, 88, 89]. The decellularized biomaterial 
contains ECM proteins like laminin and fibronectin, myelin and growth factors including 
VEGF and fibroblast growth factor-2 [90, 91].  
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ECM harvested from different organ systems, such as the brain, spinal cord or 
urinary bladder, influence neural stem cell phenotypic fate and the extent of cell invasion 
[92]. While the ECM in the peripheral tissue contains high amounts of structural proteins, 
such as collagen, fibronectin and laminin, the adult CNS is mainly composed of 
glycosaminoglycans and proteoglycans [93, 94]. In an in vitro comparison study of ECM 
derived from brain, spinal cord and urinary bladder, all ECMs increased the number of 
cells expressing neurites, but only the brain ECM increased neurite length [95].  
In addition to ECM hydrogels, natural polymers like hyaluronic acid (HA) [96, 97], 
fibrin [98], HA-methylcellulose (HAMC) [99], chitosan [100, 101] and collagen [102] have 
been used extensively to deliver cells or molecules in the CNS. Collagen is a popular 
material used in biomedical applications since it is the most abundant protein and main 
component of peripheral ECM in mammalian tissues. Collagen hydrogels have been used 
to encapsulate variety of stem cell types for tissue engineering applications because of 
its biocompatibility, mechanical strength and immunogenicity [103]. In a rodent model of 
cerebral ischemia, encapsulation of NSCs in collagen type I hydrogel showed an increase 
in cell survival (compared to injection of cells alone), formation of synapsis and facilitated 
the functional recovery of neural tissue following injury [86]. Another naturally occurring 
polysaccharide found in CNS and used for hydrogel formation is hyaluronan. It is known 
to have anti-inflammatory properties and has been shown to promote cell adhesion and 
survival [104]. Transplantation of a cross-linked hyaluronan and heparin sulfate hydrogel 
in a mice model of ischemia significantly promoted the survival of NPCs, and attenuated 
infiltration of immune cells into the graft compared with the cells delivered in suspension 
alone [76]. Also, injection of HA peptide hydrogels into the stroke cavity showed stiffness 
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dependent activation of macrophages, with stiffer hydrogels (~1300 Pa) showing an 
increased macrophage density at the host-hydrogel interface comepared to softer gels 
[97].  
Synthetic biomaterials allow precise control over material properties and 
degradation rates slowing controlled release of small molecules or drugs into the 
surrounding tissue. The commonly used biomaterials for controlled drug delivery are the 
polymeric agents polylactide (PL), polyglycolide (PG), and the copolymers of lactide and 
glycolide (PLGA). PLGA particles are loaded with bioactive molecules and delivered to 
the site of injury or embedded in hydrogels to further tune the location and rate of delivery. 
Synthetic biomaterials, unlike natural materials like collagen and Matrigel, are better 
chemically defined and biologically inert which reduces the variability and the host 
immune response. In normal untreated animals, injection of PLGA based microspheres 
evoked an inflammatory response no greater than just the needle tract [105, 106]. There 
was a peak in astrocyte activation at 1 week post-transplantation and diminished as the 
polymer degraded [105, 107, 108]. Like natural biomaterials, byproducts of synthetic 
materials can also be bioactive and influence the local microenvironment. In a recent 
study, application of lactic acid (a byproduct of PLGA) on cultured slices of developing 
mice cerebral cortex has shown to support oligodendrocyte development and myelination 
[109]. Nanoparticles and gels made from PGA, PLA and PLGA are primarily used for drug 
delivery since their degradation rate can be controlled by simply adjusting the PL:PG ratio. 
 Another synthetic polymer known to resist protein absorption and commonly used 
in biomaterial applications is poly (ethylene glycol) (PEG). Although cells do not directly 
attach to PEG hydrogels, it is most often mixed with other polymers like HA or gelatin to 
 13 
support cell attachment and migration. Epi-cortical delivery of PEG modified epidermal 
growth factor (PEG-EGF) significantly increased tissue penetration and endogenous NSC 
stimulation compared to unbound EGF [110]. PEG based hydrogels are promising in the 
fields of drug and cell delivery for many reasons, including controlled drug delivery or 
degradation rate, low immunogenicity, non-toxicity and biocompatibility.  
 
1.6.2  Injectable hydrogels 
 
Since brain injuries, such as stroke, vary in size and shape, an ideal biomaterial will fill 
the cavity space and form gel to repopulate the lost tissue. Injectable biomaterials can be 
used as a scaffold to fill the stroke cavity and promote interactions between the 
transplanted material and host tissue [71, 88, 89, 111], deliver drugs or growth factors to 
the damaged tissue, promote the attachment and engraftment of transplanted cells and 
help recruit host cells to repopulate the lost tissue [112]. Protective hydrogels derived 
from natural and synthetic polymers can incorporate cells, growth factors, and other 
therapeutics to enhance the microenvironment and provide controlled release of bioactive 
molecules.  
Crosslinking of water soluble polymers produces a hydrogel that has excellent 
nutrient and oxygen permeability, promoting cell survival inside the scaffold [113]. These 
biomaterials can be formulated to exist in liquid state at room temperature while forming 
gels in situ, allowing for minimal invasive delivery through a small-gauge needles, using 
MRI guidance [114]. For example, collagen, methylcellulose, and agarose are all 
temperature sensitive polymers and their gelation rates can easily be controlled by adding 
 14 
other natural polymers, such as hyaluronic acid [115]. The high water content of hydrogels 
makes them very biocompatible and promising candidates for tissue engineering 
applications. It is an important consideration that large volume of hydrogel injection into 
the lesion cavity or into the peri-infarct area would cause tissue disruption and increased 
intracerebral pressure [116, 117], and therefore an innovating neurosurgical technique 
that allows for the drainage of ECF should be employed to avoid additional damage [114].  
 
1.6.3  Gelation and retention 
 
An ideal hydrogel chemistry would facilitate the gelation of the material and minimize 
permeation of scaffolding from the injection site into surrounding tissue. In order to 
achieve a complete coverage of the lesion cavity, rapid gelation of hydrogel is necessary 
to avoid leakage in the tissue and support the invasion of host cells into the cavity. 
Furthermore, mixing of the extracellular fluid (ECF) present in the stroke cavity with the 
injected hydrogel could change the chemical and mechanical properties and hence 
influence the extent of gelation and retention. Therefore, it is ideal to drain the ECF before 
or during the hydrogel injection to avoid mixing and increasing the intracerebral pressure. 
In experiments where partial diffusion into the host tissue is preferred such as drug 
delivery, the hydrogel can be formulated with lower concentrations that support diffusion 
as well as partial retention in the stroke cavity [114]. 
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1.6.4  Biocompatible and non-toxic 
 
Biocompatibility of a biomaterial refers to its biological compatibility with the host tissue, 
as well as all byproducts being non-toxic and avoiding any undesirable effects on the local 
tissue environment. The long term biocompatibility of the material with the host brain 
dictates the effectiveness of the implantation. Most commonly, the number and degree of 
reactivity of microglia and astrocytes surrounding the biomaterial is used as an indicator 
of immunorejection [118], or in vivo biocompatibility. The biocompatibility of byproducts 
from biomaterial degradation must also be considered, as the byproducts are often 
bioactive which can influence the surrounding environment. Another factor affecting the 
biocompatibility of a material is dependent on the method of polymerization. 
Photopolymerization of a hydrogel, i.e. crosslinking when exposed to light, can lead to 
formation of free-radicals which are toxic to the encapsulated cells [119, 120], as well as 
the host cells, which are already under high oxidative stress after the injury. However, 
polymerization processes that are dependent on changes in temperature or pH produce 
little to no free radicals and often polymerize at physiological conditions, making these 
polymers injectable using a minimally invasive procedure.  
 
1.6.5  Biomaterial stiffness and cell invasion 
 
As mentioned before, the chemical properties of the biomaterial affect the mechanical 
properties – especially the stiffness of material after polymerization. The compressive 
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modulus measures the stiffness of the biomaterial and can be easily varied by changing 
the proportion of monomers [121], or molecular weight of monomer [122, 123]. The 
stiffness of the prepared hydrogel is known to affect cell proliferation and differentiation 
in vivo. If microtubule compression forces determined scaffold stiffness is outside their 
sensitivity range, cells reinforce by increasing or decreasing actin filament building [124]. 
Rat NSCs grown on soft (<1 kPa) hydrogels differentiated primarily into astrocytes and 
neurons, however cells cultured on stiffer (> 7kPa) gels differentiated into 
oligodendrocytes [125]. In addition, cells cultured on intermediate stiffness (3.5 kPa) 
showed the most proliferation. Similarly, MSCs respond differently to varying mechanical 
properties with cells differentiating to neural like cells on soft gels (0.1-1 kPa), osteogenic 
cells on stiffer (25-40 kPa), and myogenic cells with intermediate stiffness [126]. It is 
important to note that an ideal biomaterial will closely resemble the mechanical properties 
of the host tissue to minimize the contact stresses and an aggravated response from the 
immune cells. However, some variability exists regarding the approximate stiffness of 
healthy brain tissue, which may be related to the different testing methods and brain 
regions used for the analysis. Using confined compession tests, a stiffness of 50 kPa has 
been reported for mouse and rat brains [127]. Using magnetic resonance elastography, 
a stiffness of 25 kPa was reported in a mouse brain [128]. Other groups have reported 
even lower compressive modulus of brain ranging from 300 Pa to 10 kPa [129] [130]. 
However the use of mechanics has not been fully explored in vivo to guide the 
differentiation of transplanted cells, likely since soft biomaterials needed for neuronal 
differentiation tend to degrade faster than desired. With biodegradation and loss of 
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collagen cross links over time, the compressive modulus of the implanted material 
decreases and results in the loss of mechanical integrity, leading to the influx of host cells. 
  
1.6.6  Biodegradable 
 
Biodegradation is a natural process during which the biomaterial is degraded by the 
invading cells, proteases or hydrolysis. After full biodegradation, the biomaterials are 
broken down into their components and released in the surrounding tissue. For successful 
integration into neural networks, it is necessary that the chemical properties of the 
material allow it to degrade over time. Permanent implants could lead to chronic 
inflammation and sustained activation of glial cells (i.e. a foreign body response) around 
the implant [131]. When designing a hydrogel, the degradation rate can have effects on 
both the functionality of the hydrogel, as well as the host response. For example, a slow 
degrading hydrogel would be preferred in order to support the transplanted cells to 
develop their own ECM, extend processes and integrate into neural networks. However, 
faster degradation could result in a reduced inflammatory response in vivo, and thus it is 
important to develop materials that balance the cell supportive nature of hydrogels, as 
well as the rate of degradation to avoid any additional immune response.  
 
1.7. SPECIFIC AIMS 
 
Aim 1: To establish the concentration-dependent rheological properties of an ECM 
hydrogel that influences its delivery and in vivo interaction with host tissue. 
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Hypothesis: The use of non-invasive MR imaging will guide the location and volume of 
injection, and affords efficient delivery of ECM hydrogel (3 – 8 mg/mL) to the stroke cavity.  
a) Establish MRI-guided injection-drainage approach that minimizes tissue damage from 
ECM injection 
b) Establish the gelation and retention properties of different ECM concentrations in a 
stroke cavity with characterization of infiltrating cells 
 
Aim 2: To evaluate ECM biodegradation and behavioral impact in stroke rats 
implanted with ECM hydrogel.  
Hypothesis: Biodegradation of 8 mg/mL ECM hydrogel will promote sensory and motor 
functional improvements by restoring tissue in the stroke cavity.  
a) Quantify ECM biodegradation and cell invasion  
b) Determine the phenotypes of invading cells 
c) Evaluate the evolution of lesion volume and tissue deformations using MRI 
d) Evaluate functional changes from ECM implantation 
 
Aim 3: To evaluate the temporal evolution of cell invasion into ECM hydrogel 
injected in the stroke cavity. Hypothesis: A significant concentration-dependent cell 
invasion will occur with microglia and macrophages being polarized toward a M2 
phenotype, preceding nonimmune cells to follow and repopulate the tissue void. 
a) Establish gelation, retention and biodegradation of different ECM concentrations 
b) Compare and quantify cell invasion for different ECM concentrations 
c) Determine the phenotypes of invading cells 
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d) Determine the effect of ECM injection on host astrocytic response and tissue 
deformations in comparison to healthy and stroke groups. 
 
Aim 4: To establish and validate the in vivo visualization of macrophage invasion 
into ECM hydrogel. Hypothesis: Perfluorocarbon (PFC) nanoemulsions will afford a 
reliable discrimination of macrophages invading the ECM hydrogel from the peri-lesion 
parenchyma using 19F MR imaging. 
a) Determine the optimal imaging parameters that achieve the greatest sensitivity for PFC 
nanoemulsion 
b) Visualize and quantify macrophage invasion in stroke brain implanted with ECM 
hydrogel  
c) Establish histological validation of PFC macrophage detection 
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2.0    INTRACEREBRAL DELIVERY OF ECM HYDROGEL USING MRI 
GUIDANCE AND CHARACTERIZATION OF HOST CELL INFILTRATE 
Work in this chapter has been adapted from the following published manuscripts: 
1. Massensini AR*, Ghuman H*, Saldin LT, Medberry CJ, Keane TJ, Nicholls FJ, 
Velankar SS, Badylak SF, Modo M. Concentration-dependent rheological 
properties of ECM hydrogel for intracerebral delivery to a stroke cavity. Acta 
Biomater. 2015; 27:116-30. *Contributed equally 
2. Ghuman H, Massensini AR, Donnelly J, Kim S, Badylak SF, Modo M. ECM 
Hydrogel injection for the treatment of chronic stroke: Characterization of the 
acute host cells invasion. Biomaterials. 2016; 91:166-181. 
 
2.1 INTRODUCTION 
 
Therapeutic options for stroke remain very limited [75]. Most pharmacological agents are 
administered systemically during the acute phase to either resolve a thrombus or to 
provide neuroprotection. The focus of current therapy is the modulation of the remaining 
brain tissue response by systemic administration of agents or cells that putatively promote 
plasticity. In the absence of neuroprotection, cells in the infarct territory will die resulting 
in liquifactive necrosis and invading phagocytic cells will remove cellular debris and the 
surrounding tissue matrix [132]. A fluid-filled lesion cavity remains. A key challenge in the 
treatment of stroke is hence the removal of necrotic debris and access to the adjacent 
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viable or potentially viable tissue. The advent of regenerative medicine affords potentially 
novel strategies for integration of cells and/or therapeutic agents/materials into the 
damaged brain by intracerebral injection [74, 133]. Hydrogel forms of naturally occurring 
biomaterials composed of extracellular matrix (ECM) show in vitro chemoattraction and 
differentiation stimuli for neural stem cells and might obviate the need for exogenous cells 
[89, 91]. Alternatively, these materials may supply growth factors, mechanical properties, 
and/or signaling molecules to support delivered cells or surviving endogenous cells [134-
136]. Rheologic characterization of an ECM hydrogel intended for CNS applications is 
essential for an effective evaluation of delivery, safety and efficacy of this therapeutic 
strategy.  
 ECM concentration affects rheological properties and determines if it will form a 
hydrogel or remain in a liquid phase [137]. Without the formation of a gel phase in situ, 
the ECM will diffuse and not provide a structural support within the lesion cavity [138]. 
Additionally, the stiffness of hydrogel will influence cell invasion and phenotypic choice of 
neural progenitors [139]. Determining the rheological properties of ECM hydrogels is 
therefore important to establish the retention of scaffolding material within the lesion 
cavity and the associated host response.As lesion cavities caused by ischemic stroke 
may consist of a large volume and irregular shape, it is essential to ensure that 
administration is indeed into the tissue void rather than intraparenchymally, where this 
volume would cause tissue disruption and potentially increased intracerebral pressure 
[116, 117]. The use of non-invasive imaging, such as magnetic resonance imaging (MRI), 
can guide the volume of injection, as well as its stereotactic location, to ensure the safety 
of this approach [140, 141]. 
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 The objective of the present study was to characterize the concentration-
dependent rheologic properties of an ECM biologic scaffold material for the intended 
clinical application of minimally invasive intracerebral injection. To assay the in situ gel 
formation based on the concentration-dependent properties of the ECM, we also describe 
an innovative neurosurgical approach for its delivery in the liquid phase into the stroke 
cavity using MRI guidance. 
 
2.2 MATERIALS AND METHODS 
 
2.2.1  Extracellular matrix (ECM) based hydrogel 
 
ECM hydrogel was produced by isolating the basement membrane and tunica propria of 
porcine urinary bladder (Tissue Source, Inc., Lafayette, IN) by mechanical delamination 
[137]. Decellularization was performed by immersing the isolated layers of the bladder in 
0.1% peracetic acid in ethanol with agitation (4% v/v; 120 min; 300 rpm). A series of PBS 
and deionized water rinses removed cellular debris [137]. Decellularization was confirmed 
using Hematoxylin & Eosin, 4’,6-diamidino-2-phenylindole (DAPI) staining, agarose gel 
electrophoresis, and quantification of remnant DNA [142]. ECM was then lyophilized, 
comminuted, and solubilized with pepsin (1 mg/mL) in 0.01 N HCl. pH neutralization was 
achieved by adding 0.1 N NaOH. Approximately 70% of the ECM material is collagen 
[95], but other prominent ECM proteins, such as fibronectin, decorin, laminin subunit γ1 
are also present [143]. A variety of growth factors are also retained within the ECM 
preparation, including transforming growth factor-β, vascular endothelial growth factor-A, 
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basic fibroblast growth factor, and nerve growth factor [91], all of which are known to 
influence neuronal and endothelial cells. In addition, matrix-bound nanovesicles (MBV) 
enriched in miRNA and other signaling molecules are present within the ECM preparation 
[144]. Dilution to a desired concentration (3, 4 and 8 mg/mL) was attained by mixture with  
the appropriate volume of PBS [137]. Gelation of this preparation is concentration, pH 
and temperature-dependent. Concentrations <3 mg/mL do not readily form a hydrogel on 
the bench.  
 
2.2.2 ECM hydrogel rheology 
 
All rheological data was collected using a rheometer (AR2000, TA instruments, New 
Castle, DE) fitted with 40mm parallel plate geometry, as previously described [95, 137, 
145]. Temperature was controlled within 0.1°C using a Peltier plate. The pre-gel at either 
4 or 8 mg/mL was loaded onto the parallel plate rheometer at 10°C; a temperature 
substantially below which is required for ECM gelation readily occurs. Sample 
evaporation was minimized using mineral oil to seal the edges of the sample-plate 
interface.  
A series of rheological tests were conducted in sequence for each sample. A creep 
test was performed to measure the steady shear viscosity of the pre-gel by applying a 
constant shear stress of 1 Pa. An oscillatory time sweep was performed to measure the 
gelation kinetics of the forming ECM hydrogel by rapidly raising the temperature to 37°C 
(a temperature at which ECM gelation occurs) and applying a small 0.5% oscillatory strain 
at a frequency of 1 rad/s. After 40-60 minutes after which the gelation was deemed 
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complete, an oscillatory frequency sweep was performed to measure the complex 
viscosity (|n*|) over a frequency range (0.1 rad/s – 100 rad/s) by applying 0.5% oscillatory 
strain. Samples were evaluated in triplicate. A two-tailed Student’s t-test was performed 
to determine whether differences existed between the 4 and 8 mg/mL ECM sample 
means with the p-value set at 0.05 using SPSS Statistical Analysis Software (SPSS, IBM, 
Chicago, IL, USA). 
 
2.2.3 Middle cerebral artery occlusion (MCAO) 
 
All animal procedures complied with the US Animals Welfare Act (2010) and were 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee 
(IACUC). Sprague-Dawley rats (male, 260±15g, Taconic Labs, USA) were maintained on 
a 12-hour light/dark schedule, with food and water available ad libitum. For transient 
intraluminal right middle cerebral artery (MCA) occlusion, a rat model of stroke, a 5-0 
silicone rubber-coated monofilament (diameter 0.12 mm, length 30 mm, tip coating at 
0.35 mm for 5-6 mm, Doccol, USA) was advanced to the ostium of the MCA in the circle 
of Willis, while the animal was under isoflurane anesthesia (4% induction, 1% 
maintenance in 30% O2). The Middle cerebral artery was occluded for approximately 70 
minutes prior to reperfusion by retracting the filament to the common carotid bifurcation, 
producing an occlusion similar to the scenario in 2/3 of all cases of human ischemic 
stroke. After recovery from anesthesia, animals were assessed for forelimb flexion and 
contralateral circling. Buprenorphine (0.05 mg/kg) was administered to the animals twice 
daily for 3 days for pain relief. Daily post-operative care and neurological assessment 
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were performed until they recovered pre-operative weight [146, 147]. Animals not 
exhibiting signs of MCA damage or who failed to recover weight were excluded from the 
study.  
 
2.2.4 Magnetic resonance imaging (MRI) and infarct volume calculation 
 
Acquisition. To assess the presence, location and volume of tissue loss, MCAo rats were 
anesthetized with isoflurane (4% induction, 1% maintenance in 30% O2) and scanned 
using a T2-weighted spin-echo MRI sequence (TR = 6000 ms, TE = 8 ms, 8 Averages, 
FOV 30x30 mm, 128x128 matrix, 42 slices at 0.5 mm thickness) on a horizontal bore 9.4 
T Varian scanner 10 days post-infarction [114, 140].  
 
Lesion volume and intensity measurements. Stroke damage was defined as tissue 
with a hyperintense signal on T2-weighted images that were thresholded at 1 standard 
deviation above the mean of a rectangular region of interest (ROI) in the contralateral 
hemisphere, encompassing striatum, corpus callosum and neocortex [132, 148].  
 
2.2.5 Simultaneous extracellular fluid drainage and intracerebral ECM injection 
in stroke brains 
 
Injection of biomaterials into the lesion cavity has mainly been achieved by administering 
a high concentration of injectate that is then diluted by the extracellular fluid (ECF) present 
within the cavity. Solubilized extracellular matrix (ECM) and other materials are 
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dependent on a certain concentration to form a hydrogel in situ, otherwise the material 
will merely diffuse into the tissue parenchyma, rather than being retained within the cavity 
(Figure 2.1.A). Merely increasing the volume of injection is problematic, as this will lead 
to an increase in intracerebral pressure (ICP), compromising the remaining tissue. There 
is further a risk of biomaterial escaping the lesion cavity and, for instance, occluding 
ventricular space preventing normal flow of cerebrospinal fluid (Figure 2.1.B). In the brain, 
the trajectory of injection also needs to avoid damage to major anatomical structures and 
placement needs to be accurate to avoid damage to host tissue (Figure 2.1.C).  
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Figure 2.1. Considerations for the injection of biomaterials into a stroke cavity. 
A. Injection of an insufficient quantity or local concentration of an ECM preparation leads to a poor 
gelation within the cavity and hence does not afford a complete and homogenous coverage (2 
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weeks post-MCAo, 24 hours post-injection). Although particles of ECM that formed accumulate 
at the border or remnants of tissue (i), vast areas of host tissue and the cavity do not show any 
accumulation of ECM material (ii) indicating that concentration and volume of material is important 
to ensure proper coverage of the cavity. B. Trajectory for delivery through a needle requires 
careful planning based on in vivo non-invasive imaging. A trajectory for biomaterial delivery needs 
to avoid ventricular space, as it can lead to a puncture of the ventricular wall (yellow arrow) and 
the subsequent leakage of material into the ventricle. Such intraventricular leakage can lead to a 
decrease in biomaterial concentration in the cavity and an obstruction of cerebrospinal fluid 
movement through the ventricle with potential damage the choroid plexus. C. However, position 
of the injection tract avoiding the ventricle can damage critical neuroanatomical structures, such 
as the hippocampus, and lead to significant tissue tearing and backflow of biomaterial (i, red 
arrows). Placement of the cannula at the edge of the cavity can further damage already 
compromised tissue (white *), although it can deliver ECM material to the cavity. Nevertheless, 
an uneven distribution and heterogeneous concentration within the cavity (black *) can ensue with 
areas void of ECM containing extracellular fluid that has not been displaced (ii, white arrow). 
These examples indicate the need for appropriate neurosurgical planning of biomaterial delivery 
to ensure a homogenous and complete distribution of ECM throughout the stroke cavity. 
 
 Intracerebral delivery of biomaterials can either be achieved by dilution of the material 
in the extracellular fluid available in the tissue cavity or this fluid can be drained during 
injection and a complete replacement of the milieu can be achieved (Figure 2.2.A). To 
define 3-dimensional coordinates for stereotactic injection of biomaterials and drainage 
of extracellular fluid, MR images were compared to the rat brain atlas (Figure 2.2.B). 
 Fourteen days post-stroke, rats underwent ECM implantation by placement into a 
stereotactic frame (Kopf, USA) under isoflurane anesthesia (4% induction, 1% 
maintenance in 30% O2). A vertical skin incision exposed Bregma on the skull and 
provided guidance for the location of two Burr holes for 1) the placement of a 250 μL 
Hamilton syringe with a 24 G beveled tip metal needle (Hamilton) filled with solubilized 
ECM in PBS, as well as 2) a hole for a drainage cannula (24 G) [114]. MR images of 
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lesion location and volumes were used to define stereotactic coordinates for 
needle/cannula placements. Needles/cannula were advanced into the stroke lesion 
cavity.  
 
 
 
 
Figure 2.2. Injection-drainage of biomaterials and extracellular fluid.  
A. Delivery of material to the lesion cavity can be achieved by injection of a concentrate to be 
diluted in the extracellular fluid (ECF). For this, typically an injection site at the center of mass of 
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the cavity is targeted (dotted green line = lesion cavity) [71, 140]. However, this delivery method 
can lead to variations in material concentration and especially in case of in situ gelation can 
produce areas void of biomaterial [89]. In contrast, the creation of a second burr hole allows 
displaced ECF to be drained while biomaterial is delivered. Placement of these ideally target the 
lower parts of the cavity for injection (to facilitate displacement) and crucially the drainage cannula 
needs to be positioned at the most dorsal part of the cavity to fully exploit the Archimedes principle 
of fluid displacement. B. For injection-drainage, T2-weighted MRI scans were used to calculate 
the volume of the lesion cavity (hyperintense area), as well as to define coordinates for injection 
and drainage (AP=Anterior-Posterior; ML=Medio-Lateral; DV=Dorso-Ventral). C. Based on these 
coordinates, Burr holes were drilled into the skull at the appropriate location in relation to Bregma. 
D. Injection of a liquid hydrogel composed of extracellular matrix (ECM) through a needle/syringe 
fixed to the stereotactic device allowed injection of a volume equal to the lesion volume. As the 
biomaterial was denser than extracellular fluid (ECF), its injection led to the displacement of ECF 
from the cavity through the drainage cannula. Gelation of the ECM occurred inside the cavity, 
allowing adaptation to the topology of the lesion. 
 
 
 
Lesion-equivalent volumes of solubilized ECM were injected into the ventral posterior 
region of the cavity to displace and drain the less dense necrotic debris from the stroke 
cavity. Injection of solubilized ECM (0, 3, 4, 8 mg/mL concentrations) was controlled using 
a frame mounted injection pump (World Precision Instruments, USA) at a constant speed 
of 10 μL/min until the total volume was delivered (4-24 min). The solubilized ECM formed 
a hydrogel in situ at 37 °C body temperature. Needle and cannula were left in place for 5 
minutes to allow material to dissipate and form a gel before the needles were slowly 
withdrawn from the brain. Burr holes were filled with bone wax (Fisher) prior to suturing. 
LX4 (Ferndale, containing 4% Lidocaine) was topically applied as an analgesic, and 
buprenorphine (0.05 mg/kg) was administered via intraperitoneal injection to provide 
sustained pain relief 
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2.2.6 Intracranial pressure measurement 
 
Injection of a large volume of biomaterial may cause an increase in intracranial pressure, 
which is known to have detrimental neurological effects. A comparison of the injection-
drainage technique with no drainage (both 8 mg/ml ECM) was hence undertaken by 
monitoring intracranial pressure (ICP) during injections. A pressure sensor (WPI) 
attached to a fiber optic measurement system (RJC Enterprises) was used to measure 
ICP in mmHg. Before starting, the probe was calibrated to atmospheric pressure (=0) and 
allowed to stabilize. For ICP measurement, a burr hole was made on the contralateral 
side at coordinates equivalent to the injection site. The probe was slowly inserted into the 
contralateral hemisphere to a depth of 5mm. Bone wax was then used to seal the burr 
hole around the probe. The injection/drainage needles were inserted and ICP was 
recorded at 15 s intervals throughout the injection. After injections were completed, the 
needles were left in place for 5min with continued ICP measurement.  
 
2.2.7 Histological assessment 
 
2.2.7.1 Perfusion and immunohistochemistry. Perfusion-fixation of tissue. To 
determine the in-situ distribution of the ECM hydrogel and cell infiltration within the 
hydrogel, rats were transcardially perfused at 1, 14 or 90 days post-implantation with 
0.9% saline followed by 4% paraformaldehyde (in 0.2 M PBS) to fix brain tissue prior to 
its removal from the skull. Brains were post-fixed in 4% paraformaldehyde for 24 hours 
prior to being cryopreserved in 30% sucrose with sodium azide (Sigma) at 4 °C. Histologic 
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sections (50 μm thickness) were prepared on a cryostat (Leica) maintained at – 25 C and 
placed directly onto microscopic slides to preserve tissue morphology and deformations.  
 
Immunohistochemistry. Brain sections were washed 3x5 min with 0.01 M PBS, followed 
by 1 hr permeabilization in PBS + 0.1% Triton X-100 (Sigma) at room temperature (21 
°C). Primary antibodies (Table 1) were applied, diluted in PBS + 0.05% Triton X-100, and 
incubated at 4 °C overnight. After rinsing off the primary antibodies (3x5 min PBS), 
appropriate secondary AlexaFluor 488, 555, or 660 antibodies (1:500; Life Technologies) 
were applied for 1 hour at room temperature followed by 3x5 min washes with PBS. 
Finally, sections were coverslipped with Vectashield for fluorescence containing Hoechst 
33342 (1 μg/mL, Sigma) and stored at 4 °C prior to imaging. Visualization of antibodies 
was performed with a fluorescence microscope (Axioimager M2, Zeiss) interfaced with a 
monochrome camera driven by Stereo Investigator image capture software (MBF 
Bioscience) using a motorized stage [114]. 
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Table 1. List of antibodies used for immunohistochemistry 
 
 
Antibody Concentration Company Cat. Ref. Clone 
Collagen-I 1:250 Abcam Ab34710 Collagen I aa 1-1464 
Iba-1 1:300 Abcam Ab5076 Iba1 aa 135-147 
GFAP 1:3000 Sigma G3893 G-A-5 
DCX 1:150 Abcam Ab153668 
CAA0661`7.1 and 
AAT58219.1 
CNPase 1:200 Abcam Ab6319 11-5B 
Fox3 1:500 Abcam Ab104224 1B7 
RECA-1 1:100 Abcam Ab9774 RECA-1 
CD86 1:200 Abcam Ab53004 EP1159Y 
CD206 1:200 Santa Cruz sc-34577 C-20 
 
 
 
2.2.7.2 Cell invasion – quantification. To quantify the number and distribution of 
cells infiltrating the ECM hydrogel, a semi-automated script (Lux64R) was used. Collagen 
I was used to delineate the border between host and biomaterial [112, 114, 149, 150] to 
determine the number and phenotype of cells invading the injected ECM. Whole graft 
images were acquired at 20x magnification with brain sections stained for Hoechst (to 
identify cell nuclei) and Collagen I (to mask and delineate the host-ECM boundary to 
quantify cell invasion). A colorimetric scale ranging from blue, for cells most proximal, to 
red, indicating cells most distant from the adjacent host tissue, was used to create a color 
map of cell invasion (Figure 2.3.C), while providing measurements of distance of 
individual invading cells (Figure 2.3.D).  
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Figure 2.3. Measuring cell infiltration.  
Overview of the cell infiltration quantification approach using Lux64R and DAPI stained 
fluorescent images. Using collagen I to stain the ECM biomaterial, the distinction between the 
lesion boundary and the ECM hydrogel interface is identified (A). Using Lux64R, the lesion 
boundary is then drawn and defined (B). The cells inside the boundary are then labeled and 
counted (C). A closer view in a region of interest shows that each cell is accurately identified and 
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labeled, while measuring its distance traveled from the previously defined lesion boundary (D). 
Manual and automated cell counts using Lux64R shows cells being correctly identified for 
quantification of cell invasion (E).  
 
 
The tangent distance of infiltration from the cavity boundary was measured for each cell 
using the cavity’s center of mass as reference. To reveal a relationship between ECM 
hydrogel concentration and cell invasion, 25 μm concentric bins were used to compare 
the number and distance of invading cells in relation to center of mass for each defect. It 
is important to note that individual shapes of cavities were different, some more irregular 
than others. In some cases, the center of mass is hence not the most accurate point of 
reference towards which the cells infiltrated, but was still the most pertinent to afford a 
grouping of cell invasion and provide a comparison. Validation of this approach was 
shown by the high correlation (>95%) between manual counting and distance 
measurements against the semi-automated approach (Figure 2.3.E). All tissue sections 
containing ECM hydrogel was quantified (Figure 2.4.A).  
 
2.2.7.3 Cell infiltration – cell phenotype analysis. To determine the phenotypes 
of cells invading the injected ECM, collagen I was used to delineate the border between 
host and biomaterial. Animals injected with concentrations >3 mg/mL resulted in a 
gelation and retention within the cavity. Due to differences in the extent of material present 
within a given defect, the number of FOVs counted ranged from 5 to 15 images to cover 
the material present within the cavity (Figure 2.4.B). Where ECM hydrogel covered the 
whole defect (i.e. concentrations of ≥3 mg/mL), FOVs were equally spaced throughout 
the material within a section and counted across all anterior-posterior slices. Images were 
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acquired at 20x magnification to determine the total number of cells (i.e. Hoechst+) within 
the ECM material and to determine the phenotype of cells [112, 149]. Five to eight images 
were acquired at equally-spaced distances throughout the material within a section and 
counted across all anterior-posterior slices containing ECM hydrogel. Phenotypic markers 
for neural progenitor cells (doublecortin, DCX), neurons (Fox3), astrocytes (glial fibrillary 
acid protein, GFAP), oligodendrocytes (2’,3’-cyclic-nucleotide 3’-phospodiesterase, 
CNPase), endothelial cells (rat endothelial cell antigen 1, RECA-1), microglia (ionized 
calcium-binding adapter molecule 1, Iba-1), as well as macrophage activation (CD206 for 
the M2 phenotype, CD86 for M1 phenotype) were used for analysis. 
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Figure 2.4. Concentration-dependent retention of ECM hydrogel in the lesion cavity. 
(A) Whole hemisphere images show the gelation and retention properties of the injected ECM 
hydrogel at different concentrations. Since the ECM contains high amounts of collagen I 
compared to the host brain tissue, it can be used for histological visualization of the injected 
material. A vehicle injection (0 mg/mL) of PBS indicated no collagen I detection inside the lesion 
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cavity. At 1 and 2 mg/mL, the ECM material mostly permeated into the brain tissue, whereas at 3 
mg/mL, hydrogel formed and was retained in the cavity with some permeation into the host tissue. 
At concentrations greater than 3 mg/mL, the ECM material shows gelation with little to no signs 
of permeation into the peri-infarct tissue, retaining both its morphology, as well as its shape. In 
order to accurately characterize the invading cells, multiple images were acquired inside the ECM 
material (as shown by the yellow boxes) (B). Once the images were acquired, manual counts of 
DAPI indicated the total number of cells in the field of view and co-staining with another marker 
(Iba-1 in this case) would result in characterization of the invading cells (as shown with white 
arrows) (C).  
 
 
 
Although many mononuclear macrophages share histological markers, Iba-1 is a 
commonly used marker for brain microglia [151].  The phenotype of invading cells was 
determined by counting the number of cells positive for a given marker within a FOV 
(Figure 2C). Phenotypes were expressed as % of total cells present to account for 
differences in the number of invading cells.  
 
2.2.8 Statistical analysis 
 
Statistical analyses were performed in SPSS 17 for Mac (IBM) with significance set at 
p<.05. Specifically, a two-way ANOVA was used to compare cell invasion and the number 
of cells within each annulus, using a Bonferroni post-hoc test to validate significant 
comparisons. A one-way ANOVA with Bonferroni post-hoc testing was used to contrast 
the effects of ECM concentration on different cell phenotypes, as well as a comparison 
between lesion volumes and total cell invasion. The different ECM concentrations and the 
variance in MRI lesion volumes complied with a factorial design (also known as Design 
of Experiment, DoE) that is built on the foundation of analysis of variance by using 
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independent variables that allowed us to systematical determine their effect on measured 
data (i.e. the dependent variable), such as cell invasion, to generate contour plots (Minitab 
8). These contour plots provided an overview of the entire experimental space of these 
variables allowing us to determine potential effects of intermediary concentrations or 
lesion volumes on the dependent variables. Graphs were drawn in Prism 6 (GraphPad) 
with data point representing the mean and bars reflecting the standard deviation. 
 
2.3 RESULTS 
 
2.3.1  Pre-gel viscosity and hydrogel stiffness 
 
The rheological characteristics of the ECM hydrogel were determined before (10 °C) and 
after (37 °C) gelation was induced using a parallel plate rheometer. Before gelation, the 
viscosity of the 4 mg/mL ECM pre-gel was significantly (p=0.001) lower (0.084±0.008 
Pa*s) than the 8 mg/mL ECM pre-gel (0.443±0.062 Pa*s) (Figure 2.5.A). The storage 
modulus G’ and loss modulus G’’ of the 4 and 8 mg/mL ECM gels changed sigmoidally 
over time after temperature was raised from 10°C to 37°C (Figure 2.5.B). At long times, 
the storage modulus at both concentrations far exceeded the loss modulus indicating 
substantially solid-like gels. The maximum storage modulus of the 8 mg/mL hydrogel 
(460.4±62.5 Pa) was significantly (p≤0.001) higher than the 4 mg/mL hydrogel (76.6±10.4 
Pa), as was the maximum loss modulus (66.4±9.3Pa, 11.0±1.5 Pa, p=0.008) (Figure 
2.5.C). Half the maximum storage modulus (“50% gelation”) marks the sharp increase in 
the storage modulus curve, and time to 50% gelation did not differ significantly between 
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the 4mg/mL (3.2±0.3 minutes) and 8mg/mL (3.0±0.5 minutes) groups (Figure 2.5.D). The 
fast gelation kinetics of the ECM hydrogel was further shown in that 15% of the final 
storage modulus was reached within 3-5 minutes for both gels (4 mg/mL in 3.9±0.5 
minutes and 8 mg/mL in 4.4±0.5 minutes), and where final storage modulus is defined as 
the average storage modulus over the last 10 minutes of the time sweep test. The 
frequency sweep of the ECM hydrogel is shown for 4 mg/mL (Figure 2.5.E) and 8 mg/mL 
(Figure 2.5.F). Both moduli are only weakly dependent on frequency, and therefore the 
complex viscosity varies almost inversely with frequency, further confirming the 
predominantly solid-like nature of the gel.  
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Figure 2.5. Rheological characterization of ECM hydrogels.  
A. Viscosity of the ECM pre-gel at 10 °C was measured by applying a constant shear stress of 1 
Pa. B. Representative curves of the ECM hydrogel gelation kinetics show the storage and loss 
modulus increase sigmoidally over time. Temperature is rapidly raised from 10 °C to 37 °C, and 
a small 0.5% oscillatory strain at a frequency of 1 rad/s was applied. C. Maximum storage modulus 
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and loss modulus of the ECM hydrogel after gelation was complete at 37°C. D. Gelation time of 
the ECM hydrogels to 50% gelation, equal to 50% the maximum storage modulus. E-F. 
Representative graph of the storage modulus, loss modulus, and complex viscosity of the ECM 
hydrogels at 4mg/mL (E) and 8 mg/mL (F) plotted over angular frequencies on a log-log scale, 
measured at 37 °C by applying a small 0.5% oscillatory strain. *p≤0.01 **p≤0.001 (independent 
samples 2-sided t-test)  
 
 
Indeed, the storage and loss modulus of the 4mg/mL hydrogel was significantly lower 
than the 8 mg/mL hydrogel (p≤0.001) for the angular frequency range tested (0.1 -100 
rad/s). Both 4 and 8 mg/ml hence produce stable hydrogels in the same amount of time, 
but differ in their pre-gel viscosity, as well as their substrate stiffness. 
 
2.3.2  Injection-drainage affords efficient delivery of ECM hydrogel 
 
The delivery of 8mg/ml hydrogel to the stroke cavity using a single injection point (i.e. no 
drainage) resulted in a 67% increase in intracranial pressure (ICP) with evidence of some 
material escaping the cranial vault past the needle used for injection. Using this no-
drainage approach, it is hence difficult to control the exact concentration or volume of 
material being present within the cavity, as the injectate mixes with the fluid present in the 
cyst and it is not possible to control or monitor how much material seeps out. Injection 
with simultaneous drainage is hence proposed here as a superior method, where ICP 
only changed by 10% with excessive fluid from the cavity being displaced by the more 
dense injected biomaterial. Indeed, in this case, all excess fluid was drained extracranially 
through the additional cannula, rather than an uncontrolled escape along the injection 
needle. Importantly, in the injection-drainage condition, there was a negative correlation 
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(r=-0.98, p<.05) between lesion volume and change in ICP, i.e. the larger the volume of 
the lesion, the less change in ICP, due to a greater space for accommodating the 
hydrogel. The opposite trend was evident in the no drainage condition (r=0.97, p=0.07) 
with larger volume of injections leading to greater change in ICP. Although post-mortem 
(24hrs) there was no significant midline shift (2-5%) in either condition, drainage resulted 
in 10% less hemispheric volume shift compared to no drainage. The increase in ICP, as 
well as hemispheric volume shift, hence indicates that drainage reduces potentially 
adverse effects of intracerebral injections on brain tissue.   
 
2.3.3 Histological detection of ECM hydrogel 
 
A histologic visualization of the injected ECM material was used to investigate and 
validate the distribution and retention of material within the lesion cavity. As porcine 
(UBM-)ECM hydrogels contain a higher concentration of collagen I compared to brain 
tissue, a pig-specific mouse anti-collagen I antibody afforded the selective identification 
of the implanted hydrogel (Figure 2.6.A). In contrast, a non-specific rabbit anti-collagen I 
antibody detected both rat and pig collagen I. As ECM injection dramatically increased 
collagen I concentration, the exposure time used for image acquisition of the non-specific 
antibody can still selectively visualize the implanted materials (Figure 2.6.B). The non-
specific rabbit anti-collagen I reliably stained host collagen I, as indicated by its 
localization in the basement membrane of host blood vessels and its peri-infarct 
localization in MCAo+vehicle animals. ECM also contains a variety of other molecules 
that putatively could serve for detection purposes inside the brain (Figure 2.7). ECM 
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contains notably high levels of collagen IV, which is readily detecting the injected material, 
but is also highly expressed in glial scar tissue in the peri-infarct region. The same applies 
to chondroitin sulfate, which is extensively present in the damaged hemisphere. Laminin 
also detects the injected material, but detection is not sufficiently specific as peri-infarct 
regions undergoing angiogenesis also express high levels. Although sensitivity is good 
for these markers, selectivity of ECM hydrogel visualization is poor. In contrast, 
Hyaluronic Acid contrasts sufficiently with host background and hence affords a specific 
macroscopic detection of the injected material akin to collagen I.  
 
 
 
 45 
 
 
 
Figure 2.6. Detection of ECM hydrogel in the stroke cavity. 
A. The pig-specific collagen I antibody detects only the ECM hydrogel implanted into the stroke 
cavity, although there is some evidence of background autofluorescence and staining in damaged 
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tissue. The non-specific collagen I antibody detects the implanted hydrogel with a very intense 
staining, but also stains host brain blood vessels as well as damaged tissue. The relatively high 
concentration of collagen I in the ECM hydrogel compared to the host brain is evidenced by the 
short exposure times required to acquire images. The core of the implant is detected equally by 
the pig-specific and the non-specific antibody, but there are difference in their staining pattern (i). 
Collagen I staining clearly allows a demarcation of the implant-host interface (ii). Only the non-
specific collagen I antibody detects rat collagen present in the basement membrane of host blood 
vessels in intact tissue (iii). B. In a stroke brain injected with vehicle, there was no detection of 
pig-specific collagen I (only background fluorescence in the peri-infarct area). At the exposure 
time used for the ECM hydrogel (17ms) there was no detection of any fluorescence of the non-
specific antibody, but at a longer exposure time (200ms), collagen I staining around the infarct 
cavity was evident. The pig-specific antibody can therefore be used to distinguish porcine-derived 
ECM implants versus rat host tissue with specific staining, but the ECM hydrogel can also be 
visualized macroscopically using the non-specific antibody by adjusting the exposure time for 
image acquisition. 
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Figure 2.7. Detection of ECM hydrogel using ECM markers. 
ECM contains a variety of molecules that can be detected using immunohistochemistry. The 
higher concentrations of molecules compared to brain tissue afford its detection using different 
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antibodies against collagen IV, Hyaluronic acid, laminin and chondroitin sulfate. It is evident here 
that ECM molecules associated with glial scarring (collagen IV, chondroitin sulfate) and 
angiogenesis (laminin) are also highly expressed in the peri-infarct area and hence not ideal for 
a selective detection of ECM hydrogel. However, hyaluronic acid also emerged as a potential 
alternative marker to collagen I, both of which are abundantly present with the (UBM-)ECM 
preparations compared to brain tissue. 
 
 
2.3.4 Reliability of ECM hydrogel delivery 
 
Using the injection-drainage approach, the delivery of ECM hydrogel (8mg/ml) to the 
stroke-induced lesion cavity successfully resulted in an extensive distribution of the 
biomaterial (as indicated by collagen I staining) throughout the lesion, while conforming 
to the topology of tissue loss (Figure 2.8.A). There was a good correspondence between 
pre-implantation MRI and post-mortem immunohistochemistry (Figure 2.8.B), indicating 
that the neurosurgical planning of the delivery location, as well as the volume were 
appropriate.  
 The formation of a hydrogel within the cavity at 8mg/ml further indicates that an 
appropriate concentration of injectate was delivered throughout the lesion. Gelation 
typically resulted in the retention of ECM within the area of tissue loss, rather than 
diffusion into the adjacent host brain tissue (Figure 2.9.A).  
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Figure 2.8. Correspondence between pre-implant MRI and post-mortem distribution of 
ECM hydrogel in the stroke cavity. 
A. Coverage of the lesion using this approach is demonstrated by immunohistochemistry 24 hours 
after injection.  The lesion cavity is defined by glial scarring (GFAP), whereas the ECM hydrogel 
which contains high levels of collagen I can be detected using a collagen I antibody. It is 
remarkable that even within 24 hours there is cell invasion into the material from the host (DAPI). 
B. An overlay of the fluorescent histology images with the pre-implantation MRI indicates that 
indeed a good coverage of the cavity has been achieved. Nevertheless, it is noteworthy that the 
material did not completely cover the hyperintense area on the MRI, as tissue remnants were 
present in this region (blue arrows). This subtle difference is not evident based on the histologic 
assessment alone and indicates that further improvements in non-invasive imaging are required 
to better define microenvironments present within the infarct territory. However, if there is an 
overestimation of injection volume, the drainage of superfluous material will prevent a buildup in 
the cavity.  
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Figure 2.9. Anterior-posterior images covering the tissue cavity caused by middle cerebral 
artery occlusion. A. The ECM hydrogel (8mg/ml), as detected by collagen I staining (green), 
is fairly equally distributed throughout the cavity, defined by the lack of cells (DAPI 
staining in blue). Glial scarring (glial fibrillary acid protein in red) around the lesion cavity 
is also evident. The yellow dashed line indicates the point of injection, whereas the red 
dashed line depicts the position of the drainage cannula. In some areas, especially 
anteriorly (i), some diffusion of ECM hydrogel into the host brain was evident (yellow *), 
whereas in in other areas (red *), small “particulates” of ECM were present within non- 
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gelled areas of the cavity. A lack of hydrogel in some edge regions (white *) of the host-
biomaterial interface was also evident indicating that some further optimization (e.g. speed 
of injection) of biomaterial distribution within the lesion can further improve coverage (ii). 
B. The described approach produces fairly consistent coverage of the cavity, as can be 
seen in a further 4 examples. C. Still, further challenges for intracerebral delivery are 
apparent. Notably, the fragile peri-infarct tissue can be impacted by large volume 
injections of a high concentration of material (white arrows), whereas a denser material 
could also create a “clump” of material, leaving voids between host and material (red 
arrows), while a glial scar is forming (yellow arrows). By focusing on the tissue cavity, the 
peri-infarct tissue that is severely damaged (white *), but not lost, is not receiving 
biomaterial (red *). These aspects further highlight the importance of determining 
appropriate concentrations and speed of delivery to potentially further improve the 
delivery of biomaterials to the damaged brain. 
 
 
 
Nevertheless, in small areas at the edge of the cavity, ECM material could be found in 
the host brain tissue where it gelled (Figure 2.9.A i). There was no evidence of additional 
glial scarring in these regions. It is also worth noting that small hydrogel accumulations 
were evident in a few edge regions, where the gel did not completely replace the liquefied 
necrotic debris. Although the hydrogel conformed to the lesion topology, it is important to 
note that the 8mg/ml ECM hydrogel was mostly distinct among the different ECM 
concentrations tested and did not invade adjacent brain tissue, with glial scarring being 
evident around most of the cavity. A small “bubble” without ECM hydrogel can occur 
(Figure 2.9.A ii) if the drainage point is not at the most dorsal part of the cavity. However, 
this approach is very reproducible across different lesion sizes and topology (Figure 
2.9.B). Rheologic and turbidimetric characteristics of the biomaterial will also influence 
intracerebral distribution. For instance, a faster and stiffer polymerization in the cavity can 
displace small tissue fragments to the periphery of the cavity or provide a sharply defined 
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edge between ECM hydrogel and host tissue (Figure 2.9.C). Gelation properties defined 
by the concentration of the material therefore also define the interface with the host brain. 
 
2.3.5 Concentration-dependent retention of ECM in stroke cavity 
 
Using the injection-drainage method, it is possible to deliver a specific volume and 
concentration of ECM to the lesion cavity and determine the effect of these variables upon 
its distribution, interface with the host brain, as well as its retention within the cavity. 
Indeed, concentrations of <3mg/ml did not form a robust enough gel within the lesion 
cavity to afford retention, but rather showed diffusion of ECM into the adjacent host brain 
(Figure 2.10.A). Diffusion of ECM into the peri-infarct tissue results in a uniform 
extracellular distribution akin to tissue characteristics, such as striosomes, but is not 
associated with the basement membranes of blood vessels (Figure 2.10.B). It is likely 
that some injected ECM material remained within the cavity, but this could not be 
determined by histologic methods. At 2 mg/ml, some small ECM accumulations within the 
cavity were evident (range 3-26% coverage). At 3 mg/ml, diffusion into the host brain, as 
well as retention within the cavity, were evident (Figure 8C) with a more extensive 
coverage than the cavity (98-117% coverage). At concentrations >3mg/ml gelation and 
retention within the cavity occurred with little to no diffusion into the host brain (84-96%). 
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Figure 2.10. Concentration-dependent retention of ECM hydrogel in the lesion cavity. 
A. ECM hydrogel injection will only be retained within the lesion cavity if sufficient collagen I is 
present to afford gelation. Using the injection-drainage approach it is possible to inject accurate 
concentration of ECM into the cavity and determine retention the ECM hydrogel. A vehicle 
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injection (0mg/ml) of PBS indicated no collagen I-dependent detection (33ms) of material inside 
the lesion cavity or the host brain. At 1 and 2mg/ml ECM material mostly dissipated into the host 
brain, whereas at 3 mg/ml, ECM hydrogel was formed and retained within the cavity with some 
material gelling in the peri-infarct tissue. Higher than 3mg/ml concentration resulted in a gelation 
within the lesion cavity and little to no ECM hydrogel diffusion into adjacent host tissue. B. At 
1mg/ml ECM injection, the injected material was only visible in the peri-infarct area. The pattern 
of distribution suggests diffusion from the cavity. However, it is likely that some material was still 
present within the cavity and was lost upon sectioning due to a lack of structure (i.e. no gelation). 
C. At 3mg/ml, gelation within the cavity occurred and this material was retained during sectioning, 
but it is also evident that some injected ECM material diffused into the damaged peri-infarct tissue 
potentially through the glial scar. Based on signal intensity it is also possible to see a clear 
difference in collagen I content between 1 and 3mg/ml. It is therefore important to note that not 
only is there a difference in “inductive” material being delivered, but the structural (i.e. gelation) 
properties of the ECM are also concentration dependent. 
 
 
 
2.3.6   Host tissue-ECM interface 
 
Injection of ECM precursor gel into the lesion cavity resulted in gelation of material at 
concentrations >3 mg/mL. This in situ gelation resulted in the creation of an interface 
between the ECM hydrogel and the host tissue (Figure 2.11). However, stroke created a 
complex array of microenvironments of which cavitation is the most severe form of 
damage. Adjacent to the cavity, tissues void of neuronal cells and undergoing astrocytosis 
can be found. In some cases, an ongoing macrophage response can be seen that clears 
cellular debris and eventually removes extracellular matrix (i.e. the process of tissue 
cavitation). At concentrations >3 mg/mL a clear interface between the hydrogel and host 
tissue was evident and peri-cavity cortex was often severely damaged. ECM gel 
precursor in some instances permeated into these areas.  
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Figure 2.11. Interface between ECM hydrogel and host tissue. 
Concentrations >3 mg/mL resulted in an in situ gelation and retention within the lesion cavity 
producing an interface where the ECM hydrogel contacts with the host brain tissue. It is important 
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to note two typical microenvironments within which ECM material can be found in these stroke-
damaged brains: 1. the lesion cavity (yellow boxes); 2. severely damaged tissue that is not part 
of the lesion core (white boxes). Higher concentrations of 4 and 8 mg/mL typically completely 
filled the cavity, but also displaced some damaged tissue. The 3 mg/mL also permeated into 
damaged tissue directly adjacent to the cavity. In areas of cortical tissue damage, some 
permeation of ECM could be seen. These areas were mostly void of neurons, but significant 
amounts of microglia were present directly interacting with some of the permeating ECM. 
 
 
 
Microglia, macrophages and astrocytes can be found in large abundance around 
the lesion cavity and in areas of tissue damage. With 0 mg/mL, a high cellular density of 
microglia and astrocytes can be seen around the lesion cavity forming a scar, i.e. glia 
limitans, that defines the boundary between tissue and cavity (Figure 2.12). This interface 
is somewhat preserved at the lower concentration of ECM precursor gel (1 & 2 mg/mL), 
with some ECM forming small patches of gel at the tissue boundary agglomerating around 
tissue remnants within the cavity. Small numbers of microglia and astrocytes can be found 
within this injected ECM. At higher concentrations, where gelation of ECM occurred within 
the cavity, a more distinct interface with host tissue can be identified. A significant 
infiltration of host cells was observed, especially in areas where cavitation was small.  
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Figure 2.12. Gelation and permeation of the ECM material at the host tissue interface. 
At 0 mg/mL (PBS injection), no exogenous collagen I is detected inside the lesion cavity (as 
delineated by Iba-1 staining for microglia and GFAP for astrocytes). At 1 and 2 mg/mL, injected 
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ECM material shows poor retention inside the lesion cavity, as significant diffusion of the ECM 
material into the peri-infarct area can be seen. At 3 mg/mL, the ECM material shows hydrogel 
formation and retention inside the cavity, with some diffusion into the surrounding tissue. At 4 and 
8 mg/mL, a clear boundary can be seen at the interface between the host tissue and the ECM 
hydrogel. Concentrations >3 mg/mL resulted in complete gelation and retention of the hydrogel 
with minimal to no diffusion into the host tissue. The predominant cell phenotypes surrounding all 
cavities consist of microglia and astrocytes with evidence of cell invasion of these host cells into 
the injected material at all concentrations.  
 
 
 
At concentrations of 4 and 8 mg/mL, a well-defined delineation between ECM hydrogel 
and tissue can be observed, but host cell invasion was also evident. 
 
2.3.7   ECM hydrogel cell infiltration 
 
Both structural support and inductive cues are necessary for cells to migrate into the ECM 
biomaterial. Where there is a close interface between ECM hydrogel and the host tissue 
(Figure 2.13.A), cells infiltrated the material and migrated inward. Host cell infiltration was 
also observed across small gaps between the ECM hydrogel and host tissue (Figure 
2.13.B). However, these gaps are potentially artifacts of a differential fixation of tissue 
and hydrogel. Cell infiltration often followed a chain-like path that trailed channels within 
the collagen I staining found in the ECM hydrogel.  
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Figure 2.13. Patterns of cell invasion. 
A microscopic view of the lesion interface with the ECM hydrogel (collagen I+ area) indicates a 
higher density of DAPI+ cells surrounding the biomaterial with evidence of a concentric invasion 
of host cells (yellow arrows) into the acellular material. The predominant cellular phenotypes 
surrounding the ECM hydrogel, forming the glia limitans, are astrocytes (GFAP+ cells) and 
microglia (Iba-1+ cells) The injection-drainage approach produces a consistent coverage of the 
cavity (A). A magnified view of the interface between the host tissue and the ECM hydrogel 
reveals invading microglia migrating from the host tissue to the hydrogel (green arrow). A collagen 
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I negative staining area in some edge regions of the host-biomaterial interface was also evident 
(blue arrows), but this did not affect the invasion of some cells, although a close interface between 
host and hydrogel dramatically facilitated cell invasion (brown arrow) (B). In order for the cells to 
migrate into the damaged tissue, a structural support for the attachment and survival of the cells 
is favorable. Most commonly microglia are the cells that infiltrated the furthest into the hydrogel, 
whereas astrocytes were mostly present closer to the host tissue (C). Indeed, a guided chain-like 
migration along collagen I negative channels can be seen into the hydrogel, potentially indicating 
that hydrogel ultrastructure is also a contributing factor for initial cell invasion (D). 
 
 
Commonly the cells with the deepest infiltration distance were microglia (Iba-1+), with 
astrocytes (GFAP+) being found closer to host tissue (Figure 2.13.C).  
The availability of these cells at the tissue interface (i.e., the glial scar) may position these 
cells in a prime location for this acute (24 hrs) invasion. Infiltrating cells may form 
pathways along which other cells pursue their infiltration (Figure 2.13.D). It is unclear, 
however, if some cells remain in place or if all cells continue infiltration towards the center 
of mass (and beyond). 
 61 
 
 
 
Figure 2.14. Cell invasion – Colorimetric maps. 
Identification and labeling of cell invasion at different concentrations using Lux64R based on DAPI 
staining within a collagen I outline ROI. Using a colorimetric method ranging from light blue 
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(closest to the host boundary) to orange (furthest from host boundary), maps of cell invasion were 
created to highlight differences between ECM concentrations (A). These maps also allowed us to 
inspect the anterior-posterior invasion of cells within the ECM hydrogel. It was evident here that 
the smaller ECM hydrogel areas found at the poles of the cavity saw a more complete coverage 
of cell invasion compared to more central slices which occupied a large area (B). Invasion typically 
followed a concentric pattern that saw cells migrating to the center of mass of the injected ECM 
hydrogel, in some cases leading to very homogenous distribution of host cells through the material 
(red box). Nevertheless, important qualitative differences in cell invasion were also noted on these 
colorimetric maps. Cell invasion in some instance followed a very densely packed channel with 
blind spots within the material hardly seeing any invasion (C). In other cases, there was a no 
significant invasion (green arrow) in a very restricted region suggesting that potential host factors, 
such as scarring can influence invasion (D). Indeed, the varied pattern of invasion or the lack 
therefore indicates that technical factors, such as an air bubble (red arrow), as well as poor 
interface with host tissue (orange arrow) influence cell invasion, even though other areas of the 
gel are efficiently invaded (light green arrow) (E). The differential patterns of cell invasion into the 
same hydrogel hence strongly suggest that the host microenvironment surround the ECM material 
has a significant influence on cell invasion (F). Nevertheless even if there are blind spots within 
the hydrogel and areas of poor cell invasion at the host-gel interface, invading cells will find 
channels (yellow arrows) to move towards the center of mass (i) and are likely to continue their 
migration in the absence of encountering other cells (G). Scale bars are 5000 µm. 
 
 
 
 To illustrate the patterns of cell invasion, heat maps of individual nuclei and their 
distance of invasion were generated. It was evident here that lower concentrations, where 
no gelation and no significant retention of ECM material occurred, very few cells were 
present in the ECM material. Concentrations >3 mg/mL of ECM hydrogel resulted in large 
numbers of infiltrating cells (Figure 2.14.A). A comparison of anterior-posterior 
colorimetric maps indicated that cavity shape influenced cell invasion, with shorter 
distances between host tissue boundaries being more completely covered compared to 
greater distances, as found in the central slice of the cavity (Figure 2.14.B). Nevertheless, 
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this acute 24 hours infiltration pattern resulted in some cases with complete invasion of 
the material. A good interface between host and ECM material in itself is not the only 
determinant in the distance of infiltration. In some case, there was evidence of infiltration 
into the material, but patches within the ECM hydrogel were not uniformly infiltrated (“blind 
spots”), whereas other adjacent patches showed a strong infiltration (Figure 2.14.C). 
These “blind” patches were also evident where there was a good interface between host-
ECM (Figure 2.14.D). Other cases showed that the adjacent host tissue might not 
respond to the ECM (Figure 2.14.E & 2.14.F). In some cases, small channels of cells 
migrated towards the center of mass without there being an equal distribution of cells 
throughout the material (Figure 2.14.G). Preferential routes of colonization of the ECM 
are hence potentially important considerations in how host cells invade the material 
(Figure 2.14.G i). 
 To provide a quantitative comparison of cell invasion, the number of cells 
contained in concentric 25 µm from the host tissue edge to the center of mass of the ECM 
hydrogel were plotted to reveal total cell invasion for each concentration. The highest 
number of invading cells was found with 8 mg/mL (average of 366,280 cells), followed by 
a similar amount of cells at 4 mg/mL, with significantly fewer cells invading at 3 mg/mL 
(p<.05). There were very few cells invading the cavity in concentrations <3 mg/mL and 
none in the 0 mg/mL (as there was no identifiable ECM material present for invasion) 
(p<.001). The distance of invasion within 24 hours revealed cells invading the 8 mg/mL 
ECM hydrogel by >1500 µm of which >5500 cells were within the first 25 µm of ECM 
hydrogel (Figure 2.15.A). A cellular infiltration speed of 62.5 µm/hr can hence be 
calculated. The degree and distance of cells infiltrating at 3 mg/mL was markedly less 
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than at 4 or 8 mg/mL (p<.01). Indeed, one animal showed very little infiltration at 3 mg/mL, 
but another showed an infiltration equivalent to those at higher concentrations (Figure 
2.15.B).  
 
 
 
 
 
 
Figure 2.15. Cell invasion – Quantification. 
(A) Quantification of the cell infiltration into the infarct cavity afforded a comparison of all ECM 
concentration (mean±standard deviation) to determine how many cells invaded each 25 µm 
concentric circle from the center of the mass, as well as the total distance of invasion in relation 
to the ECM’s interface with host tissue. Mapping of individual animals revealed a spread of cell 
invasion reflecting difference in the interface between host and ECM hydrogel, as well as ECM 
concentration for 3 mg/mL (B), 4 mg/mL (C) and 8 mg/mL (D).  
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Also at 4 mg/mL, some variability in the degree and distance of cell infiltration was 
observed between different animals (Figure 2.15.C), further highlighting that factors 
beyond the concentration of the ECM and its gelation within the cavity influence cell 
invasion. The 8 mg/mL concentration performed the most consistently with all animals 
showing a good infiltration of cells (Figure 2.15.D), possibly reflecting a mass effect that 
this concentration exerts on host tissue, creating a more consistent and well defined 
interface. 
 
2.3.8   Lesion volume and ECM concentration influence cell invasion 
 
Although it is evident that concentration is a major determinant of cell invasion, lesion 
volume is also likely to be a major contributing variable. Indeed, all conditions, in which 
there was good retention of material within the lesion cavity (>3 mg/mL), showed a 
relationship between the size of defect and the number and distance of cells invading 
(r>0.8 for both). The larger the deficit (and hence the larger injected volume of ECM), the 
greater the number of cells that infiltrated the material and the greater the distance of 
infiltration. At lower concentrations, no relationship was evident, as insufficient material 
was available to warrant significant cell invasion. 
To determine how different concentrations of ECM influence cell invasion, while 
accounting for differences in lesion volume, a contour plot was created and showed a 
more complex relationship between these factors (Figure 2.16.A). Concentrations <5 
mg/mL, showed a poor invasion within 24 hours, apart for lesion volumes of 180-220 µL. 
A peak invasion of cells was observed with an 8 mg/mL concentration of ECM and a 
narrow lesion volume of 140-150 µL. Although total numbers of invading cells is an 
important indicator of inductive potential of ECM, larger lesions have more space for 
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greater numbers of cells to invade. Determination of cell density (i.e. invaded cells/µL 
volume) can mitigate this issue and provide a more accurate description of repopulation, 
but potentially can be higher in smaller lesions, as there is less space to fill (Figure 
2.16.B).  
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Figure 2.16. Contour plots. 
To determine an interaction between ECM concentration and lesion volume on the number of 
cells invading the ECM (A), cell density within the ECM material (B), as well as the distance of 
cell invasion (C), contour plots were generated to illustrate which combinations would be the most 
and least combinations.  
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Nevertheless, the overall interaction between ECM concentration and lesion volume was 
very similar between total cell invasion and cell density, with concentrations of <5 mg/mL 
having the lowest cell density per area of ECM, apart of the lesion volumes of 180-220 
µL, where cell density was slightly elevated for concentrations as low as 3 mg/mL. Higher 
cell density per area of ECM was found with concentrations >6.5 mg/mL and lesion 
volumes <240 µL. A peak acute cell density of >500 cells/µL was also associated with an 
8 mg/mL concentration and a narrow lesion volume of 140-150 µL.  
Another factor affected by ECM concentration and lesion volume is the distance of 
cell infiltration. A simple correlational analysis indicated a very strong correlation between 
the lesion volume and the distance of cell infiltration. The distance was very similar for 3, 
4 and 8 mg/mL (Table 2).  
 
 
 
Table 2. Spearman correlations between MR volume and host cell invasion 
 
 
 Lesion Volume 
3 mg/mL 4 mg/mL 8 mg/mL Combined 
 
Invasion 
 
r=0.8181 
(p=0.0910) 
 
 
r=0.8303 
(p<0.05) 
 
 
r=0.8793 
(p<0.05) 
 
 
r=0.55 (p<0.05) 
 
 
Distance 
 
r=0.87 (p=0.06) 
 
 
r=0.92 (p<0.05) 
 
 
r=0.94 (p<0.05) 
 
 
r=0.61 (p<0.01) 
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Cell invasion distance was also strongly correlated with total cell infiltration for 3 
mg/mL (r=0.90, p<.05), 4 mg/mL (r=0.84, p=0.07), and 8 mg/mL (r=0.97, p<.01), hence 
indicating a close relationship and interdependence between these different factors. A 
contour plot further highlighted this relationship (Figure 2.16.C), indicating that a 
concentration of >3 mg/mL is required for any infiltration to occur. Interestingly again, two 
separate peak spots for cell infiltration >2000 µm occurred, with larger lesions of 180-220 
µL requiring lower ECM concentrations (4-5 mg/mL) and smaller lesions of 120-180 µL 
requiring a higher ECM concentration (>7 mg/mL). 
 
2.3.9   Phenotypic characterization of cell infiltration 
 
Considering the rapid infiltration of a large number of cells, it is essential to determine the 
phenotypes of the cells, as well as their participation in the remodeling and repopulation 
process. Indeed, the chain-like migration of cells along certain tracks within the injected 
ECM suggests that certain pioneering cells pave the way for others to follow.  
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Figure 2.17. Cell invasion – phenotypic characterization. 
Phenotypic characterization of cell invasion into injected ECM (collagen I+ area) was focused on 
cell phenotypes found in the brain: neural progenitors as revealed by doublecortin (DCX+), 
oligodendocytes (CNPase+), astrocytes (GFAP), microglia (Iba-1+) and endothelial cells (RECA-
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1+). There was noted invasion of microglia with a bulbar morphology pioneering a path for 
astrocytes to follow (A). A significant number of DCX+ neural progenitors also invaded the ECM, 
presumably these were already responding to the surrounding tissue damage (B). A smaller 
number of endothelial cells was seen invading the ECM material. However, in some cases 
endothelial cells appeared to organize into tubules, but this was typically in areas where there 
were remnants of damaged tissue that were engulfed by the ECM hydrogel (C). Oligodendrocytes 
were also found to invade deep into the ECM material, but cells were mostly of an uncharacteristic 
bulbar shape (D). In addition to the “indigenous” brain cells, the infiltration of peripheral 
macrophages and their polarization towards an M1 (CD86+) or M2 (CD206+) phenotype were 
investigated (E). Almost all CD206+ cells were also positive for CD86. 
 
 
 
Iba-1 microglia are very common amongst the cells infiltrating the furthest into the 
hydrogel (Figure 2.17.A), with GFAP+ astrocytes being located closer to the host tissue. 
Astrocytes and microglia within hydrogel have a more bulbar appearance within the ECM 
than in native tissue. Interestingly, significant numbers of DCX+ neural progenitors can 
be found to infiltrate the ECM hydrogel even during this acute phase, as do endothelial 
cells (Figure 2.17.B). As these infiltrate the gel, morphologically these appear bulbar and 
can be contrasted with areas where they show a more mature morphology. A more 
mature morphologies was typically associated with ECM hydrogel surrounding remnants 
of damaged tissue (Figure 2.17.C). Oligodendrocyte progenitors (CNPase+ cells) were 
also seen to infiltrate the ECM, hence indicating that all resident brain cells can be found 
to ininfiltrate ECM hydrogel within 24 hours (Figure 2.17.D). Nevertheless, the majority 
of cells found to infiltrate the ECM acutely were monocytes (mostly macrophages) that 
expressed markers for an M1 (CD86+) and/or M2 (CD206+) phenotype, presumably 
participating in the remodeling of the ECM (Figure 2.17.E).  
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Figure 2.18. Cell invasion – Quantification of cell phenotypes. 
An 8 mg/mL ECM concentration resulted in the most significant proportion of brain cells invading 
the material. Most significantly neural (DCX+ cells) and oligodendrocyte progenitors (CNPase+ 
cells) were among the first phenotypes to invade the ECM, with astrocytes (GFAP+ cells) and 
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endothelial (RECA-1+) cells being most negligible proportions. Nevertheless, as expected a high 
proportion of microglia (IBa-1+ cells) and macrophages invaded the material. Again, an 8 mg/mL 
ECM concentration produced the most significant shift from a M1 (CD86+ cells) towards an M2 
(CD206+ cells) phenotype.  
 
 
 
A quantification of the phenotypes and comparison across ECM concentrations showed 
that 8 mg/mL recruited the highest percentage of brain-derived cells (Figure 2.18). An 
average of 8% of invading cells at the 8 mg/mL concentration were DCX+ with all other 
concentrations recruiting <3% of neural progenitors (p<.001), i.e. the key phenotype 
required for repopulation of a neural tissue. Surprisingly, the recruitment of astrocytes 
was equivalent for all groups, as well as being very similar to neural progenitors at lower 
concentrations. The only slight rise (+1%) in astrocytes’ infiltration was seen with 3 
mg/mL, but this was statistically (and most likely biologically) insignificant. 
Oligodendrocytes were the most common “neural”-derived phenotype overall with >5% 
across all concentrations and a peak of 11% of infiltrating cells at 8 mg/mL (p<.01). In 
contrast, very few endothelial cells invaded (<3%), with a peak infiltration seen again with 
8 mg/mL (4.5% of cells, p<.05). As expected, microglia were the most common phenotype 
of brain-derived cells that infiltrated the ECM with the highest proportion of cells being 
found at 8 mg/mL (p<.05). These results indicate that ~60% of cells at 8 mg/mL were 
derived from the brain, with the lowest proportion (~30%) invading from the surrounding 
tissue with a concentration of 3 mg/mL. A significant proportion of cells hence infiltrated 
from outside the brain. Monocyte (microglia/macrophage) polarization contrasting M2 
(CD206+), M1 (CD86+), or M2/M1 (CD206+/CD86+) markers indicated that an M1-like 
phenotype was the most common across all concentrations, but was lowest at 8 mg/mL 
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(p<.01). The proportion of M2/M1 marker co-expression was also highest at 8 mg/mL 
(p<.05), although 3 mg/mL was equivalent. Only M2-like (i.e. CD206+) cells were very 
scarce with <2% being present at the 8 mg/mL concentration and no significant difference 
being evident across ECM concentrations. 
 
2.4 DISCUSSION 
 
The advent of cytocompatible and injectable biomaterials offers new opportunities to treat 
brain damage. However, access to the brain, as well as its rigid confinement within the 
skull [74, 75], pose technical challenges to define an adequate in situ hydrogel formation 
based on the concentration-dependent rheological characteristics of ECM. The use of 
non-invasive imaging, such as MRI [141], ensures an efficient delivery of appropriate 
concentrations to assay gelation properties and their influence of ECM distribution in vivo. 
Herein, we described the rheologic and turbidometric characteristics of an ECM hydrogel 
with the intended clinical application of minimally invasive intracerebral delivery and 
retention in stroke. 
 It is noteworthy that ECM’s rheological characteristics are based on concentration, 
time, and temperature [137]. A high concentration of ECM here (>3mg/ml) afforded a 
robust and efficient formation of hydrogel that was retained within the lesion. These 
formulations are therefore desirable for delivery of agents without penetration of the host 
tissue, but their retention within the cavity could structurally support cell delivery or attract 
host cell invasion to recolonize areas where tissue has been lost [89]. Gradual 
degradation of the hydrogel and replacement by host tissue would be expected. 
 75 
Alternatively, lowering the hydrogel ECM concentration (<3mg/ml) might improve 
integration with the peri-infarct tissue and promote better interaction with host cells. If 
diffusion of ECM hydrogel into the damaged peri-infarct proves to be of benefit, as with 
drug delivery, then concentrations of ECM that do not gel or show a protracted gelation 
time would be desirable to afford diffusion into tissue. There is some evidence that 
diffusion of ECM into damaged brain tissue can lead to behavioral improvements [138]. 
Indeed, a concentration of 3mg/ml in the present study resulted in both a diffusion of ECM 
into the peri-infarct areas, as well as gelation and retention within the cavity. The length 
of time required for hydrogel structural support for cell invasion and subsequent de novo 
tissue formation is unknown. As hydrogel stiffness, as well as inductive properties, can 
affect cell invasion and phenotype [92, 152, 153], it is essential to further characterize the 
short-term and long-term biological properties of the ECM formulations after injection in 
the stroke-damaged brain. 
 Although much effort is geared toward designing novel biomaterials or enhancing 
the biological effects of transplanted cells, little effort is devoted to the technical 
challenges associated with delivery of these therapeutics and its interaction with host 
tissue. Yet, there is ample evidence that biophysical considerations regarding delivery of 
therapeutics to the brain can dramatically influence their therapeutic effects [154]. 
Controlling cannula placement [155, 156] and size [157, 158], using an automated 
injection pump for consistent delivery [159, 160], as well as MRI guidance [140], have 
provided greater control over factors that can influence the delivery of therapeutics to the 
brain. The tuning of the rheological properties of ECM hydrogel that potentially can 
separate the stiffness of the gel from its inductive payload will provide further opportunities 
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for the refinement of the in situ structure-function relationships required for therapeutic 
success [161-163]. An efficient local delivery at an appropriate concentration will also be 
essential for the delivery of biomaterials that serve as local drug/cell delivery vehicles [72, 
134, 135]. It was evident herein that the described approach mitigated potential adverse 
effects compared to injection of a large volume of a stiff material without drainage. Using 
the drainage-injection procedure, it will now be possible to better control the intra-cavity 
concentration of material and further optimize gelation parameters in situ in relation to the 
different biophysical and inductive properties of biomaterials. These steps are essential 
to provide a thorough preclinical evaluation of biomaterials, but also to define the technical 
challenges for clinical translation.  
Foremost of all, recruitment of host cells into the injected material requires a 
gelation and retention of material within the cavity. At 1 day post-implantation, a robust 
formation of the hydrogel can be observed at concentrations >3 mg/mL [114]. However, 
small agglomerates of ECM at the border of the tissue, as demonstrated here, can also 
attract host cells, albeit at a smaller scale. Due to the lack of structural support throughout 
the cavity, no repopulation of the cavity with host cells occurs. In contrast, gelation of the 
ECM in situ resulted in a very dramatic acute infiltration of cells into the cavity in the order 
of ~360,000 for the 8 mg/mL ECM concentration. This concentration was rheologically 
comparable to uninjured brain tissue, which could explain why this concentration was so 
efficient in attracting host cells, specifically neural progenitors and oligodendrocytes. The 
mechanical properties of the hydrogel play an important part in cell invasion and 
phenotypic differentiation [139, 164] Stiffer gels (1,000-10,000 Pa) are associated with 
astrocytes, whereas softer gels (100-1,000 Pa) are more likely to promote neuronal 
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differentiation [165]. An intermediate stiffness (400-800 Pa) provides a mixtures of cells, 
as was seen here in the 8 mg/mL condition (460 Pa), and could provide mechanical 
properties that are conducive to neural tissue engineering requiring neurons, astrocytes, 
as well as oligodendrocytes.  
 A good interface with host tissue is nevertheless also important. A lack of interface 
did not result in a good cell infiltration. Even if there was a good interface, in some cases 
there was a poor invasion. It is conceivable that the density gradient at the interface 
influences cell infiltration [166], which potentially could be due to tissue characteristics, 
such as a glia limitans, or hydrogel characteristics, such as a higher material 
concentration at the cavity edge producing a higher elastic modulus [167]. Although very 
dense material can invoke a foreign body response in the brain that leads to an 
encapsulation of material by fibrotic scarring [118], injections of hydrogels typically exhibit 
a reduced microglia and astrocytes response compared to just needle track damage 
[167]. Although microglia and astrocytes are abundantly present in the peri-cavity tissue 
[168], more neurons and oligodendrocytes invaded the ECM hydrogels than astrocytes 
within 24 hours of injection. The reciprocity in interaction between hydrogel and host brain 
is essential to determine the host tissue response and guide cell invasion or induce further 
scarring and a foreign body response [169]. Further engineering of hydrogel potentially 
promises to provide a greater control over this interaction and influence the infiltration of 
specific cell phenotypes [170]. 
Apart from the rheological properties, inductive cues provided by the ECM material 
are thought to be the key mediator of cell infiltration [171]. The 8 mg/mL concentration in 
the current study was the highest concentration implanted and hence also provided the 
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greatest abundance of inductive cues to elicit a regenerative response [171, 172]. Indeed, 
the injected ECM contains growth factors, such as vascular endothelial growth factor, 
basic fibroblast growth factor, and nerve growth factor, which can be released from the 
injected material [91, 143]. The released proteins can permeate into host tissue, create a 
gradient, and facilitates infiltration of host cells, such as microglia/macrophages [173]. It 
is thought that these immune cells exert a pioneering function in that they invade the 
ECM, leading a constructive remodeling and in this process create trails of molecules that 
attract host tissue cells to gradually repopulate the material [169]. Microglia (Iba1+) cells 
were predominant amongst the cells that infiltrated the furthest into the ECM. Their 
infiltration appeared to follow a topological trail within the ECM. The chain-like infiltration 
suggests that there are particular trails within the material that these cells preferential 
follow, although at the tissue boundary a broader cell invasion into the material is 
observed. These invasion trails are likely to be a combination of abundant signaling 
molecules that attract particular cells, as well as conducive mechanical properties, such 
as gel surface curvature within the injected material, that interact reciprocally with 
pioneering cells [174]. 
Peripheral macrophages are infiltrating the ECM material and it is thought that both 
macrophages and microglia here exerted very similar functions, notably constructive 
remodeling of the ECM hydrogel and facilitating the invasion of host organ cells. All ECM 
concentrations (apart of 0 mg/mL) invoked a macrophage/monocyte infiltration. 
Proportionally this was lowest at the 8 mg/mL concentration. However, this is due to a 
greater number of host brain cells infiltration at this concentration, but in absolute 
numbers leads a similar number of macrophages than at 3 or 4 mg/mL. Although it is 
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conceivable that microglia and macrophage infiltration are a response to recognizing a 
foreign object, the difference in cell numbers and proportions across the different 
concentrations indicate that other factors are also important. The stiffness of the injected 
material, for instance, can influence macrophage infiltration and morphology of these 
cells, with higher stiffness being associated with a greater response [175].  Although 
macrophages are involved in a foreign body response to injected material [167], this 
typically involves macrophages of an M1-like phenotype only [176]. An M1-like phenotype 
response, in the absence of a polarization towards an M2-like phenotype, is associated 
with an insufficient decellularization of ECM material [177]. Although the M1-like response 
here was dominant overall, especially in the 1 mg/mL condition, polarization towards an 
M2 phenotype, especially at 3 and 8 mg/mL, using the same ECM material, indicates that 
this was not due to a insufficient decellularization. An M2-like phenotype polarization of 
invading macrophages has indeed been linked with peripheral nerve repair [178] and the 
constructive remodeling response of injected ECM [179]. It is this M2-like polarization that 
is thought to be crucial to attract cells from the host organ to repopulate the tissue defect 
and eventually replace the injected material with new tissue [171]. 
 The infiltration of microglia and macrophages is thought to be an M1-like response 
with a shift towards an M2-like phenotype, occurring through juxtacrine or paracrine 
signaling within the ECM material [173]. It is important to stress that all infiltration into the 
material, i.e. even macrophage infiltration, was through host tissue, as there were no 
blood vessels contained within the cavity that would allow a direct infiltration of peripheral 
macrophages into the hydrogel. It is suggested that the mobilization of host brain cells 
(neurons, astrocytes, oligodendrocytes) and endothelial cells for infiltration followed a 
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chain-like migration of pioneering microglia and macrophages. This mobilization is a rapid 
process, as within 24 hours here, microglia and macrophages are seen at distances 
>1500 µm into the hydrogel. Moreover, a high proportion (~10%) of oligodendrocyte and 
neural progenitor cells was observed to follow these pioneering cells. Indeed, it is 
remarkable that within such a short time >60% of cells found within the hydrogel were 
cells required for tissue replacement. Still, it is unclear here why neural and 
oligodendrocyte progenitors were more abundant in their infiltration than astrocytes and 
endothelial cells. It is conceivable that this is due to ECM molecules required for migration 
[180]. Specifically, the abundance of ECM molecules, such as fibronectin and laminin, 
are thought to be pivotal in a repair response of neural stem cells [181, 182] and might 
explain the relative preferential infiltration of neural and oligodendrocyte progenitors. In 
contrast, the high collagen content of these ECM hydrogels might serve as a deterrent to 
astrocytes [183, 184], hence at this acute stage leading to a selective preference of neural 
progenitor infiltration. Nevertheless, the infiltration of a high proportion of neural 
progenitors is very encouraging to harness endogenous repair mechanisms into the 
lesion cavity and potentially promote the replacement of lost tissue using inductive 
biomaterials. Further investigations into the provision of appropriate paracrine and 
juxtacrine recruitment cues, as well as rheological conditions that are conducive to cell 
invasion of a neural cell population [125, 139, 164, 185] may enhance this potential.  
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2.5 CONCLUSIONS 
 
Implantation of ECM gel precursor leads to the in situ formation of a hydrogel at 
concentrations >3 mg/mL, resulting in its retention within the lesion cavity. The ECM 
material induces a host response that is characterized by a rapid and robust cell infiltration 
that is concentration-dependent, but is also influenced by the size of the lesion. ECM 
concentration further influences the phenotype of cells, with an 8 mg/mL concentration 
resulting in ~60% of brain-derived cells. This concentration produced the most significant 
polarization towards an M2-like macrophage phenotype at this acute time point, whereas 
lower concentrations exerted a less significant M2-like polarization. These results hence 
suggest that an 8 mg/mL ECM concentration promotes a significant acute endogenous 
repair response. Nevertheless, a behavioral study characterizing cell infiltration, 
biodegradation, cell repopulation and its effect on host tissue is required to provide a more 
comprehensive framework to determine the potential of ECM hydrogel as a potential 
treatment for chronic stroke. 
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3.0     LONG TERM RETENTION OF ECM HYDROGEL REDUCES LESION 
VOLUME 
The work in this chapter has been adapted from the following published manuscript: 
Ghuman H, Gerwig M, Nicholls FJ, Liu JR, Donnelly J, Badylak SF, Modo M. Long-term 
retention of ECM hydrogel after implantation into a sub-acute stroke cavity reduces 
lesion volume. Acta Biomater. 2017; 63:50-63 
 
 
3.1    INTRODUCTION 
 
The ECM hydrogel implanted into a chronic stroke lesion 1) induces a host tissue 
response that leads to a cell infiltration; 2) a structural support is required for cell infiltration 
into the cavity; 3) rheological properties akin to intact tissue promotes the most significant 
cell infiltration; 4) a significant portion of infiltrating cells are of a monocyte (i.e. 
microglia/macrophage) phenotype with a concentration-dependent polarization towards 
an M2-like phenotype and 5) a 8 mg/mL ECM concentration attracts large numbers of 
neural and oligodendrocyte progenitors within 24 hours.  
To determine the impact of injecting large volumes of ECM hydrogel on behavioral 
functions, we investigated an ECM preparation (8 mg/mL) that is retained inside the 
stroke cavity to provide structural support [114, 150], but also provides a strong signaling 
environment to recruit large numbers of host cells that can promote structural remodeling 
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of the material [112]. The objective of the present study was to evaluate if this hydrogel 
formulation of ECM undergoes biodegradation inside a stroke cavity, akin to peripheral 
soft tissues, and if its continued presence or remodeling affects host tissue deformation, 
as well behavioral impairments after a stroke. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1. Middle cerebral artery occlusion (MCAo) 
 
Please see section 2.2.3. for details.  
Rats (n=22) with lesion volume >40 mm3 (i.e. 40 μL) were randomly assigned to either 
the untreated or the ECM treated group (Figure 1A), resulting in an equivalent distribution 
of lesion volumes across both groups. Lesion volumes ranged from 72-246 μL.      
 
3.2.2. Magnetic resonance imaging (MRI) AND infarct volume calculation 
Please see section 2.2.4. for details 
 
3.2.3 Tissue deformation measurements 
 
ROIs were defined based on anatomical definitions to segment host tissue and determine 
if ECM implantation affected the deformation of the brain due to stroke damage [149]. A 
midline shift is commonly observed due to the host tissue expanding due to the lack of 
sufficient structural support, resulting from the void of the lesion cavity [186, 187]. Midline 
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shift was determined by placing a vertical line from the longitudinal fissure to the median 
eminence at Bregma +0.7, which commonly is the central slice of MCAo damage [149]. 
In the middle of the vertical line, perpendicular lines are drawn to measure the distance 
to the edge of each hemisphere. A ratio is taken of these two measurements to define the 
relative midline shift. Ventricular enlargement is also often seen as a consequence of 
tissue deformations. Volume changes of tissue parenchyma were also calculated to 
determine if stroke and ECM implantation affected structural changes in these regions.  
 
3.2.4 Behavior assessment 
 
Establishing the efficacy of ECM hydrogel injection to recover behavioral deficits in an 
animal model of stroke requires evaluation of these deficits on a variety of tests that reflect 
damage to sensorimotor, motor, and cognitive systems. Researchers blinded to the 
condition of animals performed all acquisition of data, graphing and statistical analyses. 
Animals from different groups were mixed in cages. 
 
3.2.4.1 Bilateral asymmetry test. The bilateral asymmetry test probed tactile 
extinction as a measure of sensory neglect [57, 146]. For this, two strips of equal size (6 
cm long, 0.5-0.8 cm wide) were applied with equal pressure to the saphenous part of the 
forepaw. Four trials (180 seconds each) recorded the time to contact and removal for 
each paw. Sensorimotor bias was determined by subtracting the unaffected (right) from 
the affected (left) paw. 
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3.2.4.2 Footfault test. The footfault test evaluated the animals’ ability to integrate 
motor responses by analyzing motor impairments of limb functioning and placing deficits 
during locomotion [57, 146]. The rats were placed in the Motorater System (TSE GmbH) 
with horizontal bars to record the placements of both unaffected and affected forelimbs 
over 8 trials (>60 placements). A comparison of total number of incorrect placements or 
% missed steps across groups measured performance on motor integration. 
 
3.2.4.3 Rotameter. Amphetamine-induced rotations (2.5 mg/kg in saline, i.p.) were 
measured using an automated rotameter system (TSE Systems). Rotational bias is used 
as an index of striatal damage [57, 147]. Animals were harnessed into jackets tethered to 
the rotameter system and injected with amphetamine 30 minutes prior to assessment. 
Contralateral and ipsilateral rotations were recorded for 30 minutes. 
 
3.2.5 Histological assessment 
 
3.2.5.1 Perfusion and immunohistochemistry. Please see section 2.2.7.1 
 
3.2.5.2 ECM hydrogel volume. The virtual tissue module (MBF Bioscience) tiled 
individual 20x magnification images to create a composite whole brain slice. Anterior-
posterior whole biomaterial images (500 μm apart) were acquired to measure the area 
occupied by ECM (i.e. collagen I staining), and then multiplied by the distance between 
images to approximate total volume [149]. The rate of biodegradation was calculated by 
obtaining the average ECM hydrogel volume at a reference time point (1 or 14 days) and 
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dividing it with the volume at the target time point (14 or 90 days). Degradation rate was 
defined as the change in ECM hydrogel volume divided by number of days or μL/day. 
 
3.2.5.3 Parenchyma and lesion volume. Regions of Interest (ROIs) were drawn 
on 8-bit whole brain histology images of DAPI in Fiji version 1.49 (https://fiji.sc) around 
the tissue for each hemisphere, including the ventricles. Based on the pixel intensity in 
the contralateral hemisphere, a threshold was applied to define parenchyma and create 
a binary map [149]. For each histological slice, contralateral parenchyma was defined by 
subtracting the lateral ventricle. Ipsilateral parenchyma volume was defined by 
subtracting lateral ventricle and lesion volume. Total volumes were calculated by 
multiplying area measurements by the distance to the next slice (500 μm). A ratio between 
ipsi- and contralateral parenchymal and ventricular volumes was calculated. 
 
3.2.5.4 Scarring measurements. Brain tissue sections were immunolabeled for 
glial fibrillary acid protein (GFAP) before acquiring whole brain images at 10x 
magnification, as previously described [149]. Images were acquired with 100 ms 
exposure time for all animals to provide consistent signal intensity across all sections. 
The images were then processed through Fiji to define straight lines as ROIs starting from 
the lesion boundary and drawing away from the cavity. A plot of intensity versus distance 
determined thickness of the glial scar in both cortex and striatum. The average intensity 
of the GFAP signal was then averaged and binned for every 200 μm, starting from the 
lesion boundary. ROIs were drawn in all anterior-posterior brain sections containing the 
glial scar. 
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3.2.5.5 Peri-infarct astrocytosis. Whole brain GFAP stained images were first 
converted to 8-bit images before applying a threshold to mask GFAP+ cells and create a 
binary map to determine the area covered by astrocytes in both ipsilateral (i.e. right) 
stroke-affected and contralateral (i.e. left) unaffected hemispheres [149]. The same 
threshold value was used for all brain sections to maintain consistency. ROIs were then 
drawn around the parenchyma of the ipsilateral hemisphere to determine the area fraction 
(%) represented by astrocytes.  
 
3.2.6 Statistical analysis. Statistical analyses were performed in SPSS 17 for Mac 
(IBM) with significance set at p<0.05. Specifically, a one-way ANOVA was used to 
compare cell invasion and phenotypes, using a Bonferroni post-hoc test to validate 
significant comparisons. A two-way ANOVA with Bonferroni post-hoc testing was used to 
contrast the comparison between lesion volumes, as well as behavioral data. Graphs 
were drawn in Prism 6 (GraphPad) with data points representing the mean and bars 
reflecting the standard deviation. A priori power calculations were performed in G*Power 
[188]. A power of 80% (Type II error) with a significance of p<0.05 (Type I error) is 
considered suitable [189]. With a medium effect size f of 0.25 for ANOVAs, a total sample 
size of N=36 is sufficient to achieve a power of 80% at the 5% significance level.  
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3.3 RESULTS 
 
3.3.1 ECM implantation and evolution of lesion volume 
 
The volume of implantation of ECM precursor was determined based on the hyperintense 
lesion volume, which was measured on pre-implantation T2-weighted MR images (Figure 
3.1.A) using tissue segmentation (Figure 3.1.B). After exclusion of animals with lesions 
<40 μL or no lesion, the remaining MCAo animals were randomly assigned to the 
untreated or treated MCAo groups, with both having equivalent mean lesion volumes of 
approximately 130 μL (Figure 3.1.C). Untreated and treated animals’ lesion volume was 
significantly different from controls (F=41.98, p<0.001), with treated rats showing a 
significant reduction in lesion volume at 12 weeks (p<0.05). By accounting for pre-
implantation volume, untreated animals revealed a 28% increase in volume, whereas 
lesion volume in treated rats was significantly reduced (t=2.856, p<0.01) in comparison 
to untreated animals (Figure 3.1.D). It is also noteworthy that there was a 10% decrease 
in volume compared to the 2 weeks post-infarct baseline volume, although this did not 
reach statistical significance. ECM implantation therefore attenuated the structural 
progression of stroke damage.  
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Figure 3.1. Evolution of lesion volume and tissue deformation. 
A. T2-weighted MR images of experimental groups over time reveal the hyperintense lesion cavity 
in animals with stroke damage. B. Measurement of lesion volume (red region-of-interest) based 
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on the hyperintense T2-weighted signal on MR images defined by mean signal of the contralateral 
hemisphere + 1 standard deviation (scale bar 2 mm). Ipsilateral (green) and contralateral (light 
green) parenchymal tissue, lateral ventricles (yellow) were also segmented on MR images. 
Midline shift (blue line) was calculated by a ratio between distance of the ipsilateral and 
contralateral hemisphere midpoints. C. Lesion volume was calculated for a baseline pre-
implantation time point, as well as for 4 and 12 weeks post-implantation. D. To account for 
variations in lesion volume at baseline, % change between baseline and 12 weeks were 
calculated. E. A ratio of parenchymal volume revealed a significant loss of parenchyma in stroke 
animals, which further declined a little over 12 weeks. F. A gradual shift of the midline was evident 
in both stroke groups, but was not impacted by ECM hydrogel implantation. G. An equivalent 
dramatic increase in ipsilateral lateral ventricle was evident in both stroke groups. H. The ratio 
between the ipsilateral and contralateral ventricle further reflect these gradual long-term changes 
in tissue structure after stroke. ECM hydrogel did not affect these tissue deformations. 
 
3.3.2 ECM and tissue deformation 
 
To quantitatively determine the impact of ECM implantation on host tissue structures, pre-
implantation and final MR images were further segmented. Hemispheric parenchymal 
volume was measured to determine if the reduction in lesion volume translated into novel 
brain tissue. However, there was no significant difference between treated and untreated 
animals (Figure 3.1.E). This pattern of results was also evident for a midline shift (Figure 
3.1.F), right lateral ventricular volume (Figure 3.1.G), and the ratio of left/right lateral 
ventricle (Figure 3.1.H). The lack of host tissue changes therefore suggests that changes 
in T2-weighted lesion volumes is a reflection of an attenuation of the tissue-lesion interface 
(i.e. T2 signal in lesion), rather than the generation of new tissue per se or a slowing 
ventricular enlargement. 
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3.3.3 ECM hydrogel does not impact behavioral functions 
 
To determine the impact of ECM hydrogel on the brain, a battery of behavioral tests was 
employed to evaluate functional changes associated with different brain regions affected 
by stroke. Sensorimotor functions are dependent on striatal and sensorimotor cortex, both 
affected by stroke, and readily assessed by the bilateral asymmetry test (BAT). The 
contralateral hemisphere is unaffected by stroke and serves as an internal control. The 
right forepaw here was unaffected by stroke and was equivalent in all 3 experimental 
groups (Figure 3.2.A). In contrast, the left affected forepaw exhibited a significant 
impairment in both untreated and treated MCAo animals compared to controls, with no 
evidence of ECM hydrogel altering this defect in a positive or negative fashion (Figure 
3.2.B).  
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Figure 3.2. Behavioral assessment. 
A. Bilateral asymmetry test (BAT) analyses revealed a significant sensorimotor bias in the left 
forepaw, but not in the right forepaw in untreated and treated animals. B. Treatment did not affect 
sensorimotor bias compared to untreated animals. The footfault test measured motor integration, 
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which was significantly impaired in the left affected forepaw. Treated animals performed 
comparably to untreated animals on this task. C. Amphetamine-induced rotation bias on the 
rotameter reveals striatal integrity and dopamine responsiveness. Treated and untreated rats 
exhibited a comparable asymmetry in rotation.  
 
 
 
 The footfault test is dependent on the motor loop of the striatum and motor cortex 
and demonstrates a robust long-term deficit after stroke. The right forepaw did not show 
any deficit walking over horizontal bars in any of the experimental groups (Figure 3.2.C), 
whereas the left forepaw contralateral to the stroke lesion exhibited a significant 
impairment pre-implantation (p<0.001), with no indication of change due to ECM hydrogel 
evident at any time point (Figure 3.2.D). 
 In contrast to the BAT and footfault, the rotameter evaluates pharmacologically 
induced rotations that probe the hemispheric dopamine-balance in the striatum (Figure 
3.2.E), often considered a functional measure of the degree of striatal tissue loss. There 
was no bias in clockwise rotations between any of the experimental groups, but there was 
a significant bias in counterclockwise rotations in untreated and treated animals 
(p<0.001). No difference between untreated and treated animals was evident indicating 
that ECM hydrogel did not functionally affect host striatal tissue. 
 
3.3.4 ECM hydrogel implantation decreases tissue cavitation 
 
After completion of in vivo analyses, fixed tissue was processed for histological analyses. 
Stroke and the loss of brain tissue leads to the formation of a cavity that is delineated by 
a scar formed by glial cells, forming the edge of the tissue (Figure 3.3.A). Implantation of 
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8 mg/mL ECM hydrogel into the cavity indicates that it is contained within the cavity 
delineated by gliosis. Although stroke significantly reduced the amount of parenchyma in 
the ipsilateral stroke hemisphere (F=67.58, p<0.001), the presence of ECM hydrogel in 
the lesion cavity did not significantly increase parenchymal volume in comparison to 
untreated animals (Figure 3.3.B). There was also no evidence of a structural effect of 
ECM treatment on ventricular volume, although stroke significantly enlarged the ipsilateral 
ventricle in both groups relative to controls (F=3.41, p<0.05). A comparison of lesion 
volume between untreated and treated animals indicated that there was a 19.8% 
decrease in the cavity after ECM treatment (t=2.143, p<0.05). 
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Figure 3.3. ECM hydrogel retention and glial scarring. 
A. A histological comparison between controls, untreated and treated stroke animals reveals a 
major tissue loss in the ipsilateral hemisphere, as well as the presence of ECM hydrogel within 
the lesion cavity. B. A quantification of parenchymal volume in these 3 groups indicated a 33% 
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tissue loss in animals with stroke, as well as a dramatic increase in ipsilateral ventricular volume. 
A treatment effect was evident on stroke lesion volume with a 19.8% decrease in cavity volume. 
C. ECM hydrogel was retained inside the lesion cavity in all treated animals as indicated by 
collagen I staining surrounded by host tissue. D. Along the anterior-posterior axis, ECM hydrogel 
was identifiable as a morphologically distinct entity aided by collagen I staining. E. A comparison 
between injection volume of ECM gel precursor and volume of hydrogel at 3 months revealed a 
decrease of 32%, but due to individual variability this did not reach statistical significance. F. To 
evaluate the impact of ECM hydrogel on glial scarring at the tissue interface, whole brain slice 
images covering the lesion cavity along the anterior-posterior axis were acquired for all 3 groups 
to measure the level of astrocytic (GFAP) reactivity inside striatal and cortical tissue. G. A marked 
increase in GFAP staining was evident at the border of the lesion cavity that gradually decreased 
further inside the tissue. GFAP reactivity in the stroke-damaged striatum was higher than in the 
cortex. However, there was no significant difference between untreated and treated animals. H. 
Peri-infarct astrocytosis (i.e. the area occupied by reactive astrocytes) in the ipsilateral and 
contralateral parenchyma was measured by an 8-bit conversion of whole slice images to apply a 
threshold that created a binary map. I. This binary image afforded quantification of area occupied 
and provided a comparison of the 3 experimental groups to indicate that there was no significant 
difference between untreated and treated animals, although both had significantly more 
astrocytosis than normal controls. Scale bar 2 mm. 
 
 
 
3.3.5 Slow biodegradation produces long term retention of ECM 
 
A macroscopic evaluation of the presence of ECM hydrogel revealed that the bioscaffold, 
as indicated by collagen I staining, was distributed throughout the lesion cavity (Figure 
3.3.C). Morphologically the ECM hydrogel appeared to reflect the pre-implantation MR 
lesion volume. Histological measurement of the ECM hydrogel volume along the anterior-
posterior axis (Figure 3.3.D) afforded a volumetric comparison of injected and retained 
ECM. There was a significant 32% decrease (t=6.737, p<0.001) in ECM hydrogel volume 
by 12 weeks post-implantation compared to the injected precursor volume (Figure 3.3.E). 
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Despite some biodegradation, a large amount of ECM hydrogel remains (more than 60% 
of the implanted hydrogel) within the brain of all animals at 12 weeks post-implantation. 
 
3.3.6 Glial scarring and astrocytosis is unaffected by ECM hydrogel 
 
Using whole slice imaging of histological sections along the anterior-posterior axis 
allowed a quantitative determination of the extent of scarring in host tissue (Figure 3.3.F). 
The extent of scarring was highest at the edge of the tissue and gradually declined. The 
intensity of the glial scar indicates a scar that is much more pronounced in the striatum 
than cortex. A comparison between untreated and treated animals revealed no significant 
difference in scarring in striatum or cortex (Figure 3.3.G). Thresholding and quantification 
of the area of astrocytosis in the peri-infarct area (Figure 3.3.H) also did not reveal a 
significant effect of ECM in the ipsi- or contralateral hemisphere. 
 
3.3.7 Presence of host cells is not correlated with injected and retained ECM 
volume 
 
Host cells invaded the ECM hydrogel with cells scattered throughout the bioscaffold 
(Figure 3.4.A). Quantification of cells within the hydrogel (Figure 3.4.B) indicated some 
variability with a range of 44,820 to 78,740 cells (mean = 65,050) per animal. To 
investigate if this variability is associated with the volume of injected ECM, a correlation 
analysis between these was performed (Figure 3.4.C), but did not reveal a strong 
significant correlation (r=0.33, n.s.). Lesion volume did also not predict (r=0.35, n.s.) the 
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number of cells that were present within the ECM hydrogel (Figure 3.4.D). Cells within 
the ECM hydrogel were clustered, rather than distributed in a homogenous distribution. 
In some cases, an organization along grooves was observed in the hydrogel (Figure 
3.4.E). In a few cases, the cellular organization consisted of endothelial cells forming 
tubules, but in most cases such cell accumulations consisted of other cell phenotypes. 
 
 
 
Figure 3.4. Presence of host cells in ECM hydrogel. A. A sharp boundary of DAPI cells 
defined the interface between biomaterial and host brain with some cells being present 
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within the ECM hydrogel. B. Using collagen I staining, a region-of-interest for the ECM 
hydrogel was defined and applied to the DAPI image to provide a quantification of the 
number of cells present within the hydrogel at 12 weeks post-implantation. A mean 
invasion of 65,050 cells with a range of 44,820-78,740 cells was measured. C. A non-
significant (n.s.) correlation between injection volume of ECM or histological volume of 
ECM at 12 weeks indicates that the number of invading cells was not directly related to the 
volume of ECM injected into the brain. The regression line in the scatter plot reflects the 
steepness of the correlation between the two data sets. D. There was also no significant 
association between the degree of stroke damage (i.e. lesion volume) and the number of 
invading cells, further highlighting that other factors play an important role in host cell 
invasion. E. Host cells that invaded and remained within the ECM hydrogel appear to be 
localized along topological grooves revealed by collagen I staining. Scale bars 100 m. 
 
 
 
3.3.8 Microglia and oligodendrocytes predominantly invade the ECM 
 
To assess the phenotypes of cells inside the ECM hydrogel, immunohistochemical 
markers for individual cell lineages (neural progenitors, neurons, astrocytes, 
oligodendrocytes, endothelial cells, and microglia) found in brain tissue were quantified 
(Figure 3.5.A). The vast majority of cells within the ECM were of a microglia (Iba1, 51%) 
phenotype (F=130.6, p<0.001; Figure 3.5.B), with fewer cells being oligodendrocytes 
(CNPase; 31%) and very few cells being endothelial (RECA1, 3.75) cells and astrocytes 
(GFAP, 1.3%).  
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Figure 3.5. Phenotypic characterization of cells in ECM hydrogel. 
A. Immunohistochemical characterization of individual cell phenotypes within the ECM hydrogel 
at different magnifications. B. A phenotypic analysis of cells present within the hydrogel were 
predominantly microglia (ionized calcium binding adapter molecule 1, Iba-1), as well as fewer 
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(p<0.01) cells from the oligodendrocyte lineage (2’,3’-cyclic-nucleotide 3’-phosphodiesterase, 
CNPase). Significantly (p<0.001) fewer neurons (Fox3), neural progenitors (doublecortin, DCX), 
astrocytes (glial fibrillary acid protein, GFAP) or endothelial cells (rat endothelial cell antigen 1) 
were found. C. A comparison of monocyte polarization indicated that these mostly co-expressed 
M1 (CD86) and M2 (CD206) markers, with significantly fewer cell expressing only CD86 (p<0.01) 
or CD206 (p<0.001). Scale bars 100 m. 
 
 
 
Neurons (Fox3, 4.2%) and neural progenitors (DCX, 0.15%) were rarely seen within the 
material at 90 days. A 36.4% co-expression of M1 (CD86)- and M2 (CD206)-like 
characteristics on monocytes (i.e. microglia/macrophages) was most commonly 
observed. Significantly fewer cells (F=20.27, p<0.001) presented with an exclusive M1 
(9.5%)- or M2 (4.8%)-like phenotype (Figure 6C).  
 
3.4 DISCUSSION 
 
The formation of a tissue cavity in the brain is commonly the result of a severe acute 
tissue injury, such as stroke [78] or traumatic brain injury (TBI) [190], but can also be 
caused by a surgical intervention to evacuate a hematoma [191], or the resection of a 
neoplasm [192]. The loss of tissue is associated with severe disability and structural 
deformations of host tissue leading to behavioral dysfunctions through Wallerian 
degeneration or tissue compacting [193]. As ECM hydrogel can be retained within this 
tissue cavity [114] and promote the infiltration of site-appropriate phenotypes [112], we 
here determined that an 8 mg/mL ECM hydrogel was retained long-term (12 weeks) after 
implantation with only moderate signs of biodegradation. The retention of some host cells 
that invaded was also evident. These cells were predominantly pro-repair microglia and 
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oligodendrocytes that were sparsely distributed. There was a significant effect on lesion 
volume as determined by MRI, but there was no reduction in tissue deformation caused 
by the stroke. No effect on a battery of behavioral tests was evident, indicating minimal 
impact on host tissue function. These results therefore indicate that an 8 mg/mL ECM 
concentration promoted a reduction in lesion volume, but did not undergo a rapid 
biodegradation as observed in peripheral soft tissue that could support extensive tissue 
repair. 
 
Biodegradation of ECM bioscaffold in brain 
ECM bioscaffolds typically undergo a 50% biodegradation within 30 days and are fully 
degraded between 75-90 days in volumetric soft tissue defects [194]. Bioscaffolds are 
often considered to provide the ‘soil’ to seed stem cells from the host organ [195]. 
Implantation of ECM into the stroke-damaged brain induces a very significant infiltration 
of host cells within 24 hours, akin to that observed in peripheral organs [112]. This 
initiation of a constructive remodeling response is essential for tissue repair [196] and is 
governed by a principle of dynamic reciprocity in which the ECM adapts to the structural, 
mechanical and functional needs of cells [197]. Although there was a 32% decrease in 
ECM volume over 12 weeks here, the significant retention of the hydrogel within the tissue 
cavity indicates that biodegradation of this material in the brain is slower than that in 
peripheral soft tissue.  
 Structural elements, such as pore size and fiber orientation, within the ECM 
hydrogel can influence the biodegradation properties of a scaffold [198]. ECM hydrogels 
with a denser fiber architecture typically show a slower biodegradation, as evidenced by 
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dermal ECM hydrogel taking longer to degrade than an equivalent concentration of UBM-
ECM [145]. Fiber diameter (0.7 μm), pore size (0.10 μm2), and node density (6 
nodes/μm2) are well conserved between 2 and 8 mg/mL UBM-ECM concentrations [145]. 
Pore sizes within these preparations are smaller than NSCs, which we established to 
have a diameter of ~20 μm [199]. A significant invasion of NSCs was nevertheless 
observed within 1 day post-implantation suggesting that migration itself was not hindered 
[112]. Smaller pore size in gelatin scaffolds (50-200 μm) are thought to induce 
differentiation of chondrocytes, whereas larger pores (250-500 μm) support proliferation 
[200], potentially indicating that invading NSCs differentiate rather than migrate into the 
scaffold. Still, little is known about how porosity influences neural stem cell migration and 
differentiation. It is important to note that cells can change their shape to migrate through 
smaller pores and pore size can also be enlarged by macrophages pushing apart or 
degrading fibers [201]. Although pore size provides a geometry that facilitates cell 
migration, with larger pore size increasing cell migration [200, 202], soluble factors also 
influence cell behavior by diffusing through these pores [203].  
Macrophage infiltration and their activation toward a M2-phenotype have been 
implicated in ECM remodeling [204] and been identified as a key process for tissue 
replacement [205, 206]. Cells contained within the matrix here were predominantly 
macrophages and microglia with a M2-polarization indicating that the scaffold maintained 
an appropriate biodegradation response. However, there were very few cells present here 
at 12 weeks (mean=65,050 cells) compared to those reported at 1 day 
(mean=366,278cells) post-implantation [112]. This difference of 82% fewer cells 
potentially explains the lack of or extremely slow degradation response. It remains unclear 
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why the number of cells within the material would decrease so dramatically after 1 day. A 
time course study investigating the cellular infiltration and degradation response of 
different ECM concentrations will be required to further address these issues. 
The central nervous system is known to be an immune-privileged environment that 
has limited potential for self-repair [207]. Nevertheless, the host brain response to ECM 
hydrogel implantation suggests that the bioscaffold can attract significant numbers of host 
cells to promote structural remodeling by 24 hours [112]. At 12 weeks, oligodendrocytes 
and microglia/macrophages were the dominant cell phenotypes with very few astrocytes, 
neural progenitors and neurons present. Still, the presence of neurons within the hydrogel 
is encouraging. The lack of neovascularization of the bioscaffold through endothelial cell 
invasion and organization is potentially a major factor impeding the structural remodeling 
of the implanted material. It remains unclear why revascularization of ECM hydrogel 
occurs efficiently in peripheral organs, but not in the brain. Improving the 
neovascularization of the scaffold could hence be a key factor to promote the degradation 
response and sustain invading brain cells. 
 
Structural support to host brain prevents lesion volume increase 
In addition to the release of biochemical factors from the ECM, its rheological properties 
are also likely to influence cell invasion and phenotypic differentiation. It is known that 
stiffer material tends to promote astrocytic, rather than neuronal, differentiation [165, 208]. 
Lower concentration hydrogels that are less stiff could hence undergo a more significant 
biodegradation and promote invasion of appropriate phenotypes to form a neurovascular 
environment. The slow biodegradation also maintains a stiffer environment, potentially 
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limiting further cell invasion [209], as well as morphological cell changes required to align 
and form a novel vascular structure. Mechanosensing of hydrogels by host tissue also 
influences the interface with host tissue by creating a glia scar [175]. Nevertheless, cells 
infiltrated the material upon implantation through the scar. This suggest that neither the 
stiffness of the material, nor the dense gliosis at the edge of the tissue defect provided a 
barrier to cell invasion. There was no evidence here that ECM hydrogel impacted the 
extent of scarring or peri-infarct astrocytosis, further indicating a minimal impact on 
existing brain tissue.  
As the hydrogel maintained its macroscopic structure within the cavity, it can also 
exert structural support to host brain tissue. The impact of stroke on the host brain is 
severe with a major loss of tissue leading to ventricular enlargement, progressive atrophy 
of the ipsilateral parenchyma and an enlargement of the contralateral hemisphere. These 
tissue deformations are reflected in a midline shift [187, 210], with pressure gradients 
within tissues producing secondary Wallerian degeneration of axonal connections and 
poorer outcomes [186, 211]. Reducing tissue deformation is considered beneficial to 
overall long-term deficits associated with infarction [193, 212]. A slowly degrading 
bioscaffold implanted into the stroke cavity could exert a supportive function for host 
tissue. Sufficient stiffness of the hydrogel will be required to ensure a structural support 
to surrounding tissue. Although there was minimal attenuation of ventricular enlargement 
and midline shift, a significant reduction in lesion volume compared to baseline and an 
~40% difference to the untreated animals revealed structural effects of the hydrogel on 
the lesion environment. This difference in treated and untreated animals is likely a 
combination of the cumulative effects of smaller changes in parenchymal volume and 
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right lateral ventricle. A more acute implantation of hydrogel in combination with the 
controlled local delivery of therapeutic compounds could provide new treatment 
approaches in stroke, traumatic brain injury and gliomas [213-216]. 
 
ECM hydrogel does not affect behavioral function 
ECM implantation has been reported to promote behavioral improvements in animal 
models of TBI [138, 217, 218]. However, in these cases smaller volumes at lower 
concentrations of ECM were injected without retention of material within the tissue cavity. 
We here demonstrated that the retention of urinary bladder ECM within the stroke cavity 
did not impact behavioral functions. No improvement in deficits was evident, but there 
was also no indication that the injection led to any deleterious effects. Long-term retention 
of ECM hydrogel therefore is likely to be safe for physical support and delivery of 
therapeutic factors, but a concentration of 8 mg/mL is not providing a therapeutic 
behavioral benefit by itself. It is hence possible that lower concentrations of ECM, which 
partially gel after injection, would permeate into surrounding tissue to produce beneficial 
therapeutic effects.  
 The interface and permeation of ECM into this area might be an important factor 
in achieving therapeutic efficacy. The implantation of human neural stem cells into the 
peri-infarct, for instance, has significantly improved the same behavioral deficits as 
assessed here within a 3 months’ time frame [57] and might indicate that repair of pre-
infarct tissue is a key process in achieving behavioral recovery. As lower concentrations 
(3-4 mg/mL) of ECM hydrogel permeate into this peri-infarct tissue [114], these 
concentrations might provide more favorable conditions to affect behavioral deficits [138], 
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even though these preparations do not yield as significant a cell invasion after 24 hours 
of implantation [112]. In this case, the signaling properties of ECM hydrogel would induce 
the repair of damaged tissue, rather than necessitating a structural scaffold to support the 
invasion of cells to form a de novo tissue. Although collagen I is the most abundant 
molecules in UBM- ECM hydrogel and is likely to convey its rheological properties, it also 
contains a myriad of other proteins, oligopeptides, glycosaminoglycans, proteoglycans, 
growth factors and other juxtracine/paracrine signaling molecules (including 
nanovesicles). All of these can influence the repair response by modifying macrophage 
phenotype, stem cell recruitment and mechanotransduction. However, the variety and 
complexity of these molecules and their interaction in the damaged brain pose a 
harrowing challenge to elucidate a specific mechanism of repair. Further exploration of 
these extensive structure-function relationships is required to achieve a therapeutic 
efficacy comparable to the implantation of neural stem cells in the peri-infarct area, but 
also promoting conditions that improve the structural remodeling of ECM inside the lesion 
cavity to encourage the replacement of lost tissue, as seen in peripheral organs. 
 
 
 
3.5 CONCLUSIONS 
 
The tissue loss after a stroke constitutes a major challenge to improve behavioral 
outcomes. Implantation of a bioscaffold into the cavity can potentially provide physical 
support to the remaining host brain tissue, but inductive biomaterials can also attract host 
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cells to invade. We here demonstrated that an 8 mg/mL concentration of UBM-ECM 
hydrogel can reduce the lesion cavity with minimal impact on host tissue, peri-infarct 
astrocytosis and glial scarring. The hydrogel was retained within the cavity for 12 weeks 
suggesting that the biodegradation of the material within the brain does not replicate the 
typical time course observed in peripheral tissues. Behavioral functions were not affected 
by the implantation or retention of the material within the cavity indicating that an 8 mg/mL 
preparation appears safe for the local delivery of therapeutic factors, but by itself does 
not appear to exert a therapeutic benefit in stroke. Further studies are required using 
lower concentrations of ECM hydrogel that would afford permeation into the peri-infarct 
areas and potentially sustain a host response that could reproduce the structural 
remodeling observed in peripheral organs. 
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4.0 BIODEGRADATION OF ECM HYDROGEL PROMOTES ENDOGENOUS 
BRAIN TISSUE RESTORATION 
The work in this chapter has been adapted from the following manuscript: 
Ghuman H, Mauney C, Donnelly J, Massensini AR, Badylak SF, Modo M. 
Biodegradation of ECM hydrogel promotes endogenous brain tissue restoration in a rat 
model of stroke. (In peer-review; Acta Biomaterialia) 
 
4.1 INTRODUCTION 
 
Long-term retention of ECM hydrogel is safe for physical support and delivery of 
therapeutic factors, but a concentration of 8 mg/mL is not providing a therapeutic 
behavioral benefit by itself. It is hence possible that lower concentrations of ECM, which 
partially gel after injection, would partially permeate into surrounding tissue to produce 
beneficial therapeutic effects. Although a higher concentration 8 mg/mL ECM induces the 
most cell invasion acutely, we hypothesized that weaker hydrogels will facilitate a more 
sustained endogenous cell invasion leading to a faster biodegradation that can favor 
tissue restoration. The aim of the current study was therefore to determine the histological 
time course (1, 14, 90 days) of cell invasion and biodegradation of different concentrations 
(3, 4, 8 mg/mL) of ECM hydrogel in a stroke cavity. A time course will allow us to 
determine if endogenous cells can sufficiently invade and restructure ECM hydrogel to 
promote the replacement of the scaffold with de novo tissue. Restoration of tissue within 
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the stroke cavity would indicate that the brain has the capacity to self-repair and create 
de novo tissue, but that appropriate conditions need to be engineered to facilitate this 
process. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1  Middle cerebral artery occlusion (MCAO) 
 
Please see section 2.2.3. for details.  
 
MCAo rats (n=57) were randomly assigned to one of the following groups, resulting in 
equivalent lesion volumes between groups. 
 
 
 
Table 3. MCAo animals per experimental condition 
 
 
Conditions Day 1 Day 14 Day 90 
0 mg/mL 3 5 5 
3 mg/mL 5 5 4 
4 mg/mL 5 5 5 
8 mg/mL 5 5 5 
 
 
 
4.2.2  Magnetic resonance imaging (MRI) AND infarct volume calculation 
Please see section 2.2.4. for details 
 
4.2.3 Perfusion and immunohistochemistry 
Please see section 2.2.7. for details 
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4.2.4  Tissue deformation measurements 
Please see section 3.2.3. for details 
 
4.2.5  Statistical analysis 
 
Statistical analyses were performed in SPSS 17 for Mac (IBM) with significance set at 
p<0.05. Specifically, two-way ANOVAs were used to compare group and time effects as 
independent variables, with tissue volumes, cell invasion and phenotypes as dependent 
variables. Bonferroni post-hoc tests validated overall significant comparisons. A 
LOWESS spline curve fitting was performed on the ECM volume data to represent the 
expected time line of biodegradation. Pearson correlations were calculated to determine 
associations between two dependent variables. Graphs were drawn in Prism 7 
(GraphPad) with data points representing the mean and bars reflecting the standard 
deviation. 
 
4.3 RESULTS 
 
4.3.1 Weaker ECM hydrogels undergo efficient biodegradation and reduce tissue 
cavitation 
 
The 8 mg/mL ECM preparation resulted in a stiffer bioscaffold that was consistently still  
present by 90 days post-implantation while filling the entire lesion cavity (Figure 4.1.A).  
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Figure 4.1: Macroscopic distribution of ECM hydrogel in the stroke cavity. 
A. Pre-implantation T2-weighted magnetic resonance images (MRI) were used to define 
stereotactic coordinates and calculate volumes of ECM hydrogel precursor for injection. A 
complete coverage of the lesion cavity with an ECM bioscaffold (Collagen I in green, DAPI in 
Blue) was achieved with this approach. A concentration of 8 mg/mL ECM shows limited 
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degradation over 90 days, whereas 3 and 4 mg/mL show a very efficient structural remodeling, 
with only a small amount of hydrogel being present at the final time point. B. Anterior-Posterior 
pre-implantation MRI scans revealed the location and volume of the lesion cavity for comparison 
with 3 mg/mL ECM hydrogel at 90 days post-implantation. Active tissue remodeling inside the 
ECM bioscaffold and around the lesion cavity is evident (DAPI in Blue, Collagen I in green, GFAP 
in red). C. At the lesion-tissue boundary, astrocytes (GFAP+ cells) cross the glial scar and invade 
the bioscaffold that is replacing the stroke cavity. Capillary-like structures were also apparent in 
ECM remodeling regions. 
 
 
 
A key difference between 3 and 4 mg/mL gels compared to the stiffer 8 mg/mL gels was 
that the less concentrated ECM hydrogels displaced smaller amounts of damaged tissue 
and in cases of non-communicating tissue voids, these did not fully cover areas of 
cavitation. An anterior-posterior view of the lesion cavity pre-implantation showed a 
distinct delineation of the newly formed tissue inside the original lesion void at 90 days 
(Figure 4.1.B). ECM hydrogel within the tissue void provides a scaffold that bridges the 
space between host tissue, with cells invading through the substrate to re-colonize the 
cavity (Figure 4.1.C). Lateral ventricles were enlarged in all animals, indicating some 
degree of hydrocephalus ex vacuo, which is known to occur after volumetric tissue loss. 
In animals with sub-cortical lesions, ECM hydrogel appeared to be pulling tissue together, 
whereas in large lesions that included cortical regions such contractions of tissue did not 
occur.  
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Figure 4.2. ECM biodegradation and tissue deformation. 
A. Lesion volumes calculated from T2-weighted MR images acquired 4 days before ECM injection 
(10 days post-stroke) were used to assign rats to groups with equivalent lesion volumes. B. 
Remaining volume of ECM hydrogel was quantified to determine biodegradation at 1, 14 and 90 
days post-implantation. At 90 days post-implantation a decrease in ECM volume of 94.1%, 95%, 
and 32% was recorded in the 3, 4, and 8 mg/mL. A locally weighted scatter plot smoother 
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(LOWESS) fitted curve visualize the anticipated degradation pattern with a 3 mg/mL concentration 
providing a half-life of 4.5 days, the 4 mg/mL 4.9 days and 8 mg/mL >90 days. A biodegradation 
plateau is reached for the 3 and 4 mg/mL concentration around 28 days, whereas the 8 mg/mL 
concentration plateaued at 66 days. C. Weaker 3 and 4 mg/mL ECM concentrations halted lesion 
progression, whereas the 8 mg/mL had a more limited impact on the evolution of the cavity 
compared to no treatment (0 mg/mL). D. Midline shift was calculated by a ratio between distance 
of the ipsi- and contralateral hemisphere midpoints. A gradual shift of the midline was evident in 
all groups. The 4 mg/mL condition exhibited the most promise to reduce tissue deformation. E. 
Hydrogel implantation did not affect the imbalance in ipsi- and contralateral parenchymal volumes 
that follows a stroke. F. There was also no effect on the hydrocephalus ex vacuo that ensues 
stroke damage, as evidence by the ratio of the ipsi- and contralateral lateral ventricles.  
 
 
 
A volumetric MRI comparison of lesion volume prior to implantation of hydrogel showed 
no significant differences between ECM concentrations (F=0.23, n.s.) at different time 
points (F=1.032, n.s.; Figure 4.2.A). Animals within each group therefore suffered a 
similar severity of stroke, with lesion volume pre-implantation ranging between 41-236 
μL. The histologic evaluation of hydrogel volume at different time points showed an overall 
group effect (F=27.0, p<0.001), with 0 mg/mL (PBS) being significantly different from all 
other groups (Figure 4.2.B). ECM volumes 1 day post-implantation were not significantly 
different from each other, but 3 and 4 mg/mL volumes were lower compared to 8 mg/mL, 
further confirming qualitative observations that stiffer gels achieved a greater 
displacement of damaged tissues within the cavity in addition to filling the tissue voids. A 
significant interaction (F=3.085, p<0.05) between ECM concentrations and time was also 
evident. The 8 mg/mL concentration was significantly (p<0.01) different from 3 and 4 
mg/mL on day 14 and 90. The 3 and 4 mg/mL groups showed no statistically significant 
difference in their biodegradation dynamics. The 4 mg/mL hydrogel underwent the fastest 
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degradation in the first two weeks at a rate of 6.11 μL/day (Table 4). In contrast, the 8 
mg/mL preparation only saw a biodegradation rate of 2.54 μL/day, i.e. approximately half 
the rate of the 3 and 4 mg/mL hydrogels. 
 
 
 
Table 4. Biodegradation rate of different ECM concentrations 
 
 
Concentration 3 mg/mL 4 mg/mL 8 mg/mL 
1-14 days 4.92 μL/day 6.11 μL/day 2.54 μL/day 
14-90 days 0.13 μL/day 0.19 μL/day 0.28 μL/day 
1-90 days 0.83 μL/day 1.06 μL/day 0.61 μL/day 
 
 
 
A difference between the 8 mg/mL concentration hydrogel and the less 
concentrated formulations was also evident for its potential to reduce lesion volume 
(Figure 4.2.C). The 3 and 4 mg/mL hydrogel concentrations very effectively reduced 
lesion progression (F=9.171, p<0.001). Lesion progression without treatment (0 mg/mL) 
showed an increase in lesion volume over 90 days. However, an 8 mg/mL concentration 
reduced this progression. No significant difference between groups was evident at 1 and 
14 days post-implantation, but 3 and 4 mg/mL significantly reduced lesion volume at 90 
days (F=5.414, p<0.01). ECM hydrogel-treated animals exhibited no significant overall 
reduction in midline shift compared to untreated (0 mg/mL) animals (Figure 4.2.D). 
Furthermore, ECM hydrogel treatment did not have a significant effect on parenchymal 
volume (Figure 4.2.E) or lateral ventricle volumes (Figure 4.2.F).  
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4.3.2 Glial scarring and astrocytosis are unaffected by ECM implantation 
 
To evaluate the host tissue glial response to ECM hydrogel implantation, glial scarring 
was measured in the striatum and cortex (Figure 4.3.A). It was noted qualitatively that 
only minor scarring was evident 1 day post-implantation and that a defined astrocytic 
barrier was more evident at 14 days (Figure 4.3.B). By 90 days in the 3 and 4 mg/mL, no 
defined line of an astrocytic scar was evident, but this area transformed into a wider area 
of reactive astrocytes. Quantification of scarring within the striatum showed no significant 
difference between groups (F=2.42, n.s.) or distance (F=4.53, n.s.) at day 1 post-
implantation (Figure 4.3.C). At 14 days, scarring was more pronounced for all groups at 
the cavity border (F=90.13, p<0.001), but it was equivalent for all groups (F=0.09, n.s.). 
At 90 days, a wider area of reactive astrocytes defined the cavity border, significantly 
decreasing in density as a function of distance from the stroke cavity (F=14.44, p<0.001) 
in all groups (F=1.54, n.s.). A similar pattern of results was also evident in the cortex with 
a scarring distance effect at 14 (F=62.05, p<0.001) and 90 days 31.31, p<0.001), but no 
group differences at any time point. In addition to glial scarring, reactive astrocytes were 
found in the peri-infarct area (Figure 4.3.D). A quantification of these revealed a 
significant increase between day 1 and 14 for all groups (F=25.23, p<0.001, Figure 
4.3.E). As ECM concentration was not related to the increase in the number of reactive 
astrocytes (F=0.6015, n.s.), changes in astrocytosis are likely related to the stroke 
pathology, rather than implantation of ECM hydrogel. 
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Figure 4.3. Glial scarring and tissue astrocytosis. 
A. To evaluate the impact of ECM hydrogel on glial scarring at the tissue interface, whole brain 
slices covering the lesion cavity were acquired to measure the level of astrocytic (GFAP) reactivity 
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in the striatal and cortical tissues. B. However, it is important to note clear morphological 
difference in astrocytic activity at the different time points is evident with the 14 day time point 
showing the sharpest interface border, whereas by 90 days post-implantation a complex mesh of 
astrocytic processes was blurring the line between established and regenerating tissue. C. A 
quantitative comparison indicated a marked increase in GFAP intensity at the border of cavity 1 
day post-implantation that was equivalent for all groups. A gradual decrease of reactivity away 
from the cavity border was evident. The highest increase in astrocyte reactivity was observed at 
14 days post-implantation with a surge in intensity reaching further into both striatum and cortex. 
By 90 days, the extent and intensity of glial reactivity was reducing, but not back to the level 
present on day 1. D. Peri-infarct astrocytosis was extensive in areas surrounding the ECM 
hydrogel implantation at all time points. E. A quantitative comparison mirrored the results of glial 
scarring, where an increase occurred in the 14 days post-implantation. This was nevertheless 
equivalent between all groups, including the 0 mg/mL condition indicating that this astrocytosis is 
not related to the ECM hydrogel, but either due to lesion progression or the implantation 
procedure. The 3 mg/mL condition exhibited the lowest level of astrocytosis, potentially revealing 
a minor effect of ECM permeating into peri-infarct tissue.   
 
 
4.3.3 ECM hydrogel efficiently promotes endogenous cell invasion 
 
Although the glial scar is often seen as an obstacle to regeneration, there was a 
substantial cell invasion into ECM hydrogel for all concentrations (Figure 4.4). A 
quantification of cells within the bioscaffold was achieved by defining the ECM hydrogel 
using collagen I staining, which is significantly higher in the implanted biomaterial 
compared to the host brain (Figure 4.5.A). Individual cell nuclei were counted across all 
sections containing ECM hydrogel. In absolute numbers, the 8 mg/mL ECM hydrogel 
contained the most cells at day 1 (average 366,278), whereas the 3 mg/mL preparation 
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Figure 4.4. Biodegradation of the material is crucial for supporting cell infiltration and 
tissue remodeling. Biodegradation of ECM hydrogel is concentration dependent with less 
concentrated 3 and 4 mg/mL bioscaffolds getting efficiently degraded, whereas the 8 
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mg/mL persist longer. A. At Day 90, very small amount (5.9 %) of the 3 mg/mL ECM was 
present with host cells showing an excellent invasion and structural remodeling. An even 
distribution of the invading GFAP+ cells is seen throughout the remaining hydrogel. B. 
With 4 mg/mL, chain cell invasion can be seen with GFAP+ cells filling the space in 
between patches of ECM hydrogel, as identified by collagen I staining. C. In contrast with 
these less concentrated hydrogels, a sharp boundary between the biomaterial and host 
was evident in animals injected with 8 mg/mL. Density of cells in the hydrogel at 90 days 
was much lower compared to the less concentrated gels. These observations highlight 
key differences in biodegradation and cell infiltration between different concentrations of 
ECM hydrogel.  
 
 
attracted 4x fewer cells (average 96,267, F=3.522, p<0.05, Figure 4.5.B). This pattern 
was consistent for all time points (F=6.748, p<0.01) with the 4 mg/mL condition initially 
attracting more cells and then rapidly decreasing to the level of the 3 mg/mL ECM 
hydrogels. However, the total number of invading cells is also affected by ECM hydrogel 
volume. As ECM hydrogel is rapidly degraded in the 3 and 4 mg/mL condition, but not in 
the 8 mg/mL condition, total cell invasion does not reflect the qualitative impression of cell 
content within the bioscaffold. Cell density within the ECM reflects this consideration and 
indicates that for the 8 mg/mL ECM hydrogel, cell density decreases with time, reflecting 
the slower biodegradation observed by 90 days (Figure 4.5.C). In contrast, the 4 mg/mL 
condition provides a consistent cell density indicating the mode of action for the more 
rapid biodegradation and tissue replacement (F=4.065, p<0.05). In the 3 mg/mL 
condition, cell density increased over time to reach the level of the 4 mg/mL hydrogel, 
potentially reflecting the lower inductive potential of this concentration and weaker support 
for cell migration. Efficient cell invasion was typically accompanied by blood vessels in 
degrading ECM hydrogel (Figure 4.5.D), as well as by a large number of astrocytes and 
macrophages occupying this intermittent space (Figure 4.5.E). 
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Figure 4.5. Presence of host cells in ECM hydrogel. A. Using collagen I staining, a region 
of interest (ROI) was defined around the edges of the biomaterial and applied to the DAPI 
image to provide a quantification of the number of cells present within the hydrogel. B. 
Total cell infiltration indicated that the 8 mg/mL hydrogel consistently contained the 
highest number of cells. In all conditions, a gradual decrease in total number of cells is 
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seen that is related to the biodegradation of the scaffold. C. To account for ECM hydrogel 
volume changes due to biodegradation, cell density was calculated. The 4 mg/mL hydrogel 
concentration provided a very consistent density of approximately 4000 cells/μL. Cell 
density for the 8 mg/mL decreased from a 4 mg/mL comparable level, whereas 3 mg/mL 
increased to a comparable level at 90 days. These cell density dynamics reveal key 
differences in the inductive potential of ECM hydrogel concentrations. D. Cell infiltration 
and density here focus on the bioscaffold content. However, a significant number of cells 
are evident within the previous cavity in between patches of ECM hydrogel. E. Iba-1+ 
macrophages and GFAP+ astrocytes are common phenotypes, but no scar or foreign body 
response was evident.  
 
 
4.3.4 Macrophage density affects ECM biodegradation 
 
The invasion of host cells into ECM hydrogel is dominated by macrophages. Invasion of 
these phagocytic cells occurs through the peri-infarct tissue across the glial scarring 
(Figure 4.6.A). Iba-1 cells are present with distinct morphological characteristics, such as 
a rounded or amoeboid shape, but also filopodia shapes with processes protruding into 
their surroundings (Figure 4.6.B). M1- (CD86+) and M2-like (CD206+) polarization 
markers further distinguish macrophage activity within the bioscaffold. A quantification of 
the proportion of macrophages within the ECM hydrogel showed that the 8 mg/mL 
concentration consistently contained a higher percentage of Iba-1+ macrophages 
compared to the other concentrations, increasing to approximately 50% (F=13.37, 
p<0.001, Figure 4.6.C) over time. The 3 and 4 mg/mL concentrations only contained 
about 30% macrophages at any time point and showed faster biodegradation than the 8 
mg/mL concentration. Total macrophage invasion mirrored the total cell invasion, with 8 
mg/mL containing a significantly greater quantity of cells at all time points ( p<0.001).  
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Figure 4.6. Phenotypic characterization of invading immune cells in ECM hydrogel. 
A. Invasion of Iba-1+ macrophage is evident at the tissue/hydrogel interface. Collagen I staining 
of the ECM hydrogel defined the region of analysis of macrophage invasion. Individual leader 
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cells spread through the material, typically with an amoeboid shape 1 day post-implantation. B. 
At 14 days post-implantation, clusters of Iba-1 positive cells were increasingly common, with some 
macrophages exhibiting an activated and ramified morphology. C. M1-like (CD86) and M2-like 
(CD206) polarization of macrophages was also evident with some cells expressing both markers, 
especially at 90 days. D. The 8 mg/mL ECM concentration invoke the highest proportion of 
macrophage and this increased with time. However, the total number of macrophage gradually 
decreased in all conditions. Density of macrophages within efficiently degrading hydrogel was 
high and persisted at approximately 700-800 cells/ μL. Only in the 8 mg/mL ECM hydrogel was 
there a decrease in macrophage density. E. Analysis of polarization of macrophages indicated 
that M1-like phenotypes were predominant 1 day post-implantation, but that M2-like cells were 
common 14 days post-implantation. By 90 days, both M1 and M2 were commonly found in the 
same macrophage cell. 
 
 
 
Macrophage density within the ECM hydrogel showed a gradual decrease in the 8 mg/mL 
condition, while the 4 mg/mL concentration showed a consistent density of 700-800 
cells/μL (F-3.297, p<0.05). This level was also reached and maintained by the 3 mg/mL 
preparation at 14 days post-implantation. A phenotypic shift in macrophages was evident 
with a large proportion (35-48%) showing M1-like characteristics at day 1, especially in 
the lower ECM concentrations (F=23.21, p<0.001, Figure 4.6.D). The 8 mg/mL hydrogel 
had significantly fewer M1-like macrophages at day 1 (~20%) with only a minimal 
decrease over time to reach the same level (~10%) as the 3 and 4 mg/mL bioscaffolds. 
A shift in polarization from M1-like macrophages at day 1 to M2-like at day 14 was evident 
with over 20% of cells showing M2-like characteristics for the 3 and 8 mg/mL group and 
11.6% for the 4 mg/mL preparation (F=10.25, p<0.001) compared to <4% of cells having 
only a M2-like marker expression at day 1 and 90 (F=128.8, p<0.001). With time 
(F=15.77, p<0.001), co-expression of M1-like and M2-like cell markers increased 
consistently for all groups, with 27-33% of cells co-expressing both markers (F=2.06, n.s., 
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Figure 4.6.E). These results suggest that macrophage density is a key factor driving 
biodegradation of the ECM hydrogel and that a phenotypic shift in macrophage identify is 
evident to promote a pro-repair response by 14 days post-implantation. 
 
4.3.5 Neovascularization of implanted hydrogel 
 
Neovascularization is necessary to ensure the long-term survival of invading cells. In the 
8 mg/mL ECM hydrogel, very few blood vessels were evident. In contrast, 
neovascularization was evident in the 3 and 4 mg/mL bioscaffold by 90 days, including 
branching of different vessels inside and in between the ECM hydrogel (Figure 4.7.A). In 
some cases, very tortuous structures were present (Figure 4.7.B), similar to 
angiogenesis in some peri-infarct areas post-stroke. The number of endothelial (i.e. 
RECA1+) cells invading the ECM hydrogel (Figure 4.7.C) was quantified to determine 
the cellular basis for neovascularization. The small percentage of endothelial cells that 
invaded the hydrogel 1 day post-implantation appeared to follow specific trails inside the 
ECM.  
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Figure 4.7. Vascularization of the ECM hydrogel. 
A. Neovascularization inside the hydrogel was evident at 14 days if hydrogel underwent an 
efficient biodegradation, as illustrated here in after implantation a 3 mg/mL ECM bioscaffold. B. 
However, in some cases very tortuous vessels can be seen. C. Preceding the formation of 
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vasculature is the infiltration of endothelial cells. In the 8 mg/mL condition, infiltration of endothelial 
cells is seen, but there is a lack of vascular formation. A higher magnification of a RECA-1+ cells 
highlights the early stages of alignment of individual cells that invaded the hydrogel. D. A 
quantification of endothelial cell infiltration indicated a higher infiltration in the 8 mg/mL condition 
1 day post-implantation, but a turning point is reached at 14 days where there is decrease of 
endothelial cells at this concentration. Endothelial cell infiltration was linearly increased in the 3 
and 4 mg/mL ECM hydrogel concentration, constituting almost 30% of all cells in the hydrogel at 
90 days. 
 
 
 
No significant difference between ECM concentrations was evident at 1 day post-
implantation. An inflection point occurred at 14 days, with infiltration peaking for the 8 
mg/mL (F=8.794, p<0.001). An increase to 30% of all cells being endothelial cells 
occurred in the 3 mg/mL concentration. In contrast, only 4.8% of cells within the 8 mg/mL 
hydrogel were of an endothelial phenotype by 90 days post-implantation. The lack of 
endothelial cell invasion beyond 14 days in the 8 mg/mL hydrogel indicates a key shift in 
the cellular response of cells at this time point. Neovascularization in the 3 and 4 mg/mL 
concentrations at 90 days contrasts starkly with the lack of new blood vessels in the 8 
mg/mL ECM preparation. 
 
4.3.6 Invasion of neural cells 
 
Although macrophages and endothelial cell invasion are associated with biodegradation 
and vascularization of the ECM hydrogel, neural cells are required to produce de novo 
brain tissue. The infiltration of neural progenitor (DCX+) cells is evident in the peri-infarct 
area, as well as within the degrading ECM hydrogel (Figure 4.8.A). Neural progenitors 
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were present in the ECM hydrogel as early as 1 day post-implantation. The neural 
progenitor cells mature into neurons (b-III-tubulin+ and/or NeuN+) and astrocytes 
(GFAP+) in the degrading bioscaffold (Figure 4.8.B and 4.8.C), as well as inside the 
ECM hydrogel. Small pockets of tissue developed within the degrading bioscaffold and 
presented conditions that allowed for maturation of brain cells (Figure 4.8.D), including 
the formation of axonal projections as determined by neurofilament staining (Figure 
4.8.E). Neuronal cells were typically accompanied by astrocytes and oligodendrocytes 
(Figure 4.8.F), even when sparsely distributed in the ECM hydrogel.  
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Figure 4.8. Neuronal and glial cell invasion into the ECM hydrogel. 
A. While most of the migrating neural progenitors (doublecortin, DCX) were seen at the host-
biomaterial interface, a small number of DCX+ cells could be seen inside the material. B. 
Immunostaining with beta III-tubulin (Tuj) neuron marker revealed further differentiation of these 
progenitors inside, as well as in between the remnant of ECM hydrogel. Occasionally GFAP+ 
astrocytes were adjacent to these neurons, but often these neurons were not paired with 
astrocytes. C. To verify if mature neurons were being generated in this de novo tissue, NeuN 
staining was performed to target post-mitotic neurons that typically extend processes for tissue 
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integration. Fewer of these were evident, mostly in between ECM hydrogel patches, rather than 
within the scaffold per se. D. Occasional clusters containing NeuN+ cells in between ECM 
hydrogel were also found, potentially illustrating different stages of development within newly 
forming tissue. E. Neuron and tissue maturation were evident at 90 days with some neurons 
extending neurofilament (NF) containing axons. F. Glia lineage cells also invaded the ECM 
hydrogel. There were surprisingly fewer astrocytes inside the hydrogel, whereas oligodendrocytes 
efficiently colonized the weaker 3 and 4 mg/mL scaffolds by 90 days post-injection.  
 
 
 
In the 8 mg/mL condition, the ECM appeared to still be present at 90 days with cells 
contained within the bioscaffold. A quantification of neural phenotypes for comparison 
between concentrations and time points was focused on cells within ECM hydrogel 
(Figure 4.9). Neural progenitors infiltrated the ECM hydrogel at all concentrations by day 
1, with most neural progenitors being attracted by the 8 mg/mL condition (F=10.96, 
p<0.001). However, all groups presented with a similar percentage and density of neural 
progenitors in the bioscaffold at 14 and 90 days, reflecting the further infiltration of host 
brain cells at all time points. As neural progenitors within the hydrogel differentiated, 
mature neuronal markers, such as NeuN, became more prominent and steadily increased 
from <2% to 5% in the 3 and 4 mg/mL condition (F=32.92, p<0.001). The 8 mg/mL 
hydrogel contained only 3.6% NeuN+ cells by 90 days. Accounting for ECM volume, 
density of neurons showed a further distinction between 3 and 4 mg/mL (F=11.09, 
p<0.001), with the less concentrated 3 mg/mL hydrogels showing a greater neuron 
density with an average of 226 neurons per μL ECM hydrogel. The quantity of astrocytes 
(GFAP+) within the 3 and 4 mg/mL hydrogel also gradually increased with time to 
approximately 10% cellular content, whereas significantly fewer astrocytes were present 
within the 8 mg/mL preparation (F=14.61, p<0.001).  
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Figure 4.9. Phenotypic characterization and quantification of invading neuronal cells. 
The proportion of neural cells 1 day post-implantation was approximately 30% with neural 
progenitors and oligodendrocytes being the predominant phenotypes. The 8 mg/mL ECM 
hydrogel was especially efficient in attracting neural progenitors at this time point. However, the 
proportion of neural progenitor content reduced by 14 days, as more mature phenotypes became 
more prominent, consistent with differentiation of cells and maturation of tissue. At 90 days, the 
less concentrated 3 and 4 mg/mL hydrogel contained a higher density of neurons, astrocytes and 
oligodendrocytes compared to the 8 mg/mL concentration. The 3 and 4 mg/mL ECM 
concentrations therefore provide favorable conditions for neural tissue formation. 
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Astrocyte density was approximately twice that of neuronal density and equivalent 
between both 3 and 4 mg/mL hydrogels. In contrast, oligodendrocytes were significantly 
increased in the 8 mg/mL condition to almost 30% of cells (F=13.27, p<0.01). In all ECM 
concentrations, oligodendrocytes increased with time and were the dominant neural 
phenotype by 90 days (F=42.12, p<0.001). However, considering the number of 
oligodendrocytes in relation to ECM hydrogel volume, a significant lower density of 
oligodendrocytes was evident in the 8 mg/mL concentration at 90 days compared to the 
3 and 4 mg/mL condition (F= 3.78, p<0.01). Indeed, the density of oligodendrocytes was 
3-fold greater than neuron density in the less concentrated gels. This phenotypic analysis 
of neural cells inside the ECM hydrogel shows an increasing presence of cells that are 
required to generate neural tissue within the bioscaffold, with predominance of 
oligodendrocytes. Although neurons are present, they are scarce in numbers and appear 
insufficient to replace functional brain tissue. Compared to 8 mg/mL hydrogel, the 3 and 
4 mg/mL ECM preparations achieved a greater number of neurons and astrocytes, 
potentially further highlighting the favorable properties of these concentrations for 
inducing brain tissue restoration.  
 
4.3.7 ECM biodegradation correlates with cellular density 
 
The degree of biodegradation of the ECM hydrogel is related to the stroke cavity and the 
density of cells with the remaining scaffolding (Figure 4.10). At 1 day post-implantation, 
this the remaining ECM volume was correlated to lesion volume (r=0.74, p<0.01). This 
correlation became even stronger at 90 days, with a greater spread between animals, i.e. 
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degradation of ECM produced smaller lesion volumes, whereas a lack of degradation 
resulted in larger lesion (r=0.92, p<0.01). ECM biodegradation is therefore directly 
correlated with reduced the extent of a lesion cavity. To probe if ECM biodegradation is 
linked to cell infiltration, ECM volume was correlated with the total number of invading 
cells. Initially, a non-significant medium correlation (r=0.49) was found. However, by 90 
days, an inverse relationship (r=-0.81, p<0.001) was evident indicating that lower 
amounts of ECM bioscaffolding exhibit higher cell densities.  
 135 
 
 
 
Figure 4.10. Correlations of ECM hydrogel volume and cellular content. 
To evaluate the relationship between ECM hydrogel degradation and cellular content, a 
correlational analysis at each time point was performed. ECM hydrogel volume 1 day post-
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implantation revealed a high (r>0.5) positive correlation with the density of cells that invaded. Only 
astrocytes did not exhibit an association. With time a dramatic inversion of this relationship 
occurred with cell density being negatively correlated with ECM hydrogel volume. These results 
indicate that at day 1, the ECM hydrogel volume drives the quantity of cells infiltrating (i.e. large 
volume of ECM leads to more cells infiltrating), but by 90 days it is the degradation of the ECM 
hydrogel that is the key determinant of cell density (i.e. good degradation leads to high cell 
density). 
 
 
This is consistent with the observation that efficient biodegradation in the 3 and 4 mg/mL 
conditions was accompanied by a high cell density within the bioscaffold, whereas a low 
cell density was found in the 8 mg/mL hydrogel, which underwent a limited 
biodegradation. The gradual shift from a positive to a negative correlation is evident over 
time, revealing how intertwined the process of ECM biodegradation and cell density within 
the scaffold is. 
 Further correlational analyses of cell phenotypes and their relationship to ECM 
biodegradation also demonstrated this temporal shift (Figure 4.10). Macrophage density 
is initially positively correlated with ECM volume, i.e. the larger the ECM volume, the 
higher the density of macrophages (r=0.68, p<0.01). Yet, by 14 days this relationship is 
no longer evident (r=-0.11, n.s.) and by 90 days an inverse association emerged (r=-0.68, 
p<0.05), with denser macrophage presence being related to less scaffolding remaining. 
This temporal shift was also evident for endothelial cells (r=-0.79, p<0.01 at 90 days), 
neural progenitors (r=-0.68, p<0.05 at 90 days), neurons (r=-0.52, p<0.05 at 90 days) and 
oligodendrocytes (r=-0.72, p<0.01 at 90 days). On day 1, astrocytes did not show a strong 
association with ECM volume (r=0.16, n.s.) and by 14 days post-implantation a medium 
size negative correlation emerged (r=-0.57, p<0.05) indicating that better biodegradation 
 137 
produced more astrocytes infiltration. By 90 days, this correlation was even stronger (r=-
0.8, p<0.01). Although correlation does not imply causation, astrocytes and endothelial 
cells showed stronger correlation with ECM biodegradation at 90 days than 
macrophages, potentially highlighting their involvement in ECM hydrogel biodegradation 
in the brain. 
 
4.4 DISCUSSION 
 
The long-held Ramon y Cajal dogma that the brain does not have the capacity to repair 
[219] was refuted with the discovery of neural stem cells (NSCs) in the subependymal 
zone and their response to tissue damage [220]. Peri-infarct implantation of NSCs 
promoting behavioral recovery further demonstrated the potential to promote tissue repair 
using these cells [57]. However, the dogma that lost brain tissue cannot regenerate (i.e. 
form new tissue rather than replace cells) has mostly remained unchallenged [221, 222]. 
Based on our previous work using ECM hydrogel for injection into the stroke cavity [112, 
114, 149, 150], the present study suggests that the brain has an endogenous potential to 
regenerate lost tissue if an inductive and degradable bioscaffold that can support 
neovascularization and infiltration of neural cells is provided.  
 
4.4.1. Achieving an efficient biodegradation in the brain 
 
A concentration of >3mg/mL ECM is required to achieve gelation and retention of the 
bioscaffold in a stroke lesion [114]. Increases in ECM concentration produce a stiffer and 
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denser gel, with 8 mg/mL being equivalent to brain tissue (G’ 500-1000 Pa) [223-225]. 
Acute cellular infiltration in an 8 mg/mL ECM hydrogel was greater than other 
concentrations [112], but there was limited 28% degradation of this concentration at 90 
days [149]. This relatively slow degradation of the ECM contrasts with that of peripheral 
organs, where  ECM bioscaffolds in solid configurations (such as sheets) show complete 
replacement within 75-90 days [194, 226-229]. Two key questions emerge from the 
present study: 1) Does the brain have the same capacity to degrade ECM bioscaffolds as 
other organ systems, and 2) is the biodegradation profile determined by the stiffness of 
the ECM hydrogel. The biodegradation characteristics in peripheral organs are mostly 
based on sheets of ECM, rather than hydrogel, and do not address the influence of ECM 
stiffness on tissue repair [230]. We investigated different concentrations of ECM 
hydrogels to determine the impact of their rheological properties on biodegradation at 
different time points. The stiffer 8 mg/mL showed a slow biodegradation, as previously 
reported [149], whereas the less concentrated and less stiff gels of 3 and 4 mg/mL were 
resorbed at a rate twice as fast, with an ~80% reduction in volume within 14 days. This 
biodegradation is faster than the 50% biodegradation reported at 30 days in peripheral 
soft tissue defects [194], but could be a reflection of differences in product formulation. 
Importantly, these results show that the brain is capable of ECM hydrogel degradation 
and that this may be influenced by stiffness of the biomaterial.  
The rheological properties of the ECM hydrogel are in part determined by its 
density and content of inductive material. Higher concentrations of ECM hydrogel 
package more material into the same space producing a denser scaffold that can limit 
cell invasion, but also present more biomaterial to degrade for the same volume. The 
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greater cell invasion at 1 day in the 8 mg/mL higher concentration indicates that density 
and stiffness of the material is not a barrier for infiltrating cells. In contrast, the results 
from the 3 and 4 mg/mL conditions, which contain less than half the inductive material of 
the 8 mg/mL condition, provide a continued cell invasion and biodegradation. 
Macrophage invasion was positively correlated (r=0.68) with ECM volume at 24 hours 
after implantation, but over time this relationship inverted (r=-0.68) with lower 
macrophage density being related to poor ECM degradation (i.e. larger remaining 
volume). We surmise therefore that stiffness and density, rather than the inductive 
content, of the 8 mg/mL are the main barriers to macrophage infiltration and hydrogel 
resorption. Ideally, these two variables (rheological properties and inductive content) can 
be dissociated to specifically investigate the contribution of each to cell migration and 
biodegradation. Although this level of experimental control can be readily achieved with 
synthetic polymers and peptides, the use of natural materials generally does not afford 
this distinction. 
The inductive properties of ECM bioscaffolds remain poorly understood, although 
the release of chemokine factors, the release of matrix bound nanovesicles, as well 
matricellular and juxtracrine signaling have been all been thought to play an orchestrated 
role [196]. These mechanisms have led to the concept that ECM provides the “soil” to 
seed stem cells from the host organ [195]. However, the most effective constitution of this 
“soil” remains unknown. A comparison of ECM hydrogel from different organs and their 
potential to replace lost tissue can provide a pragmatic approach to contrast favorable 
components [231]. A bottoms-up approach can also investigate different individual 
components, but it might fail to replicate some of the complexities of co-stimulation that 
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occur with natural bioscaffolds. The concept of “ground substance” has been proposed 
as an amorphous gel in extracellular space that contains ECM proteins that induce tissue 
regeneration in the absence of fibrous materials, such as collagen and elastin, which are 
mostly require for structural purposes [232]. Although this ground substance might vary 
depending on the tissue, most cell migration uses similar molecules. Molecules involved 
in the infiltration of cells might hence be well conserved between organs. In this context, 
it is interesting to speculate that the repair process observed here follows similar 
processes to those observed in wound healing [233]. A key difference is that no 
granulation tissue is formed in the CNS. Granulation tissue (typically rich in type III 
collagen) is typically weaker than actual tissue containing type I collagen [234]. This would 
concur with our observation that ECM hydrogels weaker than actual brain tissue 
performed better in promoting tissue regeneration. Provision of ECM hydrogel, as 
described here, hence would introduce a “ground substance” that serves as granulation 
tissue to support the infiltration of host cells and angiogenesis.  
 
4.4.2. Neovascularization of a brain tissue cavity 
 
A quintessential step in tissue engineering is the re- or neovascularization of de novo 
tissue [235]. Transplantation of NSCs attached to poly-lactic acid - co-glycolic acid 
(PLGA) microparticles is insufficient to efficiently vascularize newly forming tissue [71, 
89], but requires the secretion of vascular endothelial growth factor A (VEGF-A) to 
promote a neovascularization [236]. The inductive properties of ECM hydrogel are in part 
due to its growth factor content, including VEGF-A [91]. The higher 8 mg/mL ECM 
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concentration attracted higher numbers of endothelial cells compared to the lower 
hydrogel concentrations [112], but failed to produce a robust vasculature by 90 days [149] 
Incorporation of NSCs for co-delivery with ECM hydrogel also did not lead to efficient 
vascularization [89]. In contrast to these failures of neovascularization of the stroke cavity, 
here we achieved an efficient and extensive vascularization of ECM hydrogel with 3 and 
4 mg/mL weaker bioscaffolds. Although these lower concentrations produced less cell 
invasion at 24 hours post-implantation, potentially due to their lower inductive potential, 
the weaker gels afforded a more persistent invasion and greater organization of tubular 
structures within the scaffold. A neovascularization of the stroke cavity is hence possible 
without modification of the ECM hydrogel, with scaffold stiffness and density potentially 
being key determinants in promoting angiogenesis. The precise mechanisms of these 
processes require further investigation.  
One challenge in understanding the processes leading to an efficient 
vascularization is the changing properties of the bioscaffold due to cell infiltration. The 
presence of cells, such as macrophages, leads to a greater porosity, secretion of different 
chemokines, but also deposition of new ECM. The invasion of endothelial cells and 
formation of blood vessels can also contribute to this process by providing a new route 
for peripheral macrophages to invade the hydrogel from within rather than through the 
peri-infarct tissue. At 90 days, endothelial cell density was highly correlated (r=-0.79) with 
the degree of ECM biodegradation indicating the intricate connection between these two 
processes. It is likely that angiogenesis and biodegradation act in conjunction with each 
other. It is this interaction that potentially explains the stark dichotomy between very 
efficiently degraded and vascularized bioscaffolds at 3 and 4 mg/mL and the 8 mg/mL 
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concentration. Nevertheless, these differences in the time course of cellular behavior in 
the bioscaffold indicate the complexities of differentiating biomaterial properties and their 
causal influence on biological processes. Unraveling causal interactions is very 
challenging, but a time course analysis of cell invasion and their changing phenotypes in 
relation to ECM biodegradation provides novel insights into these processes and allows 
for the formulation of specific hypotheses that can be evaluated in more mechanistic 
studies.  
 
4.4.3. Temporal profile of tissue regeneration after stroke damage 
 
The migration of cells into the ECM hydrogel is a pivotal event to regenerate tissue. Acute 
cell infiltration indicates that a host response to hydrogel is very rapid. Not only 
macrophages and endothelial cells infiltrate within 24 hours, but also neural lineage cells 
that participate in peri-infarct tissue repair. Individual chain cell migration was the 
predominant method of acute infiltration by “leader cells” into the bioscaffold. This 
individual cell migration is dependent on cell-matrix interactions involving integrins and 
proteases [237]. Akin to cancer cell invasion leading to a remodeling of the tissue 
microenvironment, chains of small files followed leader cells and more extensively 
remodeled the bioscaffold. Although by 24 hours almost all areas of the scaffold contain 
individual cells, the density of cells in the scaffold shifted in the opposite directions for the 
3 vs. 8 mg/mL concentrations. The less concentrated gels showed a gradual increase in 
cell density, potentially reflecting the weaker inductive potential at the acute time point 
and an easier substrate to remodel for secondary chain migration. Eventually these 
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channels of cell infiltration supported collective sheet cell migration at 14 days that led to 
a parcellation of the scaffold into smaller patches. This collective migration is more 
dependent on cell-cell interactions with the chain rather than their interaction with 
bioscaffold [238]. The 4 mg/mL concentration provided conditions for a very stable cell 
density within the material, whereas the stiffer and denser 8 mg/mL saw a gradual decline 
in cell density, although it had the highest inductive potential at 24 hours. If secondary 
cell migration in the gel is more reliant on interactions with other cells, the stiffer 8 mg/mL 
might be too dense to allow sufficient cell interactions to promote collective sheet cell 
migration. A successful cell infiltration pattern and colonialization of the bioscaffold 
therefore share similarities to cancer cell invasion and tissue remodeling [237], although 
the composition of cell phenotype is much more diverse and dynamic.  
 The time course of ECM biodegradation and tissue restoration in peripheral tissues 
indicates a predominance of macrophages in the first wave of invasion with most of these 
undergoing a M1-like polarization and being the main source of leader cells observed in 
individual cell chain migration. However, a shift towards M2-like macrophages is thought 
to be crucial for tissue remodeling [204]. Indeed, this shift was evident in the present study 
between the 1 and 14 day time points. Stiffer gels were associated with a higher 
macrophage response [175], which is consistent with more macrophages invading the 8 
mg/mL concentration at 24 hours. Macrophage density within the hydrogel was key to 
promote a rapid biodegradation. For the 8 mg/mL concentration macrophage density 
decreased, but it consistently remained over 700 cells/μL for the 4 mg/mL and the 3 
mg/mL. A plateau was reached by 14 days and maintained thereafter. The 4 mg/mL 
condition promoted significantly less M2-like macrophages at the crucial 14 day time 
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point. However, the peak M2-like polarization for the 4 mg/mL could have occurred 
between 1 and 14 days. The inductive protein content, as well as scaffold 
density/stiffness, are likely interacting mechanisms that govern the process of 
macrophage invasion and density. 
 In peripheral tissue, this macrophage pro-repair response is followed by host 
parenchymal cell infiltration. Nevertheless, we have demonstrated that by 24 hours, host 
cells are already present within the ECM scaffold, especially DCX+ neural progenitors 
[112]. There is a persistent repair response in the stroke-damaged brain that is ongoing 
even 1 year post-infarction [239]. It is likely that these neural cells responding to repair in 
the damaged peri-infarct tissue are being attracted into the ECM hydrogel. Although little 
is known about the infiltration of neural progenitors into hydrogels, it is likely that most 
neural and endothelial cells will rely on the soluble SDF-1/CXCR4 signaling axis [240] 
and/or juxtacrine signaling by integrins (e.g. fibronectin, laminin) in the hydrogel [241]. 
Further mechanistic studies will be required to determine if there are key functional 
differences in invasion/migratory behavior between these signaling pathways in scaffold 
colonization. Although the initial cell infiltration of neural progenitors was higher in the 
stiffer 8 mg/mL hydrogel, the less concentrated 3 and 4 mg/mL hydrogel supported better 
neuron and astrocyte differentiation, corroborating in vitro evidence from using cultured 
neural stem cells [208]. Neuronal (r=-0.52) and astrocytic density (r=-0.8) was negatively 
correlated with remaining ECM volume by 90 days, further indicating that efficient 
biodegradation observed in the less concentrated hydrogels is favorable to promote de 
novo neural tissue formation. The temporal profile of tissue regeneration after a stroke in 
the brain with the 3 and 4 mg/mL concentration ECM hydrogel therefore follows a similar 
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pattern to that reported in peripheral tissues, with a predominant early macrophage 
response being gradually superseded by the invasion of neural cells by 14 days with over 
80% of scaffolding being degraded. A rapid 2-3 week biodegradation period has been 
identified as one of the requirements to promote tissue regeneration [242]. However, even 
at 90 days post-implantation there is still ongoing evidence of structural remodeling within 
this newly formed tissue. These different phases are reminiscent of the processes 
described for natural wound healing in other tissues [243], suggesting that ECM hydrogel 
acts as ground substance fostering a granulation tissue in the stroke cavity. 
 
4.5 CONCLUSIONS 
 
The brain mounts a repair response to damaged tissue, but no spontaneous regeneration 
of lost tissue occurs [222]. Despite this, the present study suggests that implantation of 
ECM hydrogel can lead to an induced regeneration of brain tissue. Specifically, the 4 
mg/mL hydrogel (G’ ~76 Pa) has the most favorable characteristics for brain regeneration. 
Using this formulation, 80% of the scaffold was degraded by 14 days post-implantation at 
a speed of 6.11 μL/day with a persistent level of 700-800 macrophages in each μL of 
ECM hydrogel. The density of mature neural cells consistently increased in the remaining 
scaffolding, reflecting the structural remodeling phase of tissue regeneration, which was 
still ongoing at 90 days post-implantation. These measurements provide clear 
performance benchmarks to compare different scaffolds and their potential for tissue 
regeneration in the brain [205]. Volumetric tissue loss after a stroke can potentially be 
treated using this approach, but functional and behavioral studies will be needed to 
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determine the therapeutic potential. Although further optimization and a better 
mechanistic understanding is required to afford greater control over the processes 
involved in tissue regeneration, in situ engineering of brain tissue using inductive 
biomaterials is encouraging and opens new therapeutic avenues. 
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5.0 NON-INVASIVE IMAGING OF PERIPHERAL MACROPHAGES INVADING 
BRAIN TISSUE AND IMPLANTED HYDROGEL USING 19F MRI 
 
5.1 INTRODUCTION 
 
Invasion of macrophages into a ECM bioscaffold is the pivotal event that drives its 
biodegradation through constructive remodeling [205]. Although the immune response to 
biomaterials was initially considered detrimental to tissue engineering efforts, over the 
past decade the importance of macrophages has been recognized as a key modulator of 
scaffold biodegradation and the ensuing tissue repair. Typically, extensive time course 
studies are required to compare dosing effects, with lesion volume and topology being 
major co-variates in measurements that are difficult to control for. Longitudinal non-
invasive assessments designed to visualize macrophage invasion would hence 
significantly facilitate our understanding of their role in scaffold degradation and also 
potentially provide avenues to monitor these therapies in the clinic [244]. Although there 
is an extensive literature demonstrating the in vivo tracking of macrophages in graft 
rejection using MRI [245-247], we are not aware of any reports detailing the non-invasive 
imaging of macrophage activity in scaffolds’ biodegradation. 
By using the phagocytic activity of circulating macrophages that allows these cells to 
engulf nano and microparticles, superparamagnetic particles of iron oxide (SPIO) are 
commonly used in MR imaging to label macrophages in vivo. In an inflammatory 
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condition, these nanoparticles are internalized by the macrophages and accumulate at 
the affected site. However, quantification of SPIO labeled cells is complicated since it 
doesn’t follow a linear relationship with concentration and the signal produced by the iron 
particles interferes with the T2-weighted analyses of lesion and peri-infarct tissue 
volumes.  
Imaging of macrophages from the reticuloendothelial (RES) system using 
perfluorcarbon (PFC) labeling and 19F MRI has been first reported 30 years ago [248]. 
For this, PFC nanoemulsions were systemically injected using the intra-venous route, 
where the agent is taken up by circulating macrophages [249-252] (Figure 5.1). 
 
 
 
 
Figure 5.1. Schematic drawing describing the use of PFCs to monitor inflammatory 
processes. After injection, the nanoparticles are taken up my circulating 
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monocytes/macrophages and infiltrate the tissues of inflammation. Due to the lack of any 
endogenous 19F signal, the detected signals are highly specific.   
 
 
 
These PFC-tagged macrophages will participate in immune and inflammatory events and 
afford a visualization of their infiltration into tissues by 19F MRI [245, 253-255]. Although 
its sensitivity is significantly weaker compared to the detection of SPIO-labeled 
macrophages [249], major advantages of 19F imaging is that there is no detectable 
fluorine in native tissue so the signal is directly detected and quantifiable (19F signal is 
proportional to number of 19F spins per voxel), and hence does not interfere with the 
visualization of lesion pathology or surrounding peri-infarct tissue. This tissue interface 
constitutes a crucial distinction to determine if macrophages invade the ECM hydrogel 
through the peri-infarct tissue. Furthermore, the use of PFC agent has been used in the 
clinic to detect implanted immunotherapeutic dendtritic cells (DCs), showing the 
technique is feasible and safe for human use [256]. Unlike PET/SPECT probes, 19F does 
not undergo radioactive decay and can be used for longitudinal studies without inducing 
toxicity to the engulfed or surrounding cells. As PFC nanoemulsions can also be prepared 
to incorporate a fluorescent moiety, it is also possible to monitor the distribution of 
macrophages in the peri-infarct and ECM hydrogel during biodegradation using 
immunohistochemistry. This approach therefore will allow us to monitor macrophage 
activity to refine bioscaffold formulations for the treatment of stroke and eventually to have 
a method that could be used in patients to evaluate the host response to bioscaffolds.  
Although 19F MR imaging has been used to visualize macrophages in peripheral 
tissues, there is a lack of studies demonstrating the utility of this approach in the brain 
[249]. The main challenge is the greater anatomical details (high resolution) required in 
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the brain that typically results in lower regional density of macrophages per voxel that 
may not be detected and therefore risks underestimating the cell number increases. We 
have previously used PFC cell labeling and 19F MRI to visualize the distribution of human 
neural stem cells (NSCs) implanted into a stroke cavity using ECM hydrogel [89]. This 
produced a homogenous distribution in a large volume area that did not require a narrow 
distinction of peri infarct tissue and scaffold. In contrast here, we aim to visualize the 
accumulation of phagocytic cells in the parenchyma and its gradual invasion into the ECM 
hydrogel. We therefore here optimized 19F MR imaging sequences of PFC to ensure 
sufficient signal and resolution that will allow us to contrast macrophage activity in the 
parenchyma and implanted hydrogel.  
 
5.2 MATERIALS AND METHODS 
 
5.2.1 PFC nanoemulsion agent for inflammatory reaction 
 
PFC nanoemulsion V-Sense VS-1000H (Celsense, Inc.) was used as a probe for 19F MRI 
imaging sequence optimization and comparison. V-sense is available at 129 mM 
concentration of CF3O(CF2CF2O)nCF3 producing a 360 mg/mL (30% vol/vol) preparation. 
The molecular weight of the nanoemulsion is 1380 g/mol, yielding 7.8x1016 fluorine atoms 
with a range of 8-14 and average of 10.5 fluorine atoms (i.e. 6.022x1023 atoms/mol) and 
an average diameter of 165 nm per nanoparticle. To afford an assessment of co-
localization of PFC inside macrophages, a dual-label nanoemulsion containing PFC and 
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DM Red fluorosence (CelSense) was used for all in vivo animal experiments. The 
excitation and emission frequencies for DM Red occur at 596/615 nm, respectively.  
  
5.2.2. 1H/19F MRI set up and acquisition 
 
1H and 19F MRI was performed on two 19F phantoms, one ex vivo head and five live 
animals using a 9.4T horizontal bore MR scanner (Bruker) and a 40 mm (1H/19F) double 
resonance coil operating at frequencies of 400.13 MHz for 1H and 376.46 MHz for 19F 
measurements. For sequence optimization, 19F scans of the phantoms and ex vivo head 
were acquired using the DOE parameters, as described in the section 5.2.3, with a total 
scan time of 20 min.  
 
In vivo MR imaging: 1H and 19F imaging were performed at three time points:  
(1) 48 hours before ECM injection (prior to PFC injection; to determine endogenous 19F 
signal) 
(2) 24 hours before ECM injection (24 hours after PFC injection; to determine baseline 
19F singal and macrophage invasion)  
(3) 24 hours after ECM injection  
While imaging, MCAo rats were anesthetized with isoflurane (4% induction, 1% 
maintenance in 30% O2) and scanned using a T2-weighted spin-echo MRI sequence (TR 
= 6000 ms, TE = 8 ms, 8 Averages, FOV 40x40 mm, 128x128 matrix, 5 slices at 1.5 mm 
thickness). After acquisition of anatomical 1H images, the resonator was then tuned to 19F 
to acquire morphologically matching 19F images. Fast imaging with steady state 
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precession (FISP) sequence with 5 slices, 1.5 mm slice thickness, 96x96 matrix size, 
40x40 FOV, 4.8 ms TR, 2.4 ms TE, 60 degree flip angle and 30,000 Hz Bandwidth was 
used to detect 19F with a total scan time of 1 hour. An external phantom vial containing 
known 19F spins density of 5.6 x 1019 spins/mm3 was placed in the field of view (FOV) and 
used as a reference during image acquisition and quantification. The FOV, slice 
geometry, and slice thickness were identical for both 1H and 19F images to allow for image 
overlay and tissue segmentation.  
 
5.2.3 19F MRI sequences and optimization 
 
To define optimal imaging parameters, we compared the most commonly used 19F MR 
sequences using a design-of-experiment (DOE) approach, where we arrayed parameters 
from a low to high value. An advantage of DOE experiments is that it is possible to 
investigate interactions between parameters and cover the experimental space in a 
contour map. This then affords the selection of optimal parameters based on read-out 
parameters, such as SNR [257].  
 
Sequences: The following sequences have been previously utilized for 19F MRI [250, 258-
262], and were compared to select the one with the greatest sensitivity for PFC 
nanoemulsion detection:  
 
1. Fast low angle shot (FLASH)  
2. Multi-slice multi-echo (MSME)  
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3. Rapid acquisition with relaxation enhancement (RARE) 
4. Zero Echo Time (ZTE)  
5. Fast imaging with steady-state precession (FISP) 
 
For standard spin echo (SE) sequences (FLASH, MSME, RARE), spins are first excited 
by a 90o radio frequency (RF) pulse, before applying a second RF pulse some time later 
(at TE) to refocus the magnetization and flip the direction of spins. This second pulse 
refocuses all reversible signal and provides optimal signal per excitation. For gradient 
echo (GE) sequences (ZTE, FISP), an intital RF pulse is applied to excite the spins using 
a flip angle < 90o, before the frequency encode gradients are applied for dephasing and 
then reversed in amplitude to form an echo at TE. Despite acquiring less signal per 
excitation for GE sequences, it allows for lower TR between excitations and more signal 
averaging for the same scan time period.  
 
19F phantom and concentrations: For sequence optimization, a 19F phantom was 
prepared by filling eight glass micro-pipet capillaries with PFC nanoemulsions to detect 
different log10 concentrations (0, 0.01, 0.1, 1, 5, 10, 50, 100 mM, n=3/concentration) 
(Figure 5.2). The capillaries were sealed at both ends and embedded in a 50 mL conical 
tube containing 2% agarose in H2O.  
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Figure 5.2. 19F phantom for sequence optimization. 
A phantom was deisgned to incorporate different concentrations of V-sense for detection using 
DOE paramaters. 
 
 
 
Repetition time (TR): Increasing the repetition time (TR) up to a certain limit increases the 
SNR, since a high TR will allow the longitudinal magnetization to approach its maximum 
and produce high signal intensities and low noise. However, high TR values can also 
produce images with poor tissue contrast and thus an optimized TR is very important to 
yield good SNR and tissue contrast. To determine the optimal TR that yields highest 19F 
SNR for each sequence, scans were acquired with varying TR (100 to 2000 ms for 
FLASH, MSME; 500 to 4000 for RARE, 3.2 to 4 ms for ZTE, 3 to 8 ms for FISP).  
 
Echo time (TE): SE sequences are based on repetition of 90o and 180o RF pulses. TE is 
the time between the 90o RF pulse and MR signal sampling. A long TE results in reduced 
signal since the protons are likely to become out of phase, while short TE reduced 
dephasing and improves SNR. For spin echo sequences (FLASH, MSME, RARE), TR 
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and TE were arrayed to determine their interactions and effect on SNR. For GE 
sequences, minimum TE values are used since we do not have to wait for the 180o pulse 
and shorter TE aloows much shorted TRs to be used, thus allowing us to repeat the pulse 
sequence more quickly.  
 
Receiver Bandwidth (BW): Receiver bandwidth is the amount of frequencies collected 
during frequency encoding phase and decreasing the receiver bandwidth increases the 
SNR. However decreasing the bandwidth beyond a certain level can increase the 
chemical shift artifacts and thus an optimal bandwidth is needed. To determine the 
optimal BW for each imaging sequence, scans were acquired with varying BW (10 to 60 
kHz for FLASH, MSME, RARE, 15 to 50 kHz for FISP; 40 to 110 kHz for ZTE).  
 
Flip angle (FA): Flip angle is the angle to which the net magnetization is rotated via the 
application of a RF excitation pulse. For spin echo pulse sequences, increasing the flip 
angle increases the SNR and thus a 90o flip is most commonly used. For gradient echo 
pulse sequences which use very short TRs for rapid repetition, using a small flip angle 
allows for a large fraction of longitudinal magnetization to remain and be available for the 
next repetition. FA can thus be varied to determine the optimal angle that yields highest 
SNR. Here we arrayed FA for all sequences (40 to 90 for FLASH, MSME RARE and 
FISP; 1 to 4 for ZTE) and for each TR to determine its effect on 19F SNR.  
 
Number of averages: Number of averages or excitations is used to represent number of 
times the data is repeatedly acquired to form the image. Signal averaging sums the signal 
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intensity together with the superimposed random noise. Increasing the scan time or 
number of averages directly sums the signal waveforms together and the uncorrelated 
noise averages out producing a higher SNR. Scans were acquired for each optimized 
sequence with scan time arrayed as 1 average (0.5 – 2.5 min), 15 min, 30 min, 60 min, 
120 min. As signal intensity is dependent on the number of acquired averages in a given 
time, a comparison of optimized sequences was performed with a maximum in vivo 
imaging time of 60 minutes. 
 
Voxel size: Increasing the matrix size reduces the volume of individual voxels, and thus 
reducing the signal received by the individual voxels. Smaller voxels will receive less 
signal and hence produce a low SNR image. Conversely, decreasing the matrix size will 
reduce the spatial resolution and increase spillover effects when the FOV is kept constant. 
Matrix sizes of 32x32 (3.12 mm3), 64x64 (0.78 mm3), 96x96 (0.35 mm3), and 128x128 
(0.2 mm3) were arrayed for each imaging sequence to determine 19F SNR and spillover 
effects on the ex vivo head.  
 
Slice thickness: Increasing the slice thickness increases the voxel size that results in an 
increase in the total amount of signal received by individual voxels. Conversely, thinner 
slices are associated with more noise and reduced SNR. To determine the effect of slice 
thickness on 19F SNR, scans were acquired with 1, 1.5, and 2 mm thickness for 19F 
phantom and ex vivo head.  
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SNR and Contour plots: To define optimal acquisition parameters for each sequence, 
contour plots were computed based on SNR measurements. To calculate SNR, ROIs 
were drawn on a T2w image on the cappilary containing the PFC nanoemulsion (i.e. 
signal) and the surrounding gelatin defines noise. The noise intensity, rather than 
standard deviation, is used as divisor to avoid introduction of a calculating bias in 
concentrations below the detection threshold. It is also important to note that the 19F signal 
is not obeying a normal distribution and hence standard deviation is not an appropriate 
measure for these types of calculations. An SNR of 1 hence indicates a signal equivalent 
to noise. Using the DOE approach, parameters for the different sequences were 
compared based on SNR and contour maps were created to visualize interactions 
between different imaging parameters and 19F SNR. The optimal values for two 
independent variables will be defined by the central point of the highest SNR contour.  
 
5.2.4. 19F/fluorescent labeling of peripheral blood mononuclear cells (PBMCs) 
 
Equal volumes of VS-1000H and VS-1000H DM Red (dual probe for MRI and 
fluorescence imaging) were used to label PBMCs in vivo. Two weeks post-stroke and 48 
hours before ECM (4 mg/mL) implantation, rats (n=3) were anesthetized using isoflurane 
and a single tail vein injection of V-sense (1200mg/kg) was administered to the animal. 
The baseline (24 hours pre-implantation) 19F scans were acquired 24 hours after PFC 
administration.  
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5.2.5. Visualization of sequence optimization on head phantom 
 
DOE acquisition of ex vivo brain images with 19F labeled immune cells will ensure the 
implementation of the most efficient imaging paradigm to detect macrophages in the ECM 
hydrogel. Two weeks following stroke and 24 hours before ECM injection, rat (n=1) was 
injected with 1200 mg/kg V-sense. 24 hours after the ECM injection, the rat was 
transcardially perfused with 0.9% saline followed by 4% paraformaldehyde (in 0.2 M PBS) 
to fix brain tissue. The head was post-fixed in 4% paraformaldehyde for 24 hours prior to 
being vaccum sealed for MR imaging. 19F scans were acquired for each imaging 
sequence with optimized TR, BW, and FA. Number of averages, slice thickness, and 
voxel size were also arrayed as discussed in section 5.2.3.  
 
5.2.6. In vivo quantification of 19F signal 
 
19F signal quantification was performed in Voxel tracker software (provided by Celsense, 
Pittsburgh PA), which fuses 1H and 19F images and enables cell or inflammation 
quantification in the region of interest. 1H and 19F images were overlayed and ROIs were 
drawn around the lesion cavity, tissue parenchyma, contralateral hemisphere, reference 
tube, noise, as well as the scalp incision site. Total number of 19F spins were calculated 
by comparing the sum of the 19F signal within a ROI to the signal generated by (1) 
reference tube with known concentration of 19F spins (5.6 x 1019 spins/mm3), and (2) 
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noise. Large leukocytes, such as macrophages, have been shown to label with 19F-PFC 
labeling agents in the high end of 1012 to lower end of 1013 19F spins per cell [254, 263]. 
1013 spins per cell was used to calculate absolute cell number and cell density. A 
peripheral inflammation site is helpful here to determine if macrophages were labeled, but 
potentially did not respond to the injected ECM hydrogel or had a delayed infiltration 
response.  
 
5.2.7 Histological validation of PFC/19F macrophage detection 
 
Post-mortem histology evaluated the overlap between the in vivo 19F imaging of 
macrophages and the distribution of macrophages within the tissue, as assessed by 
immunohistochemistry at 24 hours post-implantation. Once tissues were fixed with 4% 
paraformaldehyde, brains were removed and placed into PFA for overnight post-fixation 
prior to being transferred to 30% sucrose to provide cryoprotection for histological 
processing. Brain sections were cut at 50 μm directly onto microscopic slides to preserve 
the morphology of tissue and stored at -20°C. Immunohistochemical (IHC) analyses 
involved overnight application of primary antibodies against Iba1 
(Monocytes/Macrophages/Microglia), and collagen I to detect ECM hydrogel. To visualize 
co-localization of macrophages with the dual-label PFC nanoemulsion (red fluorescent), 
secondary antibodies conjugated to fluorescent dyes (Alexa488 green, and Alexa650 far 
red) were applied for 60 min prior to counterstaining of cell nuclei with DAPI (in blue). 19F 
labeled cell count and its overlap with Iba1 was quantified over the whole tissue sections 
using a semi-automated quantification implemented in CellProfiler.  
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5.2.8 Statistical analysis 
 
SNR calculated from noise signal rather than standard deviation follows a normal 
distribution and is linearly related to PFC concentration affording a parametric statistical 
test. Sequences, as well as parameters can hence be compared using a one-way 
ANOVAs. In the case of two independent variables, a two-way ANOVA was used.  
 
 
5.3 RESULTS 
 
5.3.1 DOE approach dictates imaging parameters with highest SNR 
 
Contour plots with SNR as the dependent variable and TR, Bandwidth and flip angle as 
independent variables were constructed for each imaging sequence (Figure 5.3). For all 
FLASH, MSME and RARE sequences, the SNR increased with increasing TR, lower 
receiver bandwidths, and higher flip angles. For ZTE, TR had a minimal impact on SNR, 
while higher flip angles and bandwidth improved SNR. For FISP, DOE interactions 
revealed a central point with maximum SNR > 250 at low TR, bandwidth and 60o flip 
angle.  
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Figure 5.3. Optimization of imaging parameters using DOE approach. 
To determine the optimal imaging parameters for different sequences, Repetition time (TR), 
Bandwidth, and flip angle were arrayed to calculate SNR for each combination. Contour plots 
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were then generated using SNR as the dependent variable. The optimal parameters for each 
imaging sequence were defined by the parameters that yielded the highest SNR. 
 
 
 
Furthermore, interactions between TR and TE for all SE sequences showed the highest 
SNR for low TE (5, 10, 20 ms for FLASH, MSME, RARE) and high TR values (1500, 1500, 
2500 for FLASH, MSME, RARE) (Figure 5.4). For MSME, a small range of optimal TR 
and TE was evident from the contour plots that yielded the maximum SNR. 
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Figure 5.4. Low TE improves SNR. 
To determine the effect of varying TR/TE on SNR, TR and TE values were arrayed to calculate 
SNR for each combination. Contour plots were then generated using SNR as the dependent 
variable. High TR and low TE values resulted in the highest SNR for all sequences. 
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Optimal imaging parameters (TR, TE, BW, FA) were then deduced from the central points 
of regions with maximum SNR. Table 5 provides optimal imaging parameters for each 
sequence that resulted in the highest SNR. These optimal parameters were used for all 
subsequent sequence comparison analysis. 
 
 
 
Table 5. Overview of optimized imaging parameters that yield the highest SNR for 
each sequence. 
 
 
Sequence 
Repetition time 
(TR, ms) 
Echo time 
(TE, ms) 
Bandwidth 
(BW, kHz) 
Flip angle (FA, 
Degrees) 
Scan time for 
1 average (s) 
FLASH 1500 5 18 90 150 
MSME 1500 10 20 90 150 
RARE 2500 20 20 90 30 
ZTE 3.6 _ 75 3.5 100 
FISP 4.8 2.4 30 60 0.5 
 
 
 
5.3.2 Optimized FISP sequence produces highest SNR 
 
Comparison of optimized sequences for 50 mM PFC nanoemulsion reveals FISP 
achieving the highest SNR of 217 followed by RARE sequence with SNR of 66. MSME 
resulted in the lowest SNR of 28 (Figure 5.5.A). Although the FISP sequence produced 
4.5x more noise than RARE, the signal intensity for FISP was 15x higher than RARE 
resulting in 3.3x higher SNR.  
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The optimized sequences were also then used to acquire 19F images from the ex 
vivo head to compare signal quality across sequences. High noise levels and low SNR 
were evident in MSME, ZTE and FLASH sequences resulting in poor localization of the 
invading macrophages (Figure 5.5.B). A robust signal at the scalp indicates accumulation 
of macrophages at peripheral injury site (incision made during ECM delivery) and serves 
as a positive control. As the signal intensity increased with increasing 19F concentrations, 
robust visualization of the signal can be seen with concentrations above 5mM (Figure 
5.5.C). For all concentrations (0-100 mM), FISP achieved the highest SNR, with the 
minimum detectable concentration at 0.1mM with SNR of 2.3 (Figure 5.5.D). All other 
sequences at concentrations of 0.1 mM and lower were undetectable and similar to noise 
intensity yielding a SNR of ~1. For the highest concentration of 100 mM, FISP achieved 
a SNR of 420 (2.8x RARE, 5.9x FLASH, 6.9x MSME and 8.7x ZTE).  
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Figure 5.5. Comparison of optimized sequences. 
A. For 50mM 19F nanoemulsion, FISP achieved the highest SNR, followed by RARE and FLASH 
sequences. B. The optimized sequences were also then used to acquire 19F images of the ex vivo 
head implanted with ECM hydrogel. FISP sequence provides a robust SNR and spatial resolution 
required to localize the 19F labeled macrophages. The peripheral inflammation from scalp incision 
serves as a positive control for macrophage response. C. A significant increase in signal intensity 
and, D. SNR was determined for 19F concentrations greater than 1mM. FISP achieved the highest 
SNR across all sequences and concentrations. 
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5.3.3 Increasing signal averaging improves SNR 
 
For all optimized sequences increasing the signal averaging or scan time from 15 mins 
to 120 mins (8x) increased the SNR by at least 2.5 times (Figure 5.6.A). At high 
concentrations (>10mM), the 19F signal was detectable (SNR >3) for all sequences using 
only 1 average (0.5 - 2.5 min scan time). Comparison of sequences for a 60 min scan 
duration revealed FISP achieving the highest SNR for all concentrations, followed by 
RARE and FLASH sequences (Figure 5.6.B).   
Effect of signal averaging on the ex vivo head was also determined by arraying 
scan times (0.5 min – 120 min) for each sequence (Figure 5.6.C). FISP and RARE 
achieved a robust localization of the 19F signal, while FLASH, MSME and ZTE showed 
poor localization and SNR inside the brain tissue as well as on the scalp incision.  
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Figure 5.6. Signal averaging improves 19F SNR. A. To determine the effects of signal 
averaging on SNR, scans were acquired for a range of scan times (0.5 min to 120 min). 
Increasing the scan times improved the SNR for all sequences and concentrations. B. A 
 169 
comparison of optimized sequences for 60 min scan time indicated FISP achieving the 
highest SNR for all concentrations, followed by RARE and FLASH. C. 19F imaging of ex 
vivo head with different scan times reveal improved SNR and macrophage localization 
with increasing scan times.  
 
 
 
5.3.4 Increasing voxel size improves SNR but affords poor spatial resolution 
 
With all sequences and 19F concentrations, the SNR increased with increasing voxel size 
from 0.2 mm3 (128x128) to 3.12 mm3 (32x32) (Figure 5.7.A). A comparison of sequences 
using 96x96 matrix size (0.35 mm3) revealed FISP achieving the highest SNR (2.8x 
RARE, 5.9x FLASH), followed by RARE and FLASH sequences (Figure 5.7.B).  
19F imaging of ex vivo head using different matrix sizes showed the spillover effects 
in smaller matrix size (32x32) resulting in poor localization of signal (Figure 5.7.C). On 
the other hand, 128x128 matrix size resulted in a lower SNR, but high spatial resolution 
allowing improved localization of the acquired signal. Thus 96x96 matrix size (i.e. 0.42 
mm in plane resolution, 0.35 mm3 volume) using a FISP sequence will provide imaging 
conditions that allow sufficient SNR and scanning time (1-2 hours) in vivo, as well as 
resolution of structural detail to provide biologically relevant information (e.g. resolve 
tissue/scaffold interface)  
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Figure 5.7. Decreasing voxel size reduces SNR, but improves macrophage localization. 
To determine the effect of varying voxel size on SNR, scans were acquired with different matrix 
sizes 128x128 – 32x32 (0.2 mm3 – 3.12 mm3). A. For all sequences and 19F concentrations, 
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increasing the voxel size improved SNR. B. Comparison of optimized sequences using 96x96 
matrix (0.35 mm3) reveals FISP achieving the highest SNR across all sequences and 
concentrations. C. 19F ex vivo images reveal spillover effects in larger voxel sizes. Although 
decreasing voxel size decreases SNR, robust localization of macrophages and minimal spillover 
effects were evident for voxel sizes < 1mm3.  
 
 
 
5.3.5 Increasing slice thickness improves SNR 
 
Increasing the slice thickness for all sequences increased the SNR. Specifically, 
increasing the slice thickness from 1 mm to 2 mm increased the SNR by at least 1.8x 
(Figure 5.8.A). For comparison of optimized sequences with 1.5 mm slice thickness, 
FISP achieved the highest SNR (1.2, 2.4, 2.8, and 4.2 times higher than RARE, FLASH, 
MSME, and ZTE sequences) (Figure 5.8.B). An ex vivo 19F scan on head with different 
slice thickness shows higher SNR and signal localization for thicker slices (Figure 5.8.C).  
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Figure 5.8. Slice thickness and SNR. To determine the effect of slice thickness on 19F SNR, 
scans were acquired with 1, 1.5, and 2 mm slice thicknesses. A. Increasing slice thickness 
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improves SNR for all sequences, with FISP achieving the highest SNR for all 19F 
concentrations. B. Comparison of optimized sequences with 1.5mm slice thickness 
achieved the highest SNR for FISP, followed by RARE and FLASH. C. Ex vivo scan with 
different slice thicknesses show improved SNR and macrophage localization with 
increasing slice thicknesses. 
 
 
 
5.3.6 PFC/19F infiltration into the brain at 24 hours post-implant 
 
24 hours after tail vein 19F injection, animals were scanned to acquire baseline 1H/19F 
images before ECM implantation. Merging the 1H and 19F scans in the pre-implantation 
(Figure 5.9.A) image shows the presence of 19F signal in the major arteries and veins in 
head, including macillary artery and linguinal vein. Minimal 19F signal is detected inside 
the brain prior to ECM injection. 24 hours after ECM injection, rats were scanned again 
to acqire 1H/19F images using the same acquisition paramaters. Post-implant images 
show extensitve accumulation of PFCs insdie the lesion cavity or ECM hydrogel, as well 
as on the peripheral scalp injury indicating active inflammatory response. Anterior-
posterior 1H/19F images of the stroke-damaged ECM treated brain shows infiltration of 
PFCs throughout the lesion cavity, with most signal detected at the central slice of ECM 
implant (Figure 5.9.B).  
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Figure 5.9. Infiltration of PFCs after ECM implantation as detected by in vivo 19F MRI. 
A. Anatomically matching 1H and 19F images from the stroke brain shows an accumulation of 
PFCs in the lesion cavity after ECM implantation. 19F signal can also be detected in the major 
arteries and veins in the head, indicating the presence and detection of PFC in the blood for upto 
48 hours after PFC injection. 19F signal from the peripheral scalp insision site provides a positive 
control for inflammation and PFC accumulation. B. Anterior-posterior 1H (T2w) and 19F images of 
the brain shows extensive infiltration and distribution of 19F signal inside the lesion cavity or ECM 
hydrogel.  
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5.3.7 In vivo quantification of 19F signal 
 
19F imaging before the tail vein PFC injection (48 hours before ECM implantation) 
revealed no endogenous 19F signal present in tissues or arteries. A ratio of 19F signal to 
noise signal revealed an SNR of 1 for all regions (Figure 5.10). An increase in SNR was 
evident 24 hours post-PFC injection indicating active flow of PFC nanoemulsions through 
various arteries and veins in brain tissue as well as in the scalp. 19F imaging 24 hours 
post-ECM implantation showed significantly increased SNRs for scalp incision site 
(98.3% increase) as well as lesion cavity (72% increase). Minor changes in SNRs (16% 
and 8% increase) were observed for the tissue parenchyma and contralateral 
hemisphere.  
A ratio of total 19F spins to volume of different regions revealed total number of 19F 
spins/μL or spin density within the ROI. The peripheral scalp incision site showed 
extensive accumulation of 19F labeled cells with a spin density of 5.4 x 1017 (4x spin 
density inside lesion cavity). The lesion cavity had a spin density of 1.3 x 1017, which was 
4x and 7x higher than spin density inside tissue parenchyma and contralateral 
hemisphere. Conversion of spin density to cell density using known number of 19F spins 
per cell (1 x 1013 spins per cell) revealed 19F labeled cell density in the different regions. 
The peripheral scalp incision site showed the most accumulation of 19F labeled cells with 
an average cell density of 53,852 cells/μL. Within the brain tissue, lesion cavity revealed 
the highest cell density of 13,300 cells/μL, while tissue parenchyma and contralateral 
hemisphere had a cell density of 3256 and 1880 cells/μL.  
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Figure 5.10. In vivo quantification of 19F signal. 
A. SNR comparison reveals no endogenous 19F signal present at 48 hours before ECM 
implantation (pre-PFC injection). 24 hours after PFC injection, SNR increased reflecting active 
flow of PFC in various blood vessels insdie and outside brain tissue. 24 hours after ECM 
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implantation, scalp and lesion cavity showed increased SNRs indicating detection of infiltrating 
macrophages. B and C. Quantification of 19F signal revealed maximum 19F cell density at the 
scalp incision site, followed by lesion cavity.  
 
 
 
5.3.8 Histological validation of ECM invading peripheral macrophages 
 
Whole hemispehere Iba1 images of the animal injected with PFC and ECM hydrogel at 1 
day post-injection shows colocalization of iba1+ cells (microglia/macrophage) and of 19F 
signal inside and around the lesion cavity (Figure 5.11). A strong signal in the peri-infarct 
is evident indicating a higher density of 19F labeled macrophages in this region.  
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Figure 5.11. 19F signal and histology overlay. 
A comparison of 19F images with histology revealed areas with high 19F intensity also contained 
high density of Iba1+ cells. 
 
 
 
Tissue sections were also stained with collagen I to show infiltration of 19F/DM Red 
labeled macrophages into the ECM hydrogel. 19F/DM Red labeled macrophages can be 
seen accumulating at a sharp boundary between the ECM and host tissue and crossing 
into the ECM hydrogel (white arrows, Figure 5.12.A). Staining with Iba1 shows co-
labeling of Dm Red and Iba1 for all 19F labeled cells. It is noteworthy to notice that 
although Iba1 stained cells can be seen in the tissue parenchyma, peripheral 
macrophages were largely accumulated in the damaged tissue.  
 
 179 
 
 
 
Figure 5.12. Histological validation of brain invading macrophages. A. Peripheral 
macrophages tagged with DM Red were seen accumulating at the peri-infarct tissue with 
 180 
gradual invasion into the ECM hydrogel. DM Red tagged macrophages also showed co 
labeling with Iba1+ cells indicating that the infiltrating cells are peripheral macrophages 
rather than brain derived microglia. B. 19F labeled macrophages were also seen in very 
close proximity to blood vessels reflecting their active recruitment into the brain tissue 
from blood.  
 
 
 
19F labeled macrophages were also found in close proximity of blood vessels indicating 
that these cells indeed migrated into the brain tissue from vessels in the peri-infarct region 
(Figure 5.12.B).  
 
5.3.9 Characterization and quantification of 19F/DM Red labeled cells 
 
Immunostaining of brain tissue sections confirmed co-labeling of 19F/DM Red labeled cells 
with Iba1 indicating that all the 19F labeled cells were peripheral macrophages/monocytes 
that engulfed the 19F label in blood and infiltrated the brain tissue and ECM hydrogel 
(Figure 5.13).   
 
 
 
 
 
 
Figure 5.13. Immunohistochemistry confirmed the colabeling of 19F and Iba1 indicating 
that all the 19F labeled cells are peripheral macrophages.  
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A quantitative analysis of 19F/DM Red cells revealed a cell density of 1086 and 14,845 
cells/μL inside the ECM hydrogel and peri-infarct tissue (Figure 5.14).  
 
 
  
 
 
Figure 5.14. Quantitative analysis of 19F/DM red labeled cells shows extensive 
accumulation of these cells in the peri-infarct area and ECM hydrogel with a cell density of 
14845 and 1086 cells/uL.  
 
 
 
5.4 DISCUSSION 
 
The aim of this study was to describe a novel approach to visualize the local inflammatory 
responses by 19F MRI using in vivo tagging of circulating macrophages with biochemically 
inert 19F agent. Our results show that the intravenous administration of PFCs in stroke 
rats results in accumulation of 19F labeled cells within the ECM hydrogel and peri-infarct 
tissue. Thus, PFCs can serve as reliable contrast agent for inflammatory processes 
revealing high specificity due to lack of any endogenous 19F signal.    
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DOE provides optimal imaging paramters  
We compared the most commonly used 19F MR sequences using a design-of-experiment 
(DOE) approach, where we arrayed parameters from a low to high value and investigated 
interactions between parameters and cover the experimental space in a contour map. 
This resulted in regions in the contour map with maximum SNR that was used to define 
optimal imaging parameters for each sequence. A comparison of the optimized 
sequences revealed FISP achieving the the most sensitivity to detect PFCs, followed by 
RARE and FLASH sequences. Effects of changing slice thickness, scan time and voxel 
size were also measured for each sequence and showed improved SNRs for thicker 
slices, longer scan time, and larger voxel size. Although thinner slices results in a 
decrease in signal intensity or SNR, it offers more number of slices that can be acquired 
for a region of interest (stroke cavity in our case). Thus, a slice thickness of 1.5 mm was 
used for in vivo experiments to cover the entire lesion area, while affording sufficient SNR 
to delineate cavity from tissue parenchyma. Similarly, as longer acquisition times improve 
SNR, we are limited by in vivo scan time. Thus, a 60 min scan time was used for animal 
experiments. In general, increasing the voxel size improves 19F SNR, since larger voxels 
contain more atoms and thus generates higher signal. However, if the source of 19F signal 
(eg. implanted cell graft) is orders of magnitude smaller than the voxel size, it would not 
lead to an increased SNR since there are no additional 19F atoms to excite in the 
surrounding tissue. Indeed, when the FOV is kept constant larger voxels tend to decrease 
SNR sue to increased under-sampling artifact. 
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In vivo detection of peripheral macrophages  
This study demonstrated the ability to use 19F MRI cell tracking to detect and measure 
signal from peripheral immune cells in vivo. Numerous studies have reported the 
challenges associated with quantifying signal loss due to iron-labeled cells. The use of 
19F MRI overcomes these issues and provides a direct measure of labeled cells without 
interfering with other scans (eg. T2). Iron-based contrast agents are readily metabolized 
in vivo, while PFC emulsions have a very stable C-F bond this is biologically inert and 
does not degrade easily [252]. Additionaly, there have not been any indications of cellular 
toxicity or effect on the viability of cells even at very hight PFC loading doses [264]. Indeed 
we did not observe any adverse effects on animals after PFC injections. Recent 19F MRI 
studies of cells loaded with PFCs ex vivo and injected into mice required long acquisition 
times (upto 3 hours) [254], and limited spacial resolution with voxel size of 26 uL 
(compared to 0.35 uL in this present work) [265]. The significantly higher sensitivity seen 
in our study is likely due to the efficient in vivo uptake of PFCs through the RES compared 
to stem cells that were incubated ex vivo.  
The in vivo imaging of rats implanted with ECM hydrogel revealed a 19F cell density 
of 13,300 cells/μL in the lesion cavity. This lesion area includes the area with ECM 
hydrogel, but also the peri-infarct areas since we currently lack the tools needed to 
discriminate area of ECM vs peri-infarct tissue in the MR scans. Ex vivo labeling of ECM 
hydrogel with contrast agents such as Gadolinium could resolve this issue and afford a 
direct comparison of 19F cell density inside ECM vs peri-inafrct tissue. Histological 
analysis of the brain tissues revelaed 19F labeled cell density to be much higher in the 
peri-infarct areas (14,845 cells/μL) compared to labeled cells inside the ECM (1086 
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cells/μL). This supports the idea that the peripheral macrophages enter the brain through 
the peri-infarct tissue with gradual invasion into the ECM hydrogel. All the 19F labeled 
cells inside as well as outside the ECM hydrogel were also positive for Iba1 indicating 
that these cells are peripheral macrophages rather than brain derived microglia. The 
spatial distribution of the 19F signal is covering the area of ECM hydrogel and indicates 
that macrophage activity is not only regulated by the presence of ECM, but ECM 
distribution defines the pattern of macrophage activity while avoiding invasion in other 
areas of the brain 
 
5.5 CONCLUSIONS 
 
At present, the evaluation of bioscaffolds to promote tissue repair relies on tedious time 
point histological studies, which require large numbers of animals due to the 
heterogeneity of lesions, as well as the biomaterial implants. Non-invasive imaging of 
macrophage dynamics will constitute a major advance to visualize the time point of 
invasion and longitudinally monitor macrophage distribution in small cohorts of animals. 
As PFC nanomeulsions and 19F MRI can be used in both animals and patients, it also 
provides a unique translational measure to monitor an efficient biodegradation and 
accelerate the clinical development of bioscaffolds. 
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6.0 DISSERTATION SYNOPSIS 
 
This work is the first implementation of ECM hydrogel implantation showing tissue 
restoration in a large stroke cavity and 19F MRI for immune cell tracking in a stroke-
damaged brain implanted with ECM hydrogel. In chapter 2, we describe an innovative 
minimally invasive technique to implant ECM hydrogel while simultaneously draining ECF 
from stroke cavity, as well as characterizing the in vivo gelation and retention properties 
of the ECM with phenotypes of infiltrating cells quantified at 1 day post-ECM implantation. 
In Chapter 3, we demonstrate that long term retention of a stiffer 8 mg/mL ECM hydrogel 
in a stroke cavity reduces lesion volume, but allows insuccifient cell invasion and 
biodegradation of the ECM to restore tissue cavity and improve behavioral outcomes. In 
chapter 4, we showed that a softer 4 mg/mL ECM affords almost a complete 
biodegradation by 3 months, and restores tissue within the cavity. The density of 
macrophages in the ECM hydrogel is a key modulator that affects biodegradation. Finally, 
in chapter 5 we optimized 19F MRI sequences to non-invasively visualize and quantify 
brain infiltrating macrophages to monitor the cellular aspects of ECM biodegradation in 
vivo.  
Although cell infiltration into the lesion cavity is the first step in regenerating the 
lost tissue, robust cell invasion and axonal growth alone may not necessarily ensure 
functional restoration [266], as researchers were unable to restore visual function even 
after inducing the mouse retinal axons to regrow and form synapses in the superior 
colliculus [267]. Further analysis revealed that the newly formed axons were not properly 
myelinated, and the addition of a voltage gated potassium channel blocker improved the 
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conduction of action potentials allowing functional restoration. For more complex 
behavioral functions, targeted behavioral training will need to accompany the period of 
increased plasticity following treatment [268], since not all plasticity is known to be 
beneficial (ex. seizures, spasticity).  
 
6.1 MAJOR FINDINGS 
 
The following are the major findings of the presented work: 
Specific Aim 1 
• Using the injection-drainage approach, ECM hydrogel can be reliably delivered to 
the stroke cavity without causing further damage to the surrounding tissue 
• Implanted ECM hydrogel shows robust concentration-dependent gelation and 
retention properties in situ  
• ECM hydrogel induces host tissue response that leads to cell infiltration 
• Structural support is required for cell invasion in the cavity 
• Microglia/Macrophages are the dominant infiltrating cells with concentration-
dependent polarization towards an M2-like phenotype 
• 8 mg/mL UBM ECM (rheological properties akin to intact tissue) promotes the most 
significant cell invasion and attracts large numbers of neural and oligodendrocytes 
progenitor cells within 24 hours 
Specific Aim 2 
• Long-term structural support inside the stroke cavity prevents the lesion size from 
increasing 
 187 
• Poor degradation of ECM leads to long term retention in stroke cavity 
• Large ECM volume injection and poor biodegradation does not impact behavioral 
outcomes 
• Poor biodegradation of ECM hydrogel significantly reduces the total number and 
density of infiltrating cells including macrophages 
• Microglia/macrophages and oligodendrocytes are the dominant cell types invading 
the ECM hydrogel at 90 day post-implantation 
Specific Aim 3 
• Biodegradation of ECM hydrogel is essential for recruting host cells and restoring 
stroke cavity 
• Softer ECM hydrogels (3 and 4 mg/mL) undergo efficient biodegradation and 
reduce tissue cavitation 
• Glial scarring and astrocytosis is not impacted by ECM implantation 
• Biodegradation of ECM hydrogel promotes neovascularization of stroke cavity 
• Microglia/macrophage density affects ECM biodegradation 
• Mature neurons are found inside around the softer ECM hydrogels at 90 day post-
injection  
Specific Aim 4 
• DOE approach allows visualization of interactions between imaging parameters 
and SNR to define optimal imaging parameters 
• FISP sequence is the most efficent in detecting PFC nanoemulsion 
• PFC nanoemulsions are engulfed by circulating macrophages before migrating to 
the site of ECM implantation 
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• In vivo 19F MRI at 1 day post-ECM injection provides a robust localization of 
infiltrating immune cells cells inside the stroke lesion cavity post transplant 
 
6.2 LIMITATIONS AND FUTURE WORK 
 
A major limitation of this work was detection of the implanted ECM hydrogel using 
immunohistochemistry and MRI. Since approximately 70% of the UBM ECM is collagen 
I, we have demonstrated that collagen I is a good surrogate marker for histologial 
distribution at early time points post-implantation. However, as the material gets degraded 
(especially 3 mg/mL at 3 months), it is unclear if this is still the case. The use of additional 
markers and morphological characteristics at later time points can further aid to identify 
the implanted material. Ex vivo covalent pre-labeling of the material prior to injection with 
florescent tetramethylrhodamine (TRITC) would allow researchers to histologically detect 
the implanted material without the need for any surrogate histoloigical markers like 
collagen I. In addition, MRI detection of the implanted hydrogel using Gadolinium-Gold 
nanoparticles tagging would allow us to delineate the 19F signal from the ECM hydrogel 
vs peri-infarct tissue.   
A second limitation of this study is lack of understanding of the identity of the 
invading neurons. Brain is highly specialized and neurons are defined by their regional 
identity, which is defined during differentiation through positional specification. Future 
experiments will evaluate the positional specification using immunohistochemistry for 
striatal (eg. Dlx2, NKX2.1) and cortical markers (eg. Pax6) to determine if the invading 
neurons express the regional positional specification markers in the striatum and cortex. 
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Another potential limitation is the homogenous delivery of ECM hydrogel in non-
communicating stroke cavities. We have seen this issue mostly with the 3 mg/mL 
hydrogel which is weaker and does not displace remnants of scar tissue that seperates 
cavity pockets. At 4 mg/mL concentration, these weak tissues are displaced and more 
homogenous distribution is observed. Using diffusion MRI scans instead of T2w scans 
would allow us to identify separate cavity pockets and target injection to individual 
pockets.  
The final limitation in this study is the time of delivery of ECM hydrogel to stroke 
cavity. Our current time of delivery is based on studies using fetal tissue transplants that 
show improved survival between 2-3 weeks post-stroke compared to more acute or 
chronic phases [269]. Nevertheless, it is possible here that improved structural 
remodeling is observed at an earlier time point. An earlier injection time point (eg. 7 days 
post-stroke) using a less concentrated hydrogel will allow researchers to investigate this 
and guide future approaches based on solid evidence.  
 
6.3 OVERALL CONCLUSIONS 
 
The work contained in this dissertation demonstrates that implantation of ECM hydrogel 
in a stroke cavity induces cellular infiltration to support endogenous repair processes. The 
novel injection-drainage approach described herein allowed us to inject large ECM 
volumes into the brain cavity without causing additional damage to the peri-infarct tissue. 
While the implantation of the stiffer 8 mg/mL hydrogel did not alter the behavioral 
outcomes, it provided a permissive microenvironment for the host cells to infiltrate into 
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the lesion cavity and reduce the lesion size by 28%. Injection of softer 3 and 4 mg/mL 
ECM showed robust biodegradation and infiltration of host cells including neurons, and 
resulted in a 50% decrease in cavity size by 3 months. In addition, the noninvasive 
imaging of brain infiltrating monocytes/macrophages using 19F MRI allowed us to 
selectively visualize and quantify the number of infiltrating cells that participate in the 
biodegradation of the ECM hydrogel. This combination of in situ gel formation that 
modulates the inflammatory and neural cell responses, and its non-invasive visualization 
using 19F MRI sets the foundation for future evaluation of biomaterials in acute brain 
injuries like stroke.  
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